P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
1.599e-31 | -70.91 | synapse | cellular component | GO:0045202 | 1473 | 37 | 19108 | 49 |
CADPS,CHRM2,KCNIP2,OLFM1,GRIK2,SCN8A,CNTN5,GRIN1,CELF4,NRXN2,NRG3,CACNA1G,RIMS2,GABBR2,GRID2,SYT1,GABRA1,STXBP5,KCNC1,GPHN,CACNA1A,GRM7,NRXN1,DLG3,GABRB2,PDE2A,GRIA3,GRIN2B,FGF12,MCTP1,HCN1,SYT7,GABRD,KCNMA1,KCTD16,ASIC2,DLG4 |
3.667e-31 | -70.08 | synaptic membrane | cellular component | GO:0097060 | 400 | 26 | 19108 | 49 |
GRIA3,PDE2A,GABRB2,DLG3,GPHN,GRM7,NRXN1,KCNC1,DLG4,KCTD16,KCNMA1,GABRD,SYT7,HCN1,GRIN2B,NRXN2,CNTN5,SCN8A,GRIN1,GRIK2,CHRM2,GABRA1,SYT1,GRID2,GABBR2,RIMS2 |
4.036e-29 | -65.38 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 25 | 18204 | 47 |
DLG3,RIMS2,GABRB2,GABRA1,GRID2,GRIA3,KCNIP2,ASIC2,CACNA1A,GABRD,CACNA1G,GRIN2B,GRIK2,NRXN1,NRXN2,SYT1,CELF4,GRM7,GRIN1,SYT7,CHRM2,CADPS,DLG4,GABBR2,FGF12 |
4.036e-29 | -65.38 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 25 | 18204 | 47 |
GRM7,CELF4,GRIN1,SYT7,CADPS,CHRM2,GABBR2,FGF12,DLG4,GRIK2,NRXN1,SYT1,NRXN2,ASIC2,CACNA1A,GABRD,CACNA1G,GRIN2B,RIMS2,DLG3,GABRB2,GABRA1,KCNIP2,GRID2,GRIA3 |
1.048e-28 | -64.43 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 25 | 18204 | 47 |
GRID2,GRIA3,KCNIP2,RIMS2,DLG3,GABRB2,GABRA1,CACNA1G,GRIN2B,ASIC2,CACNA1A,GABRD,NRXN1,NRXN2,SYT1,GRIK2,CHRM2,CADPS,DLG4,GABBR2,FGF12,CELF4,GRM7,GRIN1,SYT7 |
5.112e-28 | -62.84 | synaptic signaling | biological process | GO:0099536 | 459 | 25 | 18204 | 47 |
GRIK2,NRXN1,SYT1,NRXN2,GRM7,CELF4,SYT7,GRIN1,CHRM2,CADPS,FGF12,GABBR2,DLG4,DLG3,RIMS2,GABRA1,GABRB2,KCNIP2,GRIA3,GRID2,ASIC2,CACNA1A,GABRD,GRIN2B,CACNA1G |
4.694e-25 | -56.02 | cell junction | cellular component | GO:0030054 | 2224 | 37 | 19108 | 49 |
KCTD16,DLG4,ASIC2,KCNMA1,FGF12,MCTP1,HCN1,SYT7,GABRD,GRIN2B,GRIA3,GABRB2,PDE2A,KCNC1,GPHN,NRXN1,CACNA1A,GRM7,DLG3,STXBP5,SYT1,GABRA1,GRID2,CACNA1G,RIMS2,GABBR2,NRG3,CELF4,NRXN2,KCNIP2,GRIK2,OLFM1,CNTN5,SCN8A,GRIN1,CADPS,CHRM2 |
9.784e-23 | -50.68 | postsynaptic membrane | cellular component | GO:0045211 | 280 | 19 | 19108 | 49 |
GRID2,GABRD,HCN1,GABBR2,GRIN2B,DLG4,KCTD16,KCNMA1,GABRA1,GRIN1,SCN8A,GABRB2,GRIK2,GRM7,GPHN,DLG3,KCNC1,CHRM2,GRIA3 |
1.297e-22 | -50.40 | monoatomic ion channel complex | cellular component | GO:0034702 | 344 | 20 | 19108 | 49 |
HCN1,GABRD,GRID2,GRIN2B,CACNA1G,STXBP5,DLG4,CACNA1H,GABRA1,KCNMA1,GRIK2,KCNIP2,GABRB2,SCN8A,GRIN1,KCNC1,DLG3,CACNA1A,DPP10,GRIA3 |
9.430e-22 | -48.41 | cell-cell signaling | biological process | GO:0007267 | 822 | 25 | 18204 | 47 |
DLG3,RIMS2,GABRB2,GABRA1,GRID2,GRIA3,KCNIP2,CACNA1A,ASIC2,GABRD,CACNA1G,GRIN2B,GRIK2,NRXN1,NRXN2,SYT1,CELF4,GRM7,GRIN1,SYT7,CADPS,CHRM2,DLG4,GABBR2,FGF12 |
1.420e-21 | -48.00 | regulation of membrane potential | biological process | GO:0042391 | 463 | 21 | 18204 | 47 |
GRIN1,GABRD,CACNA1H,CELF4,ASIC2,DLG4,FGF12,SCN8A,CACNA1G,GRIN2B,GRIK2,GABRB2,GABRA1,RIMS2,KCNMA1,HCN1,GRID2,NRXN1,KCNC1,GRIA3,KCNIP2 |
1.335e-20 | -45.76 | transmembrane transporter complex | cellular component | GO:1902495 | 434 | 20 | 19108 | 49 |
GABRA1,KCNMA1,DLG4,CACNA1H,STXBP5,CACNA1G,GRIN2B,GABRD,GRID2,HCN1,GRIA3,DPP10,DLG3,CACNA1A,KCNC1,GRIN1,SCN8A,GRIK2,GABRB2,KCNIP2 |
4.402e-20 | -44.57 | transporter complex | cellular component | GO:1990351 | 461 | 20 | 19108 | 49 |
SCN8A,GRIN1,KCNIP2,GABRB2,GRIK2,CACNA1A,DLG3,KCNC1,GRIA3,DPP10,GRID2,GABRD,HCN1,GRIN2B,CACNA1G,CACNA1H,DLG4,STXBP5,GABRA1,KCNMA1 |
1.503e-18 | -41.04 | postsynapse | cellular component | GO:0098794 | 646 | 21 | 19108 | 49 |
KCNC1,CHRM2,GRM7,GPHN,DLG3,GABRB2,GRIK2,GRIN1,SCN8A,CELF4,GRIA3,GRIN2B,GABBR2,HCN1,GRID2,GABRD,KCNMA1,GABRA1,KCTD16,ASIC2,DLG4 |
2.558e-18 | -40.51 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 17 | 10285 | 29 |
GABRB2,GABRA1,GRIK2,KCNC1,GRIN2B,GABBR2,SYT1,GRIA3,DLG4,GRIN1,KCNMA1,HCN1,SYT7,CACNA1A,NRXN2,NRXN1,DLG3 |
2.741e-18 | -40.44 | gated channel activity | molecular function | GO:0022836 | 320 | 17 | 18094 | 48 |
GRIN1,KCNIP2,GRIN2B,HCN1,ASIC2,KCNMA1,KCNC1,CACNA1G,GABRB2,CACNA1H,KCNT1,GRIK2,GRID2,CACNA1A,GABRD,GABRA1,GRIA3 |
2.943e-18 | -40.37 | plasma membrane region | cellular component | GO:0098590 | 1278 | 26 | 19108 | 49 |
GABRB2,PDE2A,KCNC1,DLG3,GPHN,GRM7,NRXN1,GRIA3,SYT7,HCN1,GABRD,GRIN2B,KCTD16,DLG4,KCNMA1,GRIK2,SCN8A,CNTN5,GRIN1,CHRM2,NRXN2,GRID2,RIMS2,GABBR2,SYT1,GABRA1 |
2.438e-17 | -38.25 | monoatomic ion channel activity | molecular function | GO:0005216 | 441 | 18 | 18094 | 48 |
KCNT1,GRIK2,GRID2,GABRD,CACNA1A,GABRA1,GRIA3,KCNIP2,GRIN1,GRIN2B,ASIC2,HCN1,KCNMA1,KCNC1,CACNA1G,CACNA1H,GABRB2,SCN8A |
6.164e-17 | -37.33 | presynapse | cellular component | GO:0098793 | 569 | 19 | 19108 | 49 |
HCN1,MCTP1,SYT7,RIMS2,STXBP5,KCTD16,DLG4,SYT1,GRIK2,CNTN5,SCN8A,GRIN1,PDE2A,KCNC1,CADPS,CHRM2,NRXN1,GRM7,NRXN2 |
1.186e-16 | -36.67 | neuron projection | cellular component | GO:0043005 | 1331 | 25 | 19108 | 49 |
GRIA3,TENM1,GABRB2,GPHN,GRM7,DLG3,KCNC1,ASIC2,DLG4,NTRK3,GABRD,HCN1,SYT7,GRIN2B,GRIN1,SCN8A,CNTN5,KCNIP2,OLFM1,GRIK2,CHRM2,GABRA1,SYT1,GRID2,GABBR2 |
2.340e-16 | -35.99 | presynaptic membrane | cellular component | GO:0042734 | 168 | 13 | 19108 | 49 |
KCTD16,SYT1,HCN1,SYT7,RIMS2,NRXN2,CNTN5,SCN8A,PDE2A,GRIK2,NRXN1,KCNC1,CHRM2 |
2.377e-16 | -35.98 | channel activity | molecular function | GO:0015267 | 502 | 18 | 18094 | 48 |
ASIC2,HCN1,GRIN2B,KCNIP2,GRIN1,CACNA1H,SCN8A,GABRB2,KCNC1,CACNA1G,KCNMA1,KCNT1,GRIK2,GRIA3,GABRA1,GABRD,CACNA1A,GRID2 |
2.461e-16 | -35.94 | passive transmembrane transporter activity | molecular function | GO:0022803 | 503 | 18 | 18094 | 48 |
GABRA1,GRIA3,GRID2,GABRD,CACNA1A,GRIK2,KCNT1,KCNC1,CACNA1G,CACNA1H,GABRB2,SCN8A,KCNMA1,GRIN2B,ASIC2,HCN1,KCNIP2,GRIN1 |
1.289e-15 | -34.28 | cell projection | cellular component | GO:0042995 | 2398 | 30 | 19108 | 49 |
CHRM2,OLFM1,GRIK2,KCNIP2,GRIN1,SCN8A,CNTN5,NRXN2,RIMS2,GABBR2,GRID2,SYT1,GABRA1,KCNC1,DLG3,GPHN,GRM7,CACNA1A,NRXN1,GABRB2,TENM1,GRIA3,GRIN2B,SYT7,HCN1,GABRD,NTRK3,KCTD16,DLG4,ASIC2 |
2.313e-15 | -33.70 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 17 | 18204 | 47 |
CHRM2,GRIN2B,MCTP1,DLG4,GRM7,CACNA1A,CELF4,SYT7,GRIN1,GRIA3,NRXN1,GRID2,NRG3,SYT1,STXBP5,RIMS2,GRIK2 |
2.391e-15 | -33.67 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 17 | 18204 | 47 |
CELF4,GRM7,CACNA1A,SYT7,GRIN1,GRIN2B,CHRM2,DLG4,MCTP1,STXBP5,RIMS2,GRIK2,NRXN1,GRIA3,NRG3,GRID2,SYT1 |
2.549e-15 | -33.60 | receptor complex | cellular component | GO:0043235 | 409 | 16 | 19108 | 49 |
GABRA1,DLG4,KCTD16,STXBP5,GABBR2,GRIN2B,GABRD,GRID2,ALK,NTRK3,GRIA3,DLG3,GRM7,GRIN1,GRIK2,GABRB2 |
3.198e-15 | -33.38 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 18 | 19108 | 49 |
SCN8A,GRIN1,GRIK2,KCNIP2,DLG3,CACNA1A,KCNC1,GRIA3,DPP10,GRID2,HCN1,GABBR2,CACNA1G,GRIN2B,DLG4,CACNA1H,STXBP5,KCNMA1 |
2.916e-14 | -31.17 | plasma membrane | cellular component | GO:0005886 | 5538 | 40 | 19108 | 49 |
CSMD2,GRIN2B,NTRK3,GABRD,HCN1,KCNT1,SYT7,KCNMA1,DLG4,ASIC2,KCTD16,GPHN,NRXN1,GRM7,CACNA1A,DLG3,KCNC1,PDE2A,GABRB2,GRIA3,TENM1,DPP10,GABBR2,RIMS2,CACNA1G,GRID2,ALK,GABRA1,SYT1,CACNA1H,STXBP5,CHRM2,GRIN1,SCN8A,CNTN5,KCNIP2,GRIK2,GPR85,NRXN2,NRG3 |
3.207e-14 | -31.07 | - | gene3d domains | 1.10.287.70 | 148 | 12 | 14470 | 47 |
GRIN1,HCN1,KCNMA1,KCNT1,SCN8A,GRIK2,GRID2,CACNA1H,CACNA1G,KCNC1,CACNA1A,GRIA3 |
4.915e-14 | -30.64 | ligand-gated monoatomic ion channel activity | molecular function | GO:0015276 | 186 | 12 | 18094 | 48 |
GRIK2,KCNT1,GRID2,GABRD,GABRA1,GRIA3,GRIN1,GRIN2B,ASIC2,HCN1,KCNMA1,GABRB2 |
5.242e-14 | -30.58 | ligand-gated channel activity | molecular function | GO:0022834 | 187 | 12 | 18094 | 48 |
GRIN1,GRIK2,KCNT1,GRIN2B,ASIC2,HCN1,GRID2,KCNMA1,GABRD,GABRA1,GABRB2,GRIA3 |
1.257e-13 | -29.71 | regulation of postsynaptic membrane potential | biological process | GO:0060078 | 106 | 10 | 18204 | 47 |
HCN1,GRID2,GRIN2B,GRIA3,GRIN1,GRIK2,GABRB2,GABRD,GABRA1,CELF4 |
2.158e-13 | -29.16 | Protein-protein interactions at synapses | REACTOME pathways | R-HSA-6794362 | 72 | 9 | 10285 | 29 |
GRIN1,DLG4,GRIA3,SYT1,NRXN1,DLG3,NRXN2,SYT7,GRIN2B |
2.478e-13 | -29.03 | neuron to neuron synapse | cellular component | GO:0098984 | 365 | 14 | 19108 | 49 |
GRIA3,GRM7,GPHN,DLG3,CHRM2,SCN8A,GRIN1,GRIK2,SYT1,DLG4,STXBP5,GRIN2B,GRID2,SYT7 |
2.536e-13 | -29.00 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 18 | 18094 | 48 |
KCNT1,GRIK2,GABRA1,GRIA3,GRID2,GABRD,CACNA1A,GRIN2B,ASIC2,HCN1,KCNIP2,GRIN1,CACNA1G,KCNC1,CACNA1H,SCN8A,GABRB2,KCNMA1 |
4.632e-13 | -28.40 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 18 | 18204 | 47 |
GRIN2B,CACNA1G,SCN8A,CACNA1A,ASIC2,CACNA1H,GABRD,GRIN1,KCNIP2,GRIA3,KCNC1,GRID2,HCN1,KCNT1,KCNMA1,GABRA1,GABRB2,GRIK2 |
6.071e-13 | -28.13 | cell periphery | cellular component | GO:0071944 | 6020 | 40 | 19108 | 49 |
GPR85,NRXN2,NRG3,CHRM2,CNTN5,SCN8A,GRIN1,KCNIP2,GRIK2,GABRA1,SYT1,CACNA1H,STXBP5,GABBR2,CACNA1G,RIMS2,ALK,GRID2,GRIA3,TENM1,DPP10,NRXN1,GPHN,GRM7,CACNA1A,DLG3,KCNC1,PDE2A,GABRB2,KCNMA1,ASIC2,DLG4,KCTD16,CSMD2,GRIN2B,NTRK3,GABRD,HCN1,SYT7,KCNT1 |
9.030e-13 | -27.73 | membrane protein complex | cellular component | GO:0098796 | 1261 | 21 | 19108 | 49 |
CACNA1G,GRIN2B,GABBR2,HCN1,GRID2,GABRD,KCNMA1,GABRA1,STXBP5,CACNA1H,DLG4,KCNC1,CACNA1A,DLG3,GABRB2,KCNIP2,GRIK2,GRIN1,SCN8A,DPP10,GRIA3 |
1.526e-12 | -27.21 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 17 | 18094 | 48 |
KCNMA1,GABRB2,SCN8A,CACNA1H,KCNC1,CACNA1G,GRIN1,KCNIP2,HCN1,ASIC2,GRIN2B,CACNA1A,GABRD,GRIA3,GABRA1,KCNT1,GRIK2 |
2.081e-12 | -26.90 | regulation of biological quality | biological process | GO:0065008 | 2936 | 29 | 18204 | 47 |
NRXN1,HCN1,OLFM1,GPHN,KCNMA1,GRIK2,DLG4,FGF12,CELF4,SYT7,GRIN1,CACNA1H,GRIA3,KCNC1,GRID2,KCNIP2,PDE2A,RIMS2,DLG3,GABRA1,GABRB2,GRIN2B,SCN8A,CACNA1G,MCTP1,TENM1,ASIC2,CACNA1A,GABRD |
2.204e-12 | -26.84 | monoatomic cation channel activity | molecular function | GO:0005261 | 331 | 13 | 18094 | 48 |
KCNT1,GRIN2B,GRIK2,ASIC2,HCN1,KCNIP2,GRIN1,KCNC1,CACNA1G,CACNA1H,SCN8A,KCNMA1,CACNA1A |
2.425e-12 | -26.75 | Interactions of neurexins and neuroligins at synapses | REACTOME pathways | R-HSA-6794361 | 58 | 8 | 10285 | 29 |
GRIN1,DLG4,NRXN1,DLG3,SYT1,SYT7,NRXN2,GRIN2B |
2.660e-12 | -26.65 | transmitter-gated monoatomic ion channel activity | molecular function | GO:0022824 | 59 | 8 | 18094 | 48 |
GRIN1,GRIN2B,GRIK2,GRID2,GABRD,GABRA1,GABRB2,GRIA3 |
2.660e-12 | -26.65 | transmitter-gated channel activity | molecular function | GO:0022835 | 59 | 8 | 18094 | 48 |
GRIN1,GRIN2B,GRIK2,GRID2,GABRD,GABRA1,GABRB2,GRIA3 |
3.378e-12 | -26.41 | cation channel complex | cellular component | GO:0034703 | 205 | 11 | 19108 | 49 |
KCNMA1,DPP10,DLG4,CACNA1H,CACNA1A,CACNA1G,KCNC1,SCN8A,GRIK2,KCNIP2,HCN1 |
3.533e-12 | -26.37 | neurotransmitter receptor activity | molecular function | GO:0030594 | 97 | 9 | 18094 | 48 |
GRIN1,CHRM2,GRIK2,GRIN2B,GABRD,GRID2,GABRB2,GRIA3,GABRA1 |
6.530e-12 | -25.75 | ANF_lig-bd_rcpt | interpro domains | IPR001828 | 37 | 7 | 18521 | 50 |
GRIN1,GRID2,GRM7,GRIK2,GABBR2,GRIA3,GRIN2B |
7.101e-12 | -25.67 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 11 | 10285 | 29 |
GRIN1,GRIK2,GABRB2,GRIA3,DLG4,GABRA1,DLG3,SYT1,GRIN2B,GABBR2,CACNA1A |
7.422e-12 | -25.63 | ANF_receptor | pfam domains | PF01094 | 37 | 7 | 17795 | 49 |
GRM7,GRIN2B,GABBR2,GRIN1,GRIK2,GRIA3,GRID2 |
9.716e-12 | -25.36 | Peripla_BP_I | interpro domains | IPR028082 | 39 | 7 | 18521 | 50 |
GRID2,GRIN1,GABBR2,GRIK2,GRM7,GRIN2B,GRIA3 |
9.748e-12 | -25.35 | monoatomic ion transport | biological process | GO:0006811 | 964 | 18 | 18204 | 47 |
GRID2,GRIA3,KCNC1,KCNIP2,HCN1,KCNMA1,KCNT1,GRIK2,GABRB2,GABRA1,CACNA1G,SCN8A,GRIN2B,CACNA1A,ASIC2,GRIN1,GABRD,CACNA1H |
9.813e-12 | -25.35 | ionotropic glutamate receptor complex | cellular component | GO:0008328 | 41 | 7 | 19108 | 49 |
GRIK2,DLG4,GRID2,GRIN1,GRIN2B,DLG3,GRIA3 |
1.108e-11 | -25.23 | postsynaptic neurotransmitter receptor activity | molecular function | GO:0098960 | 70 | 8 | 18094 | 48 |
CHRM2,GRIN2B,GRIK2,GRIA3,GABRB2,GABRA1,GABRD,GRID2 |
1.308e-11 | -25.06 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 17 | 19108 | 49 |
NRXN1,GPHN,GRM7,CACNA1A,KCNC1,CHRM2,GRIN1,KCNIP2,GRIK2,OLFM1,GRIA3,GRID2,GABRD,HCN1,GABRA1,ASIC2,DLG4 |
1.400e-11 | -24.99 | extracellular ligand-gated monoatomic ion channel activity | molecular function | GO:0005230 | 72 | 8 | 18094 | 48 |
GRID2,GABRD,GABRA1,GRIA3,GABRB2,GRIN1,GRIN2B,GRIK2 |
2.093e-11 | -24.59 | voltage-gated monoatomic ion channel activity | molecular function | GO:0005244 | 171 | 10 | 18094 | 48 |
HCN1,KCNT1,GRIN2B,KCNIP2,GRIN1,CACNA1H,CACNA1G,KCNC1,CACNA1A,KCNMA1 |
2.314e-11 | -24.49 | neurotransmitter receptor complex | cellular component | GO:0098878 | 46 | 7 | 19108 | 49 |
GRIK2,GRIN1,GRID2,DLG4,GRIN2B,GRIA3,DLG3 |
2.350e-11 | -24.47 | voltage-gated channel activity | molecular function | GO:0022832 | 173 | 10 | 18094 | 48 |
KCNT1,GRIN2B,HCN1,GRIN1,KCNIP2,CACNA1G,KCNC1,CACNA1H,KCNMA1,CACNA1A |
2.701e-11 | -24.33 | postsynaptic specialization membrane | cellular component | GO:0099634 | 125 | 9 | 19108 | 49 |
DLG4,GRIA3,GRIK2,GABRB2,GRID2,SCN8A,GRIN2B,DLG3,GPHN |
2.719e-11 | -24.33 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 25 | 19108 | 49 |
ASIC2,DLG4,GRIN2B,HCN1,SYT7,NTRK3,GABRD,TENM1,GRIA3,KCNC1,GRM7,GPHN,DLG3,GABRB2,SYT1,GABRA1,GABBR2,GRID2,CHRM2,KCNIP2,OLFM1,GRIK2,CNTN5,SCN8A,GRIN1 |
2.874e-11 | -24.27 | cell communication | biological process | GO:0007154 | 5010 | 35 | 18204 | 47 |
GABBR2,FGF12,DLG4,ALK,CHRM2,CADPS,GRIN1,SYT7,GRM7,CELF4,SYT1,NRXN2,HCN1,NRG3,NRXN1,GRIK2,OLFM1,GPR85,MCTP1,SCN8A,CACNA1G,GRIN2B,GABRD,ASIC2,CACNA1A,TENM1,KCNIP2,NTRK3,GRID2,GRIA3,GABRB2,GABRA1,RIMS2,DLG3,PDE2A |
3.795e-11 | -23.99 | modulation of excitatory postsynaptic potential | biological process | GO:0098815 | 49 | 7 | 18204 | 47 |
GRIK2,GRIN1,CELF4,RIMS2,DLG4,GRIN2B,NRXN1 |
5.575e-11 | -23.61 | glutamate receptor activity | molecular function | GO:0008066 | 26 | 6 | 18094 | 48 |
GRIK2,GRIN2B,GRIN1,GRM7,GRIA3,GRID2 |
8.207e-11 | -23.22 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 13 | 18094 | 48 |
CACNA1H,SCN8A,CACNA1G,KCNC1,CACNA1A,KCNMA1,ASIC2,HCN1,KCNT1,GRIK2,GRIN2B,KCNIP2,GRIN1 |
8.232e-11 | -23.22 | transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | molecular function | GO:1904315 | 53 | 7 | 18094 | 48 |
GRIN2B,GRIK2,GRIA3,GABRB2,GABRA1,GABRD,GRID2 |
1.004e-10 | -23.02 | regulation of system process | biological process | GO:0044057 | 571 | 14 | 18204 | 47 |
CACNA1G,CHRM2,GRIN2B,DLG4,FGF12,CELF2,CELF4,ASIC2,GRIN1,CACNA1H,NRXN1,KCNIP2,RIMS2,GRIK2 |
1.061e-10 | -22.97 | Nicotine addiction | KEGG pathways | ko05033 | 40 | 7 | 7161 | 28 |
GRIN1,GABRD,GRIN2B,GABRB2,CACNA1A,GABRA1,GRIA3 |
1.061e-10 | -22.97 | Nicotine addiction | KEGG pathways | hsa05033 | 40 | 7 | 7161 | 28 |
GRIA3,GABRA1,CACNA1A,GABRB2,GRIN2B,GABRD,GRIN1 |
1.079e-10 | -22.95 | neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential | molecular function | GO:0099529 | 55 | 7 | 18094 | 48 |
GRID2,GABRD,GABRA1,GABRB2,GRIA3,GRIN2B,GRIK2 |
1.437e-10 | -22.66 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | REACTOME pathways | R-HSA-112314 | 146 | 9 | 10285 | 29 |
GRIN1,GRIK2,GABRB2,GRIA3,DLG4,GABRA1,DLG3,GRIN2B,GABBR2 |
1.646e-10 | -22.53 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 15 | 18204 | 47 |
GRIN2B,SCN8A,CACNA1G,CACNA1A,ASIC2,GRIN1,CACNA1H,GABRD,KCNC1,KCNIP2,HCN1,KCNT1,KCNMA1,GABRA1,GABRB2 |
1.664e-10 | -22.52 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 18 | 18094 | 48 |
GRID2,GABRD,CACNA1A,GABRA1,GRIA3,GRIK2,KCNT1,KCNMA1,CACNA1G,KCNC1,CACNA1H,GABRB2,SCN8A,KCNIP2,GRIN1,GRIN2B,ASIC2,HCN1 |
2.151e-10 | -22.26 | - | gene3d domains | 3.40.50.2300 | 50 | 7 | 14470 | 47 |
GRIN1,GRIN2B,GRM7,GRID2,GRIK2,GRIA3,GABBR2 |
2.238e-10 | -22.22 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 14 | 18094 | 48 |
ASIC2,HCN1,GRIN2B,KCNIP2,GRIN1,CACNA1H,SCN8A,CACNA1G,KCNC1,KCNMA1,KCNT1,GRIK2,GRIA3,CACNA1A |
2.934e-10 | -21.95 | dendrite | cellular component | GO:0030425 | 620 | 14 | 19108 | 49 |
ASIC2,DLG4,GABRA1,HCN1,GRID2,GABRD,GRIA3,KCNIP2,GRIK2,GRIN1,KCNC1,CHRM2,GRM7,GPHN |
3.060e-10 | -21.91 | dendritic tree | cellular component | GO:0097447 | 622 | 14 | 19108 | 49 |
HCN1,GABRD,GRID2,ASIC2,DLG4,GABRA1,GRIK2,KCNIP2,GRIN1,CHRM2,KCNC1,GPHN,GRM7,GRIA3 |
4.542e-10 | -21.51 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 30 | 16828 | 48 |
FGF12,CNTN5,KCNMA1,CACNA1G,CELF5,GABRB2,NRXN2,SYT7,RIMS2,CACNA1H,GRIA3,RALYL,CELF4,GRIN1,HCN1,SCN8A,TENM1,ALK,PDE2A,MCTP1,KCNC1,CADPS,NRG3,CACNA1A,SYT1,CSMD2,GRM7,STXBP5,GRID2,NTRK3 |
4.542e-10 | -21.51 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 30 | 16828 | 48 |
STXBP5,GRM7,CSMD2,SYT1,CACNA1A,NTRK3,GRID2,PDE2A,ALK,TENM1,SCN8A,HCN1,NRG3,CADPS,KCNC1,MCTP1,CACNA1H,RIMS2,CELF4,GRIN1,RALYL,GRIA3,GABRB2,CELF5,KCNMA1,CACNA1G,FGF12,CNTN5,SYT7,NRXN2 |
5.431e-10 | -21.33 | axon | cellular component | GO:0030424 | 650 | 14 | 19108 | 49 |
KCNC1,CHRM2,GRM7,OLFM1,GRIK2,GRIN1,CNTN5,SCN8A,HCN1,SYT7,NTRK3,GABRD,SYT1,DLG4 |
6.165e-10 | -21.21 | asymmetric synapse | cellular component | GO:0032279 | 333 | 11 | 19108 | 49 |
GRIA3,CHRM2,DLG3,GRM7,GPHN,GRIK2,SCN8A,GRIN1,DLG4,GRIN2B,GRID2 |
6.243e-10 | -21.19 | synapse assembly | biological process | GO:0007416 | 118 | 8 | 18204 | 47 |
ASIC2,GABRA1,GABRB2,NRXN1,NRG3,GRID2,NRXN2,CNTN5 |
6.824e-10 | -21.11 | transporter activity | molecular function | GO:0005215 | 1211 | 18 | 18094 | 48 |
GRIN2B,ASIC2,HCN1,KCNIP2,GRIN1,CACNA1G,KCNC1,CACNA1H,GABRB2,SCN8A,KCNMA1,GRIK2,KCNT1,GABRA1,GRIA3,GRID2,CACNA1A,GABRD |
7.144e-10 | -21.06 | regulation of nervous system process | biological process | GO:0031644 | 120 | 8 | 18204 | 47 |
GRIK2,GRIN1,CELF4,RIMS2,DLG4,FGF12,NRXN1,GRIN2B |
8.236e-10 | -20.92 | transmembrane transport | biological process | GO:0055085 | 1264 | 18 | 18204 | 47 |
GRIK2,GABRA1,GABRB2,KCNT1,KCNMA1,HCN1,GRIA3,KCNC1,GRID2,KCNIP2,GRIN1,CACNA1H,GABRD,ASIC2,CACNA1A,GRIN2B,CACNA1G,SCN8A |
9.741e-10 | -20.75 | Iontro_rcpt_C | interpro domains | IPR001320 | 18 | 5 | 18521 | 50 |
GRIN1,GRIA3,GRID2,GRIN2B,GRIK2 |
9.741e-10 | -20.75 | Ionotropic_Glu_rcpt | interpro domains | IPR015683 | 18 | 5 | 18521 | 50 |
GRIK2,GRIA3,GRIN1,GRID2,GRIN2B |
9.741e-10 | -20.75 | Glu/Gly-bd | interpro domains | IPR019594 | 18 | 5 | 18521 | 50 |
GRIA3,GRIN1,GRIN2B,GRID2,GRIK2 |
9.741e-10 | -20.75 | Iono_Glu_rcpt_met | interpro domains | IPR001508 | 18 | 5 | 18521 | 50 |
GRIK2,GRIA3,GRIN1,GRID2,GRIN2B |
1.070e-09 | -20.66 | Lig_chan-Glu_bd | pfam domains | PF10613 | 18 | 5 | 17795 | 49 |
GRIN2B,GRIK2,GRIA3,GRIN1,GRID2 |
1.070e-09 | -20.66 | Lig_chan | pfam domains | PF00060 | 18 | 5 | 17795 | 49 |
GRIA3,GRIN1,GRIK2,GRID2,GRIN2B |
1.076e-09 | -20.65 | signaling | biological process | GO:0023052 | 4968 | 33 | 18204 | 47 |
GRIK2,OLFM1,GPR85,SYT1,NRXN2,NRG3,NRXN1,GRIN1,SYT7,GRM7,CELF4,GABBR2,FGF12,DLG4,ALK,CADPS,CHRM2,GABRB2,GABRA1,DLG3,RIMS2,PDE2A,KCNIP2,NTRK3,GRID2,GRIA3,GABRD,ASIC2,CACNA1A,TENM1,MCTP1,CACNA1G,GRIN2B |
1.200e-09 | -20.54 | plasma membrane signaling receptor complex | cellular component | GO:0098802 | 191 | 9 | 19108 | 49 |
GRIK2,GRID2,GRIN1,GRIN2B,GABBR2,DLG3,STXBP5,DLG4,GRIA3 |
1.606e-09 | -20.25 | glutamate receptor signaling pathway | biological process | GO:0007215 | 45 | 6 | 18204 | 47 |
GRID2,GRIA3,GRIN2B,GRM7,GRIN1,GRIK2 |
1.687e-09 | -20.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 15 | 16828 | 48 |
ALK,PDE2A,HCN1,NRG3,SYT7,GABBR2,MCTP1,GRM7,OLFM1,SYT1,GRIN2B,CSMD2,RALYL,GRID2,CELF4 |
1.843e-09 | -20.11 | receptor clustering | biological process | GO:0043113 | 46 | 6 | 18204 | 47 |
NRXN2,DLG4,GRIK2,DLG3,GPHN,NRXN1 |
2.445e-09 | -19.83 | SALM protein interactions at the synapses | REACTOME pathways | R-HSA-8849932 | 21 | 5 | 10285 | 29 |
GRIN1,DLG3,DLG4,GRIN2B,GRIA3 |
2.741e-09 | -19.71 | Neuroactive ligand-receptor interaction | KEGG pathways | hsa04080 | 276 | 11 | 7161 | 28 |
GRM7,GABRA1,GABRD,GRID2,GRIK2,GRIA3,CHRM2,GRIN1,GABRB2,GABBR2,GRIN2B |
2.741e-09 | -19.71 | Neuroactive ligand-receptor interaction | KEGG pathways | ko04080 | 276 | 11 | 7161 | 28 |
GRIN1,GRIN2B,GABBR2,GABRB2,GRID2,CHRM2,GRIA3,GRIK2,GABRD,GRM7,GABRA1 |
3.612e-09 | -19.44 | voltage-gated monoatomic cation channel activity | molecular function | GO:0022843 | 143 | 8 | 18094 | 48 |
KCNMA1,CACNA1A,KCNC1,CACNA1G,CACNA1H,KCNIP2,KCNT1,HCN1 |
3.689e-09 | -19.42 | nervous system development | biological process | GO:0007399 | 2185 | 22 | 18204 | 47 |
GABRA1,GABRB2,OLFM1,HCN1,NRXN2,NTRK3,KCNIP2,KCNC1,NRXN1,NRG3,GRID2,GRIN1,GRM7,ASIC2,TENM1,FGF12,CNTN5,DLG4,ALK,GRIN2B,CHRM2,SCN8A |
4.327e-09 | -19.26 | PBPe | smart domains | SM00079 | 18 | 5 | 9717 | 36 |
GRIN1,GRIA3,GRIN2B,GRID2,GRIK2 |
4.327e-09 | -19.26 | Lig_chan-Glu_bd | smart domains | SM00918 | 18 | 5 | 9717 | 36 |
GRIA3,GRIN2B,GRIK2,GRID2,GRIN1 |
5.722e-09 | -18.98 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 11 | 19108 | 49 |
CADPS,CHRM2,DLG3,GRIK2,SCN8A,NRXN2,NRG3,HCN1,GRID2,SYT1,DLG4 |
6.141e-09 | -18.91 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 13 | 18094 | 48 |
GRIK2,KCNT1,CACNA1A,KCNIP2,GRIN1,GRIN2B,ASIC2,HCN1,KCNMA1,CACNA1G,KCNC1,CACNA1H,SCN8A |
6.687e-09 | -18.82 | potassium channel complex | cellular component | GO:0034705 | 101 | 7 | 19108 | 49 |
DLG4,HCN1,KCNIP2,GRIK2,KCNMA1,KCNC1,DPP10 |
6.687e-09 | -18.82 | postsynaptic density membrane | cellular component | GO:0098839 | 101 | 7 | 19108 | 49 |
GRIA3,DLG3,GRIN2B,GRID2,SCN8A,DLG4,GRIK2 |
7.259e-09 | -18.74 | membrane | cellular component | GO:0016020 | 9220 | 43 | 19108 | 49 |
GRID2,ALK,GABBR2,RIMS2,CACNA1G,CACNA1H,STXBP5,GABRA1,SYT1,SCN8A,GRIN1,CNTN5,KCNIP2,GRIK2,CADPS,CHRM2,NRG3,GPR85,NRXN2,NTRK3,GABRD,HCN1,MCTP1,KCNT1,SYT7,CSMD2,GRIN2B,DLG4,ASIC2,KCTD16,KCNMA1,PDE2A,GABRB2,NRXN1,GRM7,CACNA1A,GPHN,DLG3,KCNC1,CSMD1,GRIA3,TENM1,DPP10 |
9.354e-09 | -18.49 | Periplasmic binding protein-like II | gene3d domains | 3.40.190.10 | 23 | 5 | 14470 | 47 |
GRIN1,GRIK2,GRIN2B,GRID2,GRIA3 |
1.042e-08 | -18.38 | synapse organization | biological process | GO:0050808 | 333 | 10 | 18204 | 47 |
GABRB2,GABRA1,GPHN,ASIC2,NRXN2,DLG4,CNTN5,NRG3,GRID2,NRXN1 |
1.422e-08 | -18.07 | postsynaptic specialization | cellular component | GO:0099572 | 345 | 10 | 19108 | 49 |
DLG4,GRIA3,GRIK2,GABRB2,GRID2,GRIN1,SCN8A,GRIN2B,DLG3,GPHN |
1.526e-08 | -18.00 | excitatory synapse | cellular component | GO:0060076 | 65 | 6 | 19108 | 49 |
DLG4,GRIA3,SYT1,GRIN1,SCN8A,GRID2 |
1.632e-08 | -17.93 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 7 | 18521 | 50 |
KCNC1,CACNA1H,CACNA1G,HCN1,SCN8A,CACNA1A,KCNMA1 |
1.761e-08 | -17.85 | positive regulation of excitatory postsynaptic potential | biological process | GO:2000463 | 32 | 5 | 18204 | 47 |
RIMS2,NRXN1,GRIN2B,DLG4,GRIN1 |
1.851e-08 | -17.81 | Ion_trans | pfam domains | PF00520 | 109 | 7 | 17795 | 49 |
KCNC1,CACNA1G,SCN8A,KCNMA1,HCN1,CACNA1H,CACNA1A |
2.213e-08 | -17.63 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 13 | 16828 | 48 |
GRIA3,CELF4,GRID2,RALYL,CELF2,GRM7,NRXN1,MCTP1,NRG3,SYT7,DPP10,FGF12,SCN8A |
2.254e-08 | -17.61 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 13 | 16828 | 48 |
SCN8A,FGF12,MCTP1,NRXN1,DPP10,NRG3,SYT7,GRM7,CELF2,GRIA3,RALYL,GRID2,CELF4 |
2.878e-08 | -17.36 | action potential | biological process | GO:0001508 | 124 | 7 | 18204 | 47 |
GRIK2,HCN1,FGF12,KCNC1,SCN8A,CACNA1G,KCNIP2 |
3.510e-08 | -17.17 | system process | biological process | GO:0003008 | 2015 | 20 | 18204 | 47 |
FGF12,CNTN5,DLG4,GRIN2B,SCN8A,CACNA1G,CACNA1H,GRIN1,GRM7,CSMD1,ASIC2,CELF4,HCN1,NRXN2,KCNIP2,NRXN1,GRID2,GRIK2,KCNMA1,PDE2A |
3.572e-08 | -17.15 | NMDARECEPTOR | prints domains | PR00177 | 18 | 5 | 5227 | 30 |
GRIA3,GRIN1,GRIK2,GRID2,GRIN2B |
3.710e-08 | -17.11 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 12 | 18204 | 47 |
GRIN2B,CACNA1G,SCN8A,ASIC2,CACNA1A,CACNA1H,GRIN1,KCNIP2,KCNC1,HCN1,KCNT1,KCNMA1 |
4.394e-08 | -16.94 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 6 | 18204 | 47 |
NRXN1,GRIN2B,GRM7,GRIK2,GRIN1,SYT1 |
4.581e-08 | -16.90 | metal ion transport | biological process | GO:0030001 | 630 | 12 | 18204 | 47 |
KCNC1,KCNIP2,HCN1,KCNT1,KCNMA1,GRIN2B,SCN8A,CACNA1G,CACNA1A,ASIC2,GRIN1,CACNA1H |
5.082e-08 | -16.79 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 12 | 18204 | 47 |
KCNT1,KCNMA1,KCNIP2,KCNC1,HCN1,CACNA1A,ASIC2,CACNA1H,GRIN1,GRIN2B,CACNA1G,SCN8A |
6.280e-08 | -16.58 | ligand-gated monoatomic cation channel activity | molecular function | GO:0099094 | 135 | 7 | 18094 | 48 |
KCNMA1,GRIN1,KCNT1,GRIN2B,GRIK2,ASIC2,HCN1 |
7.138e-08 | -16.46 | localization | biological process | GO:0051179 | 4474 | 29 | 18204 | 47 |
GABRD,ASIC2,CACNA1A,CACNA1G,SCN8A,GRIN2B,GABRB2,GABRA1,RIMS2,DLG3,STXBP5,KCNIP2,GRID2,KCNC1,GRIA3,CACNA1H,GRIN1,SYT7,DPP10,DLG4,CADPS,GRIK2,KCNMA1,KCNT1,GPHN,SYT1,NRXN2,HCN1,NRXN1 |
7.749e-08 | -16.37 | glutamate-gated receptor activity | molecular function | GO:0004970 | 16 | 4 | 18094 | 48 |
GRIA3,GRIN2B,GRIK2,GRIN1 |
7.820e-08 | -16.36 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 18 | 16828 | 48 |
GRID2,CELF4,RALYL,KCTD16,GRM7,CSMD2,SYT1,GRIN2B,NRG3,SYT7,MCTP1,KCNIP2,PDE2A,ALK,CACNA1G,FGF12,CNTN5,HCN1 |
7.820e-08 | -16.36 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 18 | 16828 | 48 |
NRG3,SYT7,KCNIP2,MCTP1,ALK,PDE2A,CACNA1G,CNTN5,HCN1,FGF12,RALYL,GRID2,CELF4,KCTD16,GRM7,SYT1,GRIN2B,CSMD2 |
8.111e-08 | -16.33 | regulation of synaptic plasticity | biological process | GO:0048167 | 219 | 8 | 18204 | 47 |
GRID2,GRIN2B,DLG4,MCTP1,RIMS2,GRIN1,SYT7,GRIK2 |
9.748e-08 | -16.14 | postsynaptic density | cellular component | GO:0014069 | 317 | 9 | 19108 | 49 |
GRIK2,GRIN1,GRID2,SCN8A,GRIN2B,DLG3,GPHN,DLG4,GRIA3 |
9.833e-08 | -16.13 | signal release from synapse | biological process | GO:0099643 | 88 | 6 | 18204 | 47 |
SYT1,SYT7,NRXN2,RIMS2,NRXN1,CADPS |
9.833e-08 | -16.13 | neurotransmitter secretion | biological process | GO:0007269 | 88 | 6 | 18204 | 47 |
SYT7,NRXN2,SYT1,NRXN1,CADPS,RIMS2 |
1.059e-07 | -16.06 | GRIK5 (glutamate ionotropic receptor kainate type subunit 5) | protein interactions | 2901 | 18 | 4 | 19454 | 49 |
GRID2,DLG3,GRIK2,DLG4 |
1.096e-07 | -16.03 | voltage-gated potassium channel complex | cellular component | GO:0008076 | 90 | 6 | 19108 | 49 |
KCNIP2,HCN1,KCNC1,DLG4,KCNMA1,DPP10 |
1.096e-07 | -16.03 | multicellular organism development | biological process | GO:0007275 | 3957 | 27 | 18204 | 47 |
HCN1,NRXN2,NRXN1,NRG3,OLFM1,FGF12,DLG4,ALK,CHRM2,GRIN1,GRM7,CELF4,NTRK3,KCNIP2,KCNC1,GRID2,GABRA1,GABRB2,DLG3,PDE2A,CNTN5,GRIN2B,CACNA1G,SCN8A,ASIC2,CSMD1,TENM1 |
1.127e-07 | -16.00 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 28 | 16828 | 48 |
CSMD2,GRIN2B,SYT1,GRM7,KCNT1,GRID2,NTRK3,TENM1,HCN1,SCN8A,PDE2A,ALK,KCNC1,MCTP1,NRG3,RIMS2,OLFM1,CACNA1H,GRIA3,KCTD16,GRIN1,CELF4,CNTN5,FGF12,CACNA1G,CHRM2,NRXN1,GABBR2 |
1.127e-07 | -16.00 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 28 | 16828 | 48 |
NRXN1,GABBR2,CACNA1G,CNTN5,FGF12,CHRM2,GRIA3,KCTD16,GRIN1,CELF4,RIMS2,CACNA1H,OLFM1,KCNC1,MCTP1,NRG3,TENM1,SCN8A,HCN1,PDE2A,ALK,KCNT1,GRID2,NTRK3,CSMD2,SYT1,GRIN2B,GRM7 |
1.183e-07 | -15.95 | Unblocking of NMDA receptor, glutamate binding and activation | REACTOME pathways | R-HSA-438066 | 17 | 4 | 10285 | 29 |
DLG4,GRIA3,GRIN2B,GRIN1 |
1.339e-07 | -15.83 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 4 | 19454 | 49 |
DLG3,NRXN2,NRXN1,DLG4 |
1.461e-07 | -15.74 | positive regulation of synaptic transmission | biological process | GO:0050806 | 157 | 7 | 18204 | 47 |
GRIK2,GRIN1,RIMS2,SYT1,DLG4,GRIN2B,NRXN1 |
1.498e-07 | -15.71 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 13 | 16828 | 48 |
GRID2,CELF4,RALYL,GRIA3,CELF2,GRM7,NRG3,SYT7,DPP10,NRXN1,MCTP1,SCN8A,FGF12 |
1.746e-07 | -15.56 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 3 | 18094 | 48 |
NRXN1,DLG4,NRXN2 |
1.762e-07 | -15.55 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 34 | 16828 | 48 |
FGF12,CNTN5,KCNMA1,GPR85,CACNA1G,GABRB2,NRXN2,SYT7,DPP10,RIMS2,OLFM1,CACNA1H,GRIA3,KCTD16,GRIK2,CELF4,GRIN1,HCN1,SCN8A,PDE2A,ALK,KCNC1,MCTP1,CADPS,NRG3,GABRA1,CSMD2,CACNA1A,GRIN2B,STXBP5,GRM7,KCNT1,GRID2,NTRK3 |
1.762e-07 | -15.55 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 34 | 16828 | 48 |
GABRB2,KCNMA1,CACNA1G,GPR85,CNTN5,FGF12,SYT7,DPP10,NRXN2,CACNA1H,OLFM1,RIMS2,GRIK2,CELF4,GRIN1,GRIA3,KCTD16,PDE2A,ALK,SCN8A,HCN1,CADPS,GABRA1,NRG3,KCNC1,MCTP1,STXBP5,GRM7,CSMD2,GRIN2B,CACNA1A,NTRK3,GRID2,KCNT1 |
1.934e-07 | -15.46 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 7 | 7161 | 28 |
GRM7,GRIA3,GRIK2,GRIN1,CACNA1A,GRIN2B,DLG4 |
1.934e-07 | -15.46 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 7 | 7161 | 28 |
GRIN1,CACNA1A,DLG4,GRIN2B,GRM7,GRIK2,GRIA3 |
2.212e-07 | -15.32 | GABA receptor complex | cellular component | GO:1902710 | 21 | 4 | 19108 | 49 |
GABRD,GABRB2,GABBR2,GABRA1 |
2.440e-07 | -15.23 | system development | biological process | GO:0048731 | 3533 | 25 | 18204 | 47 |
GRM7,GRIN1,ALK,CHRM2,FGF12,DLG4,OLFM1,NRXN1,NRG3,HCN1,NRXN2,CSMD1,ASIC2,TENM1,GRIN2B,CACNA1G,SCN8A,CNTN5,PDE2A,GABRA1,GABRB2,NTRK3,KCNIP2,KCNC1,GRID2 |
3.016e-07 | -15.01 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 36 | 16828 | 48 |
NRXN1,NRXN2,GABBR2,SYT7,DPP10,CNTN5,FGF12,KCNMA1,CACNA1G,GABRB2,GRIA3,KCTD16,CELF4,GRIK2,DLG4,RALYL,RIMS2,CELF2,OLFM1,CACNA1H,KCNC1,MCTP1,NRG3,CADPS,GABRA1,TENM1,HCN1,PDE2A,ALK,KCNT1,GRID2,CSMD2,CACNA1A,GRIN2B,STXBP5,GRM7 |
3.078e-07 | -14.99 | GABA receptor activity | molecular function | GO:0016917 | 22 | 4 | 18094 | 48 |
GABRB2,GABBR2,GABRA1,GABRD |
3.167e-07 | -14.97 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 38 | 16828 | 48 |
CELF4,GRIK2,FAM131A,RALYL,GRIA3,KCTD16,CACNA1H,OLFM1,RIMS2,DLG3,DPP10,NRXN2,NRXN1,GABBR2,KCNIP2,GABRB2,CHRM2,GABRD,CACNA1G,KCNMA1,GPR85,CNTN5,NTRK3,KCNT1,STXBP5,GRM7,CSMD2,GRIN2B,SYT1,CACNA1A,NRG3,GABRA1,CADPS,KCNC1,ALK,TENM1,SCN8A,HCN1 |
3.167e-07 | -14.97 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 38 | 16828 | 48 |
KCNT1,NTRK3,CSMD2,GRIN2B,SYT1,CACNA1A,STXBP5,GRM7,KCNC1,NRG3,GABRA1,CADPS,TENM1,SCN8A,HCN1,ALK,KCTD16,GRIA3,GRIK2,CELF4,FAM131A,RALYL,RIMS2,CACNA1H,OLFM1,NRXN2,NRXN1,GABBR2,KCNIP2,DLG3,DPP10,GABRD,GPR85,KCNMA1,CACNA1G,CNTN5,GABRB2,CHRM2 |
3.331e-07 | -14.91 | ionotropic glutamate receptor signaling pathway | biological process | GO:0035235 | 23 | 4 | 18204 | 47 |
GRIN1,GRIK2,GRIA3,GRIN2B |
3.604e-07 | -14.84 | establishment of localization | biological process | GO:0051234 | 3887 | 26 | 18204 | 47 |
GRIK2,KCNMA1,KCNT1,SYT1,NRXN2,HCN1,NRXN1,CACNA1H,GRIN1,SYT7,DLG4,CADPS,GABRB2,GABRA1,RIMS2,STXBP5,KCNIP2,GRID2,KCNC1,GRIA3,GABRD,CACNA1A,ASIC2,SCN8A,CACNA1G,GRIN2B |
3.676e-07 | -14.82 | behavior | biological process | GO:0007610 | 619 | 11 | 18204 | 47 |
GRIK2,GRIN1,GRM7,CSMD1,FGF12,DLG4,HCN1,NRXN2,ALK,NRXN1,GRIN2B |
3.801e-07 | -14.78 | monoatomic cation transport | biological process | GO:0006812 | 766 | 12 | 18204 | 47 |
KCNC1,KCNIP2,HCN1,KCNT1,KCNMA1,GRIN2B,CACNA1G,SCN8A,ASIC2,CACNA1A,GRIN1,CACNA1H |
3.812e-07 | -14.78 | regulation of neuronal synaptic plasticity | biological process | GO:0048168 | 58 | 5 | 18204 | 47 |
GRIN1,GRIK2,DLG4,MCTP1,GRIN2B |
3.862e-07 | -14.77 | transport | biological process | GO:0006810 | 3615 | 25 | 18204 | 47 |
NRXN1,SYT1,HCN1,NRXN2,KCNT1,KCNMA1,GRIK2,CADPS,CACNA1H,SYT7,GRIN1,KCNIP2,GRIA3,KCNC1,GRID2,STXBP5,RIMS2,GABRA1,GABRB2,GRIN2B,SCN8A,CACNA1G,CACNA1A,ASIC2,GABRD |
4.518e-07 | -14.61 | transmembrane signaling receptor activity | molecular function | GO:0004888 | 1251 | 15 | 18094 | 48 |
GPR85,GABBR2,GRIK2,GRID2,GABRD,GABRA1,GRIA3,ALK,GRIN1,GRIN2B,CHRM2,NTRK3,NRXN2,GRM7,GABRB2 |
4.775e-07 | -14.55 | DLG2 (discs large MAGUK scaffold protein 2) | protein interactions | 1740 | 62 | 5 | 19454 | 49 |
GRIN1,GRIN2B,GRID2,DLG4,DLG3 |
6.059e-07 | -14.32 | cell junction assembly | biological process | GO:0034329 | 285 | 8 | 18204 | 47 |
NRXN1,GRID2,NRG3,CNTN5,NRXN2,ASIC2,GABRA1,GABRB2 |
6.359e-07 | -14.27 | signaling receptor activity | molecular function | GO:0038023 | 1474 | 16 | 18094 | 48 |
GABRD,GRID2,GRIA3,ALK,GABRA1,GPR85,GABBR2,GRIK2,NRXN1,GRM7,GABRB2,NRXN2,NTRK3,GRIN1,CHRM2,GRIN2B |
6.359e-07 | -14.27 | molecular transducer activity | molecular function | GO:0060089 | 1474 | 16 | 18094 | 48 |
GRIN1,GRIN2B,CHRM2,NRXN1,NTRK3,NRXN2,GABRB2,GRM7,GPR85,GRIK2,GABBR2,GRID2,GABRD,GABRA1,GRIA3,ALK |
6.955e-07 | -14.18 | GRIK2 (glutamate ionotropic receptor kainate type subunit 2) | protein interactions | 2898 | 28 | 4 | 19454 | 49 |
GRID2,DLG3,GRIK2,DLG4 |
7.295e-07 | -14.13 | Volt_channel_dom_sf | interpro domains | IPR027359 | 63 | 5 | 18521 | 50 |
KCNC1,CACNA1G,SCN8A,CACNA1H,CACNA1A |
7.630e-07 | -14.09 | synaptic transmission, GABAergic | biological process | GO:0051932 | 28 | 4 | 18204 | 47 |
GABRD,GABRB2,GABBR2,GABRA1 |
7.897e-07 | -14.05 | excitatory postsynaptic potential | biological process | GO:0060079 | 67 | 5 | 18204 | 47 |
GRIK2,GRIN1,CELF4,GRIN2B,GRID2 |
8.083e-07 | -14.03 | potassium channel activity | molecular function | GO:0005267 | 122 | 6 | 18094 | 48 |
KCNC1,KCNT1,GRIK2,HCN1,KCNMA1,KCNIP2 |
8.175e-07 | -14.02 | cell junction organization | biological process | GO:0034330 | 532 | 10 | 18204 | 47 |
ASIC2,GPHN,GABRB2,GABRA1,NRG3,GRID2,NRXN1,CNTN5,NRXN2,DLG4 |
8.793e-07 | -13.94 | GABAergic synapse | KEGG pathways | ko04727 | 88 | 6 | 7161 | 28 |
GABRB2,CACNA1A,GABBR2,GPHN,GABRD,GABRA1 |
8.793e-07 | -13.94 | GABAergic synapse | KEGG pathways | hsa04727 | 88 | 6 | 7161 | 28 |
GABRA1,GABRB2,CACNA1A,GABBR2,GABRD,GPHN |
8.834e-07 | -13.94 | regulation of presynaptic membrane potential | biological process | GO:0099505 | 29 | 4 | 18204 | 47 |
GRIK2,GRIA3,GRIN2B,KCNC1 |
8.834e-07 | -13.94 | gamma-aminobutyric acid signaling pathway | biological process | GO:0007214 | 29 | 4 | 18204 | 47 |
GABRA1,GABRB2,GABRD,GABBR2 |
8.834e-07 | -13.94 | postsynaptic membrane organization | biological process | GO:0001941 | 29 | 4 | 18204 | 47 |
DLG4,NRXN2,NRXN1,GPHN |
8.870e-07 | -13.94 | neuron projection terminus | cellular component | GO:0044306 | 128 | 6 | 19108 | 49 |
KCNC1,SYT1,CHRM2,GRIN1,DLG4,GRIK2 |
1.037e-06 | -13.78 | nervous system process | biological process | GO:0050877 | 1376 | 15 | 18204 | 47 |
FGF12,CNTN5,DLG4,GRIN2B,SCN8A,GRIN1,GRM7,ASIC2,CSMD1,CELF4,HCN1,NRXN2,NRXN1,GRID2,GRIK2 |
1.073e-06 | -13.75 | Morphine addiction | KEGG pathways | hsa05032 | 91 | 6 | 7161 | 28 |
GABRD,GABRA1,CACNA1A,GABBR2,GABRB2,PDE2A |
1.073e-06 | -13.75 | Morphine addiction | KEGG pathways | ko05032 | 91 | 6 | 7161 | 28 |
GABRD,GABRA1,CACNA1A,GABBR2,GABRB2,PDE2A |
1.128e-06 | -13.70 | scaffold protein binding | molecular function | GO:0097110 | 70 | 5 | 18094 | 48 |
GRID2,GRIK2,CACNA1G,DLG4,CACNA1H |
1.214e-06 | -13.62 | chemical synaptic transmission, postsynaptic | biological process | GO:0099565 | 73 | 5 | 18204 | 47 |
GRID2,CELF4,GRIN2B,GRIN1,GRIK2 |
1.330e-06 | -13.53 | ligand-gated ion channel signaling pathway | biological process | GO:1990806 | 32 | 4 | 18204 | 47 |
GRIN2B,GRIA3,GRIK2,GRIN1 |
1.330e-06 | -13.53 | lower_third | COSMIC cancer mutations | lower_third | 7961 | 39 | 16828 | 48 |
KCNT1,GRID2,NTRK3,CACNA1A,GRIN2B,CSMD2,GRM7,STXBP5,KCNC1,CADPS,GABRA1,NRG3,HCN1,SCN8A,TENM1,ALK,PDE2A,KCTD16,GRIA3,FAM131A,RALYL,CELF4,GRIK2,GRIN1,RIMS2,CELF2,CACNA1H,GABBR2,NRXN1,NRXN2,DPP10,SYT7,CNTN5,CACNA1G,KCNMA1,GABRD,CELF5,CHRM2,GABRB2 |
1.512e-06 | -13.40 | regulation of transport | biological process | GO:0051049 | 1621 | 16 | 18204 | 47 |
RIMS2,STXBP5,KCNIP2,KCNC1,SYT1,ASIC2,GRM7,DPP10,TENM1,GRIN1,SYT7,GRIN2B,CADPS,FGF12,MCTP1,DLG4 |
1.539e-06 | -13.38 | neurotransmitter transport | biological process | GO:0006836 | 140 | 6 | 18204 | 47 |
RIMS2,SYT7,NRXN1,CADPS,SYT1,NRXN2 |
1.773e-06 | -13.24 | Voltage-gated potassium channels. Chain C | gene3d domains | 1.20.120.350 | 63 | 5 | 14470 | 47 |
CACNA1A,KCNC1,CACNA1G,CACNA1H,SCN8A |
1.780e-06 | -13.24 | GRIN3A (glutamate ionotropic receptor NMDA type subunit 3A) | protein interactions | 116443 | 10 | 3 | 19454 | 49 |
DLG4,GRIN2B,GRIN1 |
2.426e-06 | -12.93 | response to metal ion | biological process | GO:0010038 | 343 | 8 | 18204 | 47 |
CACNA1G,KCNC1,KCNIP2,DLG4,SYT1,GPHN,KCNMA1,CACNA1H |
2.642e-06 | -12.84 | dense core granule | cellular component | GO:0031045 | 38 | 4 | 19108 | 49 |
SYT7,STXBP5,SYT1,CADPS |
3.009e-06 | -12.71 | Solute-binding_3/MltF_N | interpro domains | IPR001638 | 11 | 3 | 18521 | 50 |
GRIN2B,GRIA3,GRIN1 |
3.053e-06 | -12.70 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 14 | 16828 | 48 |
HCN1,ALK,CHRM2,GABBR2,MCTP1,NRG3,SYT7,GRIN2B,CSMD2,GRM7,RALYL,GRID2,NTRK3,CELF4 |
3.053e-06 | -12.70 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 14 | 16828 | 48 |
GRIN2B,CSMD2,GRM7,RALYL,NTRK3,GRID2,CELF4,HCN1,ALK,CHRM2,GABBR2,MCTP1,NRG3,SYT7 |
3.188e-06 | -12.66 | SBP_bac_3 | pfam domains | PF00497 | 11 | 3 | 17795 | 49 |
GRIN2B,GRIN1,GRIA3 |
3.275e-06 | -12.63 | DLG4 (discs large MAGUK scaffold protein 4) | protein interactions | 1742 | 163 | 6 | 19454 | 49 |
DLG3,GRIN1,DLG4,GRIK2,GRIA3,GRIN2B |
3.653e-06 | -12.52 | potassium ion transmembrane transporter activity | molecular function | GO:0015079 | 158 | 6 | 18094 | 48 |
KCNIP2,KCNMA1,HCN1,KCNC1,KCNT1,GRIK2 |
3.705e-06 | -12.51 | GRIA2 (glutamate ionotropic receptor AMPA type subunit 2) | protein interactions | 2891 | 42 | 4 | 19454 | 49 |
GRID2,GRIK2,DLG4,GRIA3 |
4.360e-06 | -12.34 | Activation of Ca-permeable Kainate Receptor | REACTOME pathways | R-HSA-451308 | 12 | 3 | 10285 | 29 |
GRIK2,DLG3,DLG4 |
4.360e-06 | -12.34 | Ionotropic activity of Kainate Receptors | REACTOME pathways | R-HSA-451306 | 12 | 3 | 10285 | 29 |
DLG3,GRIK2,DLG4 |
4.375e-06 | -12.34 | hippocampal mossy fiber to CA3 synapse | cellular component | GO:0098686 | 43 | 4 | 19108 | 49 |
SYT1,GRIK2,SYT7,STXBP5 |
4.489e-06 | -12.31 | calcium ion transmembrane import into cytosol | biological process | GO:0097553 | 95 | 5 | 18204 | 47 |
CACNA1H,GRIN1,CACNA1A,GRIN2B,CACNA1G |
4.702e-06 | -12.27 | developmental process | biological process | GO:0032502 | 5716 | 30 | 18204 | 47 |
GABRA1,GABRB2,PDE2A,RIMS2,DLG3,KCNC1,GRID2,NTRK3,KCNIP2,TENM1,CSMD1,ASIC2,CNTN5,GRIN2B,SCN8A,CACNA1G,OLFM1,HCN1,NRXN2,SYT1,NRXN1,NRG3,GRIN1,CACNA1H,CELF4,GRM7,DLG4,FGF12,CHRM2,ALK |
4.803e-06 | -12.25 | Activation of NMDA receptor upon glutamate binding and postsynaptic events | REACTOME pathways | R-HSA-442755 | 41 | 4 | 10285 | 29 |
GRIN1,DLG4,GRIA3,GRIN2B |
4.823e-06 | -12.24 | cellular component assembly | biological process | GO:0022607 | 2472 | 19 | 18204 | 47 |
GRIN2B,CNTN5,DLG4,ASIC2,CELF4,CELF2,SYT7,GRIN1,CELF5,NRXN1,KCNC1,GRID2,NRG3,SYT1,HCN1,NRXN2,KCTD16,GABRA1,GABRB2 |
4.908e-06 | -12.22 | synaptic transmission, glutamatergic | biological process | GO:0035249 | 44 | 4 | 18204 | 47 |
GRIK2,GRID2,GRIN2B,GRIA3 |
4.985e-06 | -12.21 | sodium channel activity | molecular function | GO:0005272 | 43 | 4 | 18094 | 48 |
HCN1,SCN8A,ASIC2,GRIK2 |
5.030e-06 | -12.20 | regulation of cell communication | biological process | GO:0010646 | 3541 | 23 | 18204 | 47 |
CHRM2,ALK,DLG4,FGF12,CELF4,GRM7,SYT7,GRIN1,NRXN1,NRG3,SYT1,KCTD16,GRIK2,GRIN2B,MCTP1,TENM1,CACNA1A,GRIA3,GRID2,NTRK3,PDE2A,STXBP5,RIMS2 |
5.195e-06 | -12.17 | VGCC_Ca_Na | interpro domains | IPR043203 | 13 | 3 | 18521 | 50 |
CACNA1G,CACNA1H,SCN8A |
5.245e-06 | -12.16 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 45 | 16828 | 48 |
DLG4,RALYL,KCTD16,CELF2,CACNA1H,DPP10,SYT7,KCNIP2,CHRM2,CNTN5,FGF12,CELF5,NTRK3,GRID2,KCNT1,STXBP5,GRIN2B,SYT1,GPHN,NRG3,KCNC1,HCN1,FAM131A,CELF4,GRIK2,GRIN1,GRIA3,OLFM1,RIMS2,GABBR2,NRXN1,NRXN2,KCNMA1,CACNA1G,GABRD,GRM7,CACNA1A,CSMD2,CADPS,GABRA1,MCTP1,ALK,PDE2A,SCN8A,TENM1 |
5.917e-06 | -12.04 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 36 | 16828 | 48 |
DLG3,SYT7,DPP10,NRXN1,NRXN2,KCNIP2,GABBR2,GABRB2,GABRD,CELF5,CNTN5,FGF12,CACNA1G,GRIN1,CELF4,RALYL,KCTD16,GRIA3,CELF2,CACNA1H,RIMS2,GABRA1,NRG3,MCTP1,PDE2A,ALK,TENM1,HCN1,GRID2,NTRK3,KCNT1,STXBP5,GRM7,CSMD2,GRIN2B,SYT1 |
6.248e-06 | -11.98 | high voltage-gated calcium channel activity | molecular function | GO:0008331 | 14 | 3 | 18094 | 48 |
CACNA1H,CACNA1G,CACNA1A |
6.293e-06 | -11.98 | voltage-gated potassium channel activity | molecular function | GO:0005249 | 99 | 5 | 18094 | 48 |
KCNMA1,KCNIP2,KCNC1,KCNT1,HCN1 |
6.891e-06 | -11.89 | low voltage-gated calcium channel activity | molecular function | GO:0008332 | 2 | 2 | 18094 | 48 |
CACNA1H,CACNA1G |
6.982e-06 | -11.87 | calcium-ion regulated exocytosis | biological process | GO:0017156 | 48 | 4 | 18204 | 47 |
RIMS2,CADPS,SYT1,SYT7 |
7.147e-06 | -11.85 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 14 | 16828 | 48 |
GRIK2,OLFM1,GRM7,CSMD2,CACNA1A,RIMS2,GRIN2B,NRG3,KCNIP2,ALK,CHRM2,CNTN5,HCN1,SCN8A |
7.147e-06 | -11.85 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 14 | 16828 | 48 |
CACNA1A,GRIN2B,RIMS2,CSMD2,GRM7,OLFM1,GRIK2,HCN1,CNTN5,SCN8A,ALK,CHRM2,KCNIP2,NRG3 |
7.941e-06 | -11.74 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 48 | 16828 | 48 |
GRM7,CACNA1A,CSMD2,ALK,PDE2A,SCN8A,TENM1,GABRA1,CADPS,MCTP1,OLFM1,RIMS2,FAM131A,GRIK2,CELF4,GRIN1,GRIA3,KCNMA1,GPR85,CACNA1G,GABRD,GABBR2,NRXN2,NRXN1,STXBP5,SYT1,GRIN2B,NTRK3,GRID2,KCNT1,HCN1,GPHN,NRG3,KCNC1,CACNA1H,CELF2,DLG4,RALYL,KCTD16,CHRM2,GABRB2,FGF12,CNTN5,CELF5,DPP10,SYT7,DLG3,KCNIP2 |
8.459e-06 | -11.68 | signal release | biological process | GO:0023061 | 188 | 6 | 18204 | 47 |
SYT1,SYT7,NRXN2,RIMS2,NRXN1,CADPS |
9.099e-06 | -11.61 | anatomical structure development | biological process | GO:0048856 | 5207 | 28 | 18204 | 47 |
OLFM1,NRXN2,HCN1,NRG3,NRXN1,CACNA1H,GRIN1,GRM7,CELF4,FGF12,DLG4,ALK,CHRM2,GABRB2,GABRA1,DLG3,PDE2A,KCNIP2,NTRK3,GRID2,KCNC1,CSMD1,ASIC2,TENM1,CNTN5,SCN8A,CACNA1G,GRIN2B |
9.207e-06 | -11.60 | SNARE binding | molecular function | GO:0000149 | 107 | 5 | 18094 | 48 |
STXBP5,CACNA1A,SYT1,SYT7,GRIK2 |
9.577e-06 | -11.56 | ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | molecular function | GO:0099507 | 16 | 3 | 18094 | 48 |
GRIK2,GRIN2B,GRIA3 |
9.961e-06 | -11.52 | GRIN2C (glutamate ionotropic receptor NMDA type subunit 2C) | protein interactions | 2905 | 17 | 3 | 19454 | 49 |
DLG3,DLG4,GRIN1 |
1.052e-05 | -11.46 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 33 | 16828 | 48 |
HCN1,ALK,KCNC1,GABRA1,CADPS,NRG3,CSMD2,GRIN2B,CACNA1A,GRM7,KCNT1,GRID2,NTRK3,CELF5,GABRD,CACNA1G,KCNMA1,CNTN5,GABRB2,CHRM2,NRXN2,NRXN1,GABBR2,DPP10,RIMS2,CACNA1H,CELF2,KCTD16,GRIA3,GRIK2,CELF4,FAM131A,RALYL |
1.081e-05 | -11.43 | response to stimulus | biological process | GO:0050896 | 7803 | 35 | 18204 | 47 |
ALK,CHRM2,FGF12,GABBR2,DLG4,GRM7,CELF4,CACNA1H,SYT7,GRIN1,NRXN1,NRG3,SYT1,HCN1,NRXN2,KCNMA1,GPR85,OLFM1,GPHN,GRIK2,GRIN2B,CACNA1G,MCTP1,CSMD1,ASIC2,CACNA1A,TENM1,NTRK3,KCNIP2,KCNC1,GRIA3,GRID2,RIMS2,PDE2A,GABRB2 |
1.105e-05 | -11.41 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 26 | 16828 | 48 |
CACNA1H,RIMS2,CELF4,RALYL,KCTD16,GRIA3,CELF5,FGF12,KCNMA1,SYT7,DPP10,NRXN2,KCNIP2,GABBR2,GRM7,CSMD2,SYT1,GRIN2B,GRID2,ALK,HCN1,SCN8A,NRG3,CADPS,GABRA1,MCTP1 |
1.281e-05 | -11.27 | calcium ion-regulated exocytosis of neurotransmitter | biological process | GO:0048791 | 18 | 3 | 18204 | 47 |
SYT7,SYT1,RIMS2 |
1.298e-05 | -11.25 | cardiac muscle cell action potential | biological process | GO:0086001 | 56 | 4 | 18204 | 47 |
FGF12,SCN8A,CACNA1G,KCNIP2 |
1.335e-05 | -11.22 | CREB phosphorylation through the activation of CaMKII | REACTOME pathways | R-HSA-442729 | 17 | 3 | 10285 | 29 |
DLG4,GRIN2B,GRIN1 |
1.363e-05 | -11.20 | GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) | protein interactions | 2904 | 58 | 4 | 19454 | 49 |
DLG3,DLG4,GRIN2B,GRIN1 |
1.404e-05 | -11.17 | mouth | COSMIC cancer mutations | mouth | 9004 | 40 | 16828 | 48 |
GRIA3,KCTD16,RALYL,DLG4,FAM131A,GRIK2,GRIN1,RIMS2,CELF2,CACNA1H,KCNIP2,GABBR2,NRXN1,NRXN2,DLG3,SYT7,CNTN5,CACNA1G,KCNMA1,GABRD,CELF5,CHRM2,GABRB2,KCNT1,GRID2,NTRK3,CACNA1A,GRIN2B,SYT1,CSMD2,GRM7,MCTP1,KCNC1,CADPS,GABRA1,NRG3,HCN1,SCN8A,ALK,PDE2A |
1.423e-05 | -11.16 | calcium channel activity | molecular function | GO:0005262 | 117 | 5 | 18094 | 48 |
CACNA1A,GRIN1,CACNA1H,GRIN2B,CACNA1G |
1.460e-05 | -11.13 | SYNGAP1 (synaptic Ras GTPase activating protein 1) | protein interactions | 8831 | 59 | 4 | 19454 | 49 |
GRIN1,GRIN2B,DLG4,DLG3 |
1.492e-05 | -11.11 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 3 | 19108 | 49 |
GRID2,SCN8A,GRIA3 |
1.492e-05 | -11.11 | GABA-A receptor complex | cellular component | GO:1902711 | 19 | 3 | 19108 | 49 |
GABRA1,GABRD,GABRB2 |
1.518e-05 | -11.10 | excitatory synapse assembly | biological process | GO:1904861 | 19 | 3 | 18204 | 47 |
NRXN2,NRXN1,GRID2 |
1.518e-05 | -11.10 | vocalization behavior | biological process | GO:0071625 | 19 | 3 | 18204 | 47 |
NRXN1,DLG4,NRXN2 |
1.518e-05 | -11.10 | response to potassium ion | biological process | GO:0035864 | 19 | 3 | 18204 | 47 |
KCNC1,CACNA1H,DLG4 |
1.557e-05 | -11.07 | DLG1 (discs large MAGUK scaffold protein 1) | protein interactions | 1739 | 214 | 6 | 19454 | 49 |
NTRK3,GRIN1,GRIN2B,KCNC1,DLG3,GRIK2 |
1.599e-05 | -11.04 | protein localization to synapse | biological process | GO:0035418 | 59 | 4 | 18204 | 47 |
DLG4,NRXN2,ASIC2,NRXN1 |
1.648e-05 | -11.01 | GABA-A receptor activity | molecular function | GO:0004890 | 19 | 3 | 18094 | 48 |
GABRD,GABRA1,GABRB2 |
1.696e-05 | -10.98 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 33 | 16828 | 48 |
KCNT1,GRID2,NTRK3,CACNA1A,SYT1,GRIN2B,CSMD2,GRM7,MCTP1,KCNC1,NRG3,CADPS,GABRA1,HCN1,SCN8A,ALK,PDE2A,KCTD16,FAM131A,RALYL,DLG4,GRIN1,GRIK2,CACNA1H,GABBR2,NRXN2,DLG3,SYT7,CNTN5,CACNA1G,KCNMA1,GABRD,CELF5 |
1.861e-05 | -10.89 | Baiap2 (brain-specific angiogenesis inhibitor 1-associated protein 2) | protein interactions | 108100 | 3 | 2 | 19454 | 49 |
DLG4,DLG3 |
1.895e-05 | -10.87 | Ras activation uopn Ca2+ infux through NMDA receptor | REACTOME pathways | R-HSA-442982 | 19 | 3 | 10285 | 29 |
GRIN2B,DLG4,GRIN1 |
1.897e-05 | -10.87 | NLGN2 (neuroligin 2) | protein interactions | 57555 | 63 | 4 | 19454 | 49 |
DLG4,NRXN1,NRXN2,DLG3 |
1.906e-05 | -10.87 | syntaxin binding | molecular function | GO:0019905 | 60 | 4 | 18094 | 48 |
SYT7,SYT1,STXBP5,CACNA1A |
1.913e-05 | -10.86 | regulation of signaling | biological process | GO:0023051 | 3534 | 22 | 18204 | 47 |
MCTP1,DLG4,ALK,CHRM2,GRIN2B,GRIN1,SYT7,CACNA1A,GRM7,TENM1,CELF4,SYT1,NTRK3,GRID2,NRG3,GRIA3,NRXN1,GRIK2,RIMS2,STXBP5,PDE2A,KCTD16 |
1.933e-05 | -10.85 | cellular component biogenesis | biological process | GO:0044085 | 2716 | 19 | 18204 | 47 |
CELF5,KCNC1,NRXN1,GRID2,NRG3,SYT1,HCN1,NRXN2,KCTD16,GABRA1,GABRB2,GRIN2B,CNTN5,DLG4,ASIC2,CELF4,CELF2,SYT7,GRIN1 |
1.934e-05 | -10.85 | KCND2 (potassium voltage-gated channel subfamily D member 2) | protein interactions | 3751 | 21 | 3 | 19454 | 49 |
DPP10,DLG4,KCNIP2 |
1.954e-05 | -10.84 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
2.078e-05 | -10.78 | synaptic vesicle exocytosis | biological process | GO:0016079 | 63 | 4 | 18204 | 47 |
CADPS,RIMS2,SYT7,SYT1 |
2.118e-05 | -10.76 | synaptic vesicle | cellular component | GO:0008021 | 222 | 6 | 19108 | 49 |
SYT1,GRIN1,DLG4,MCTP1,STXBP5,SYT7 |
2.139e-05 | -10.75 | VDCC_T_a1 | interpro domains | IPR005445 | 3 | 2 | 18521 | 50 |
CACNA1H,CACNA1G |
2.501e-05 | -10.60 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 17 | 16828 | 48 |
KCNIP2,GABBR2,KCNC1,NRXN2,DPP10,NRG3,FGF12,HCN1,GPR85,ALK,CHRM2,KCTD16,GRIN2B,CSMD2,GRM7,CELF2,STXBP5 |
2.528e-05 | -10.59 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 20 | 16828 | 48 |
ALK,PDE2A,SCN8A,CELF5,GABRA1,CADPS,NRG3,GABBR2,MCTP1,GRM7,OLFM1,RIMS2,GRIN2B,SYT1,CSMD2,RALYL,GRID2,CELF4,GRIA3,KCNT1 |
2.656e-05 | -10.54 | multicellular organismal process | biological process | GO:0032501 | 6177 | 30 | 18204 | 47 |
TENM1,ASIC2,CSMD1,SCN8A,CACNA1G,GRIN2B,CNTN5,PDE2A,DLG3,GABRB2,GABRA1,GRID2,KCNC1,KCNIP2,NTRK3,CELF4,GRM7,GRIN1,CACNA1H,CHRM2,ALK,DLG4,FGF12,OLFM1,KCNMA1,GRIK2,NRG3,NRXN1,NRXN2,HCN1 |
2.673e-05 | -10.53 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 15 | 16828 | 48 |
FAM131A,GRIK2,NTRK3,GRID2,KCTD16,KCNT1,CACNA1H,CACNA1A,RIMS2,DPP10,DLG3,ALK,PDE2A,CNTN5,CACNA1G |
2.673e-05 | -10.53 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 15 | 16828 | 48 |
CACNA1A,RIMS2,CACNA1H,KCNT1,KCTD16,GRIK2,NTRK3,GRID2,FAM131A,CNTN5,CACNA1G,PDE2A,ALK,DLG3,DPP10 |
2.715e-05 | -10.51 | regulation of localization | biological process | GO:0032879 | 2028 | 16 | 18204 | 47 |
TENM1,GRM7,DPP10,ASIC2,SYT7,GRIN1,CADPS,GRIN2B,DLG4,FGF12,MCTP1,STXBP5,RIMS2,KCNC1,KCNIP2,SYT1 |
2.750e-05 | -10.50 | GABAA/Glycine_rcpt | interpro domains | IPR006028 | 22 | 3 | 18521 | 50 |
GABRD,GABRB2,GABRA1 |
2.810e-05 | -10.48 | regulation of monoatomic ion transmembrane transport | biological process | GO:0034765 | 347 | 7 | 18204 | 47 |
KCNIP2,ASIC2,DPP10,KCNC1,GRIN2B,FGF12,GRIN1 |
2.943e-05 | -10.43 | transmembrane transporter binding | molecular function | GO:0044325 | 136 | 5 | 18094 | 48 |
KCNIP2,DPP10,RIMS2,FGF12,KCNC1 |
2.943e-05 | -10.43 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 5 | 18094 | 48 |
CACNA1H,GRIN2B,CACNA1G,CACNA1A,GRIN1 |
2.989e-05 | -10.42 | voltage-gated sodium channel activity | molecular function | GO:0005248 | 23 | 3 | 18094 | 48 |
HCN1,SCN8A,ASIC2 |
3.002e-05 | -10.41 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 5 | 7161 | 28 |
GRIN1,CACNA1G,CACNA1H,GRIN2B,GRIA3 |
3.002e-05 | -10.41 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 5 | 7161 | 28 |
GRIA3,GRIN2B,CACNA1H,GRIN1,CACNA1G |
3.022e-05 | -10.41 | export from cell | biological process | GO:0140352 | 485 | 8 | 18204 | 47 |
KCNIP2,CADPS,NRXN1,SYT1,NRXN2,STXBP5,RIMS2,SYT7 |
3.022e-05 | -10.41 | regulation of transmembrane transport | biological process | GO:0034762 | 485 | 8 | 18204 | 47 |
ASIC2,DPP10,GRIN1,KCNIP2,GRIN2B,KCNC1,FGF12,DLG4 |
3.115e-05 | -10.38 | neuronal cell body | cellular component | GO:0043025 | 489 | 8 | 19108 | 49 |
CACNA1A,NRXN1,CHRM2,KCNC1,GABRD,OLFM1,GRIK2,ASIC2 |
3.215e-05 | -10.34 | muscle contraction | biological process | GO:0006936 | 238 | 6 | 18204 | 47 |
FGF12,CACNA1G,SCN8A,KCNIP2,CACNA1H,KCNMA1 |
3.222e-05 | -10.34 | GRIN2A (glutamate ionotropic receptor NMDA type subunit 2A) | protein interactions | 2903 | 72 | 4 | 19454 | 49 |
GRIN1,GRIN2B,DLG4,DLG3 |
3.360e-05 | -10.30 | exocytic vesicle | cellular component | GO:0070382 | 241 | 6 | 19108 | 49 |
SYT1,DLG4,STXBP5,GRIN1,MCTP1,SYT7 |
3.383e-05 | -10.29 | ion channel regulator activity | molecular function | GO:0099106 | 140 | 5 | 18094 | 48 |
KCNIP2,DPP10,FGF12,NRXN1,NRXN2 |
3.717e-05 | -10.20 | Grin2a (glutamate receptor, ionotropic, NMDA2A (epsilon 1)) | protein interactions | 14811 | 4 | 2 | 19454 | 49 |
GRIN1,GRIN2B |
3.742e-05 | -10.19 | biological regulation | biological process | GO:0065007 | 12501 | 44 | 18204 | 47 |
SYT7,FGF12,CADPS,KCNMA1,GPR85,OLFM1,HCN1,NRXN2,NRG3,CACNA1A,TENM1,GRIN2B,CACNA1G,STXBP5,DLG3,PDE2A,NTRK3,KCNIP2,GRIA3,KCNC1,CACNA1H,GRIN1,GRM7,DPP10,CELF4,GABBR2,DLG4,ALK,CHRM2,GRIK2,GPHN,KCTD16,SYT1,CELF5,NRXN1,GABRD,ASIC2,CELF2,MCTP1,SCN8A,GABRA1,GABRB2,RIMS2,GRID2 |
3.838e-05 | -10.17 | Retrograde endocannabinoid signaling | KEGG pathways | ko04723 | 101 | 5 | 7161 | 28 |
GABRB2,CACNA1A,GABRD,GABRA1,GRIA3 |
3.838e-05 | -10.17 | Retrograde endocannabinoid signaling | KEGG pathways | hsa04723 | 101 | 5 | 7161 | 28 |
GRIA3,GABRA1,GABRD,CACNA1A,GABRB2 |
3.953e-05 | -10.14 | AMPA glutamate receptor complex | cellular component | GO:0032281 | 26 | 3 | 19108 | 49 |
DLG3,GRIA3,DLG4 |
3.994e-05 | -10.13 | neuromuscular process | biological process | GO:0050905 | 149 | 5 | 18204 | 47 |
NRXN1,GRID2,CSMD1,DLG4,FGF12 |
4.002e-05 | -10.13 | channel regulator activity | molecular function | GO:0016247 | 145 | 5 | 18094 | 48 |
KCNIP2,DPP10,FGF12,NRXN1,NRXN2 |
4.027e-05 | -10.12 | response to inorganic substance | biological process | GO:0010035 | 505 | 8 | 18204 | 47 |
KCNMA1,GPHN,CACNA1H,KCNIP2,KCNC1,CACNA1G,SYT1,DLG4 |
4.098e-05 | -10.10 | C2_dom | interpro domains | IPR000008 | 143 | 5 | 18521 | 50 |
CADPS,SYT1,MCTP1,SYT7,RIMS2 |
4.135e-05 | -10.09 | transporter regulator activity | molecular function | GO:0141108 | 146 | 5 | 18094 | 48 |
DPP10,FGF12,NRXN1,KCNIP2,NRXN2 |
4.144e-05 | -10.09 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | biological process | GO:0007193 | 75 | 4 | 18204 | 47 |
GABBR2,PDE2A,CHRM2,GRM7 |
4.145e-05 | -10.09 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 23 | 16828 | 48 |
CACNA1H,GRIA3,KCTD16,CELF4,RALYL,CELF5,FGF12,NRXN2,KCNIP2,GABBR2,SYT7,CSMD2,GRIN2B,SYT1,GRM7,GRID2,HCN1,SCN8A,ALK,MCTP1,GABRA1,CADPS,NRG3 |
4.271e-05 | -10.06 | K_chnl_Slo-like | interpro domains | IPR047871 | 4 | 2 | 18521 | 50 |
KCNT1,KCNMA1 |
4.271e-05 | -10.06 | DLG1-like | interpro domains | IPR016313 | 4 | 2 | 18521 | 50 |
DLG3,DLG4 |
4.271e-05 | -10.06 | DLG1_PEST_dom | interpro domains | IPR019590 | 4 | 2 | 18521 | 50 |
DLG4,DLG3 |
4.271e-05 | -10.06 | DLG1-4_PDZ_assoc | interpro domains | IPR019583 | 4 | 2 | 18521 | 50 |
DLG4,DLG3 |
4.271e-05 | -10.06 | CELF3/4/5/6_RRM1 | interpro domains | IPR034648 | 4 | 2 | 18521 | 50 |
CELF5,CELF4 |
4.271e-05 | -10.06 | K_chnl_BK_asu | interpro domains | IPR003929 | 4 | 2 | 18521 | 50 |
KCNT1,KCNMA1 |
4.366e-05 | -10.04 | positive regulation of exocytosis | biological process | GO:0045921 | 76 | 4 | 18204 | 47 |
SYT1,SYT7,STXBP5,CADPS |
4.441e-05 | -10.02 | PDZ_assoc | pfam domains | PF10600 | 4 | 2 | 17795 | 49 |
DLG3,DLG4 |
4.441e-05 | -10.02 | BK_channel_a | pfam domains | PF03493 | 4 | 2 | 17795 | 49 |
KCNT1,KCNMA1 |
4.594e-05 | -9.99 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 20 | 16828 | 48 |
GRM7,OLFM1,SYT1,GRIN2B,RIMS2,CSMD2,RALYL,GRID2,CELF4,GRIA3,KCNT1,ALK,PDE2A,SCN8A,CELF5,CADPS,GABRA1,NRG3,GABBR2,MCTP1 |
4.676e-05 | -9.97 | learning | biological process | GO:0007612 | 154 | 5 | 18204 | 47 |
CSMD1,NRXN1,DLG4,GRIN1,NRXN2 |
4.735e-05 | -9.96 | GABA-ergic synapse | cellular component | GO:0098982 | 78 | 4 | 19108 | 49 |
GABRB2,CNTN5,GABRD,GABRA1 |
4.755e-05 | -9.95 | face | COSMIC cancer mutations | face | 2139 | 17 | 16828 | 48 |
GPR85,HCN1,FGF12,CHRM2,ALK,KCNC1,NRXN2,GABBR2,KCNIP2,NRG3,DPP10,CSMD2,GRIN2B,STXBP5,CELF2,GRM7,KCTD16 |
4.831e-05 | -9.94 | protein complex oligomerization | biological process | GO:0051259 | 256 | 6 | 18204 | 47 |
SYT1,HCN1,GRIN1,KCNC1,GRIN2B,KCTD16 |
4.844e-05 | -9.94 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 15 | 16828 | 48 |
CACNA1H,CSMD2,GRIN2B,RIMS2,GRIK2,CELF4,NTRK3,GRID2,RALYL,ALK,CADPS,NRG3,DLG3,DPP10,GABBR2 |
4.978e-05 | -9.91 | presynaptic active zone | cellular component | GO:0048786 | 79 | 4 | 19108 | 49 |
GRM7,RIMS2,SCN8A,HCN1 |
5.050e-05 | -9.89 | calcium ion import across plasma membrane | biological process | GO:0098703 | 28 | 3 | 18204 | 47 |
CACNA1G,CACNA1A,CACNA1H |
5.124e-05 | -9.88 | GRIP1 (glutamate receptor interacting protein 1) | protein interactions | 23426 | 81 | 4 | 19454 | 49 |
FGF12,GRIK2,GRIA3,GRM7 |
5.240e-05 | -9.86 | CACNG2 (calcium voltage-gated channel auxiliary subunit gamma 2) | protein interactions | 10369 | 29 | 3 | 19454 | 49 |
DLG3,DLG4,GRIN1 |
5.379e-05 | -9.83 | regulation of blood circulation | biological process | GO:1903522 | 261 | 6 | 18204 | 47 |
CACNA1H,ASIC2,CELF2,KCNIP2,CACNA1G,CHRM2 |
5.623e-05 | -9.79 | protein heterooligomerization | biological process | GO:0051291 | 29 | 3 | 18204 | 47 |
GRIN2B,GRIN1,SYT1 |
5.623e-05 | -9.79 | calcium ion import into cytosol | biological process | GO:1902656 | 29 | 3 | 18204 | 47 |
CACNA1G,CACNA1A,CACNA1H |
5.643e-05 | -9.78 | C2 | prosite domains | PS50004 | 142 | 5 | 12186 | 36 |
SYT7,SYT1,RIMS2,CADPS,MCTP1 |
5.886e-05 | -9.74 | regulation of neurotransmitter secretion | biological process | GO:0046928 | 82 | 4 | 18204 | 47 |
RIMS2,STXBP5,SYT1,MCTP1 |
6.236e-05 | -9.68 | neuronal action potential | biological process | GO:0019228 | 30 | 3 | 18204 | 47 |
SCN8A,GRIK2,HCN1 |
6.410e-05 | -9.65 | neuronal dense core vesicle membrane | cellular component | GO:0099012 | 5 | 2 | 19108 | 49 |
STXBP5,CADPS |
6.492e-05 | -9.64 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
6.492e-05 | -9.64 | potassium ion transmembrane transport | biological process | GO:0071805 | 165 | 5 | 18204 | 47 |
HCN1,KCNC1,KCNT1,KCNIP2,KCNMA1 |
6.512e-05 | -9.64 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 17 | 16828 | 48 |
GRIA3,KCNT1,RALYL,GRID2,CELF4,RIMS2,GRIN2B,CSMD2,GRM7,CACNA1H,GABBR2,NRXN2,NRG3,CACNA1G,HCN1,FGF12,ALK |
6.512e-05 | -9.64 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 17 | 16828 | 48 |
RALYL,GRID2,CELF4,GRIA3,KCNT1,GRM7,CACNA1H,RIMS2,GRIN2B,CSMD2,NRG3,GABBR2,NRXN2,ALK,CACNA1G,FGF12,HCN1 |
6.764e-05 | -9.60 | monoatomic ion-gated channel activity | molecular function | GO:0022839 | 30 | 3 | 18094 | 48 |
KCNMA1,ASIC2,KCNT1 |
7.011e-05 | -9.57 | CREB phosphorylation through the activation of Ras | REACTOME pathways | R-HSA-442742 | 29 | 3 | 10285 | 29 |
GRIN1,GRIN2B,DLG4 |
7.089e-05 | -9.55 | NLGN3 (neuroligin 3) | protein interactions | 54413 | 88 | 4 | 19454 | 49 |
NRXN1,DLG3,NRXN2,DLG4 |
7.092e-05 | -9.55 | protein localization to cell junction | biological process | GO:1902414 | 86 | 4 | 18204 | 47 |
NRXN2,DLG4,NRXN1,ASIC2 |
7.249e-05 | -9.53 | localization within membrane | biological process | GO:0051668 | 549 | 8 | 18204 | 47 |
STXBP5,DPP10,DLG3,GPHN,GRIK2,NRXN1,DLG4,NRXN2 |
7.271e-05 | -9.53 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 17 | 16828 | 48 |
NRG3,GABBR2,NRXN2,ALK,HCN1,FGF12,CACNA1G,RALYL,CELF4,GRID2,GRIA3,KCNT1,GRM7,CACNA1H,RIMS2,GRIN2B,CSMD2 |
7.330e-05 | -9.52 | learning or memory | biological process | GO:0007611 | 276 | 6 | 18204 | 47 |
GRIN1,NRXN2,DLG4,NRXN1,GRIN2B,CSMD1 |
7.690e-05 | -9.47 | regulation of exocytosis | biological process | GO:0017157 | 171 | 5 | 18204 | 47 |
SYT1,SYT7,STXBP5,RIMS2,CADPS |
7.700e-05 | -9.47 | cell body | cellular component | GO:0044297 | 556 | 8 | 19108 | 49 |
ASIC2,CHRM2,KCNC1,NRXN1,CACNA1A,GRIK2,OLFM1,GABRD |
7.717e-05 | -9.47 | dendritic spine | cellular component | GO:0043197 | 172 | 5 | 19108 | 49 |
DLG4,ASIC2,GRIN1,GRID2,GRIA3 |
7.970e-05 | -9.44 | MAGUK_N_PEST | smart domains | SM01277 | 4 | 2 | 9717 | 36 |
DLG4,DLG3 |
8.150e-05 | -9.41 | neuron spine | cellular component | GO:0044309 | 174 | 5 | 19108 | 49 |
GRIA3,GRID2,GRIN1,DLG4,ASIC2 |
8.335e-05 | -9.39 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 47 |
KCNC1,NRXN1,NRXN2 |
8.412e-05 | -9.38 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 42 | 16828 | 48 |
CNTN5,FGF12,CACNA1G,KCNMA1,GABRD,CELF5,CHRM2,GABBR2,NRXN1,NRXN2,DPP10,SYT7,RIMS2,CELF2,CACNA1H,GRIA3,FAM131A,DLG4,RALYL,GRIK2,CELF4,GRIN1,HCN1,SCN8A,TENM1,ALK,PDE2A,MCTP1,KCNC1,GPHN,NRG3,CADPS,GABRA1,CACNA1A,SYT1,GRIN2B,CSMD2,GRM7,STXBP5,KCNT1,GRID2,NTRK3 |
8.412e-05 | -9.38 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 42 | 16828 | 48 |
CACNA1G,KCNMA1,FGF12,CNTN5,CELF5,GABRD,CHRM2,GABBR2,NRXN2,NRXN1,DPP10,SYT7,RIMS2,CACNA1H,CELF2,GRIA3,FAM131A,DLG4,RALYL,CELF4,GRIK2,GRIN1,SCN8A,HCN1,TENM1,ALK,PDE2A,MCTP1,KCNC1,GPHN,CADPS,GABRA1,NRG3,GRIN2B,SYT1,CACNA1A,CSMD2,GRM7,STXBP5,KCNT1,NTRK3,GRID2 |
8.632e-05 | -9.36 | Felodipine Action Pathway | SMPDB pathways | SMP0000377 | 57 | 4 | 1369 | 7 |
CACNA1H,CACNA1G,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Nitrendipine Action Pathway | SMPDB pathways | SMP0000382 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CACNA1G,CHRM2 |
8.632e-05 | -9.36 | Nifedipine Action Pathway | SMPDB pathways | SMP0000379 | 57 | 4 | 1369 | 7 |
KCNIP2,CHRM2,CACNA1H,CACNA1G |
8.632e-05 | -9.36 | Fosphenytoin (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000326 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Verapamil Action Pathway | SMPDB pathways | SMP0000375 | 57 | 4 | 1369 | 7 |
CACNA1H,CACNA1G,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Quinidine Action Pathway | SMPDB pathways | SMP0000323 | 57 | 4 | 1369 | 7 |
CACNA1H,CACNA1G,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Nimodipine Action Pathway | SMPDB pathways | SMP0000380 | 57 | 4 | 1369 | 7 |
CACNA1H,CACNA1G,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Nebivolol Action Pathway | SMPDB pathways | SMP0000366 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1G,CHRM2,CACNA1H |
8.632e-05 | -9.36 | Dobutamine Action Pathway | SMPDB pathways | SMP0000662 | 57 | 4 | 1369 | 7 |
CACNA1H,CHRM2,CACNA1G,KCNIP2 |
8.632e-05 | -9.36 | Metoprolol Action Pathway | SMPDB pathways | SMP0000302 | 57 | 4 | 1369 | 7 |
KCNIP2,CHRM2,CACNA1H,CACNA1G |
8.632e-05 | -9.36 | Pindolol Action Pathway | SMPDB pathways | SMP0000306 | 57 | 4 | 1369 | 7 |
KCNIP2,CHRM2,CACNA1H,CACNA1G |
8.632e-05 | -9.36 | Acebutolol Action Pathway | SMPDB pathways | SMP0000296 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CACNA1G,CHRM2 |
8.632e-05 | -9.36 | Isradipine Action Pathway | SMPDB pathways | SMP0000378 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CHRM2,CACNA1G |
8.632e-05 | -9.36 | Flecainide Action Pathway | SMPDB pathways | SMP0000331 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CHRM2,CACNA1G |
8.632e-05 | -9.36 | Levobunolol Action Pathway | SMPDB pathways | SMP0000666 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Nadolol Action Pathway | SMPDB pathways | SMP0000303 | 57 | 4 | 1369 | 7 |
CHRM2,CACNA1G,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Isoprenaline Action Pathway | SMPDB pathways | SMP0000663 | 57 | 4 | 1369 | 7 |
CACNA1H,CACNA1G,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Bisoprolol Action Pathway | SMPDB pathways | SMP0000300 | 57 | 4 | 1369 | 7 |
CACNA1G,CACNA1H,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Sotalol Action Pathway | SMPDB pathways | SMP0000660 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1G,CACNA1H,CHRM2 |
8.632e-05 | -9.36 | Nisoldipine Action Pathway | SMPDB pathways | SMP0000381 | 57 | 4 | 1369 | 7 |
CACNA1G,CACNA1H,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Timolol Action Pathway | SMPDB pathways | SMP0000659 | 57 | 4 | 1369 | 7 |
KCNIP2,CHRM2,CACNA1H,CACNA1G |
8.632e-05 | -9.36 | Bopindolol Action Pathway | SMPDB pathways | SMP0000657 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1G,CACNA1H,CHRM2 |
8.632e-05 | -9.36 | Disopyramide Action Pathway | SMPDB pathways | SMP0000325 | 57 | 4 | 1369 | 7 |
CACNA1G,CACNA1H,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Amlodipine Action Pathway | SMPDB pathways | SMP0000376 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CACNA1G,CHRM2 |
8.632e-05 | -9.36 | Mexiletine Action Pathway | SMPDB pathways | SMP0000329 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1G,CACNA1H,CHRM2 |
8.632e-05 | -9.36 | Atenolol Action Pathway | SMPDB pathways | SMP0000298 | 57 | 4 | 1369 | 7 |
CACNA1H,CACNA1G,CHRM2,KCNIP2 |
8.632e-05 | -9.36 | Bevantolol Action Pathway | SMPDB pathways | SMP0000668 | 57 | 4 | 1369 | 7 |
CACNA1H,CHRM2,CACNA1G,KCNIP2 |
8.632e-05 | -9.36 | Procainamide (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000324 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1G,CHRM2,CACNA1H |
8.632e-05 | -9.36 | Carteolol Action Pathway | SMPDB pathways | SMP0000658 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Ibutilide Action Pathway | SMPDB pathways | SMP0000332 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Penbutolol Action Pathway | SMPDB pathways | SMP0000305 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1G,CHRM2,CACNA1H |
8.632e-05 | -9.36 | Epinephrine Action Pathway | SMPDB pathways | SMP0000661 | 57 | 4 | 1369 | 7 |
CACNA1H,CHRM2,CACNA1G,KCNIP2 |
8.632e-05 | -9.36 | Amiodarone Action Pathway | SMPDB pathways | SMP0000665 | 57 | 4 | 1369 | 7 |
CACNA1H,CHRM2,CACNA1G,KCNIP2 |
8.632e-05 | -9.36 | Esmolol Action Pathway | SMPDB pathways | SMP0000301 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Practolol Action Pathway | SMPDB pathways | SMP0000669 | 57 | 4 | 1369 | 7 |
KCNIP2,CHRM2,CACNA1H,CACNA1G |
8.632e-05 | -9.36 | Oxprenolol Action Pathway | SMPDB pathways | SMP0000304 | 57 | 4 | 1369 | 7 |
CHRM2,CACNA1H,CACNA1G,KCNIP2 |
8.632e-05 | -9.36 | Bupranolol Action Pathway | SMPDB pathways | SMP0000670 | 57 | 4 | 1369 | 7 |
KCNIP2,CHRM2,CACNA1H,CACNA1G |
8.632e-05 | -9.36 | Betaxolol Action Pathway | SMPDB pathways | SMP0000299 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Arbutamine Action Pathway | SMPDB pathways | SMP0000664 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Diltiazem Action Pathway | SMPDB pathways | SMP0000359 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CHRM2,CACNA1G |
8.632e-05 | -9.36 | Tocainide Action Pathway | SMPDB pathways | SMP0000330 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CACNA1G,CHRM2 |
8.632e-05 | -9.36 | Alprenolol Action Pathway | SMPDB pathways | SMP0000297 | 57 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
8.632e-05 | -9.36 | Propranolol Action Pathway | SMPDB pathways | SMP0000307 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1G,CHRM2,CACNA1H |
8.632e-05 | -9.36 | Muscle/Heart Contraction | SMPDB pathways | SMP0000588 | 57 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CHRM2,CACNA1G |
8.632e-05 | -9.36 | Metipranolol Action Pathway | SMPDB pathways | SMP0000667 | 57 | 4 | 1369 | 7 |
KCNIP2,CHRM2,CACNA1H,CACNA1G |
8.811e-05 | -9.34 | potassium ion transport | biological process | GO:0006813 | 176 | 5 | 18204 | 47 |
HCN1,KCNC1,KCNIP2,KCNMA1,KCNT1 |
8.945e-05 | -9.32 | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | 3507 | 22 | 16828 | 48 |
CSMD2,GRIN2B,STXBP5,GRM7,GRID2,TENM1,SCN8A,HCN1,PDE2A,ALK,KCNC1,GABRA1,RIMS2,CACNA1H,GRIK2,CELF4,GRIN1,CELF5,CACNA1G,NRXN2,SYT7,DPP10 |
9.020e-05 | -9.31 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 4 | 18094 | 48 |
GRIN2B,GRIA3,GRIN1,CACNA1A |
9.092e-05 | -9.31 | ErbB4 signaling events | Pathway Interaction DB | erbb4_pathway | 32 | 3 | 2226 | 7 |
DLG4,GRIN2B,NRG3 |
9.169e-05 | -9.30 | GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) | protein interactions | 2902 | 94 | 4 | 19454 | 49 |
GRIN1,GRIN2B,DLG3,DLG4 |
9.227e-05 | -9.29 | protein tetramerization | biological process | GO:0051262 | 92 | 4 | 18204 | 47 |
KCNC1,GRIN2B,HCN1,GRIN1 |
9.254e-05 | -9.29 | Carvedilol Action Pathway | SMPDB pathways | SMP0000367 | 58 | 4 | 1369 | 7 |
CACNA1G,CHRM2,CACNA1H,KCNIP2 |
9.254e-05 | -9.29 | Labetalol Action Pathway | SMPDB pathways | SMP0000368 | 58 | 4 | 1369 | 7 |
CACNA1H,CHRM2,CACNA1G,KCNIP2 |
9.363e-05 | -9.28 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | 1803 | 15 | 16828 | 48 |
NTRK3,GRIK2,GRIN1,KCTD16,GRIA3,CACNA1H,OLFM1,CACNA1A,NRG3,NRXN2,MCTP1,ALK,TENM1,SCN8A,HCN1 |
9.363e-05 | -9.28 | functioning | COSMIC cancer mutations | functioning | 1803 | 15 | 16828 | 48 |
ALK,TENM1,SCN8A,HCN1,NRG3,NRXN2,MCTP1,CACNA1H,OLFM1,CACNA1A,NTRK3,GRIN1,GRIK2,GRIA3,KCTD16 |
9.383e-05 | -9.27 | secretion by cell | biological process | GO:0032940 | 420 | 7 | 18204 | 47 |
SYT7,RIMS2,STXBP5,SYT1,NRXN2,NRXN1,CADPS |
9.463e-05 | -9.27 | Activation of Kainate Receptors upon glutamate binding | REACTOME pathways | R-HSA-451326 | 32 | 3 | 10285 | 29 |
DLG3,GRIK2,DLG4 |
9.521e-05 | -9.26 | TVDCCALPHA1 | prints domains | PR01629 | 3 | 2 | 5227 | 30 |
CACNA1H,CACNA1G |
9.722e-05 | -9.24 | imitative learning | biological process | GO:0098596 | 6 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
9.722e-05 | -9.24 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
9.722e-05 | -9.24 | vocal learning | biological process | GO:0042297 | 6 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
9.908e-05 | -9.22 | Axon guidance | REACTOME pathways | R-HSA-422475 | 549 | 8 | 10285 | 29 |
CACNA1H,GRIN2B,CACNA1G,DLG3,DLG4,NRG3,GRIN1,SCN8A |
9.909e-05 | -9.22 | Lidocaine (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000328 | 59 | 4 | 1369 | 7 |
CACNA1H,CHRM2,CACNA1G,KCNIP2 |
9.986e-05 | -9.21 | NCAM signaling for neurite out-growth | REACTOME pathways | R-HSA-375165 | 276 | 6 | 10285 | 29 |
CACNA1H,GRIN2B,CACNA1G,DLG4,NRG3,GRIN1 |
1.011e-04 | -9.20 | SCN5A (sodium voltage-gated channel alpha subunit 5) | protein interactions | 6331 | 36 | 3 | 19454 | 49 |
FGF12,DLG4,DLG3 |
1.027e-04 | -9.18 | glutamate-gated calcium ion channel activity | molecular function | GO:0022849 | 6 | 2 | 18094 | 48 |
GRIN1,GRIN2B |
1.085e-04 | -9.13 | positive regulation of synaptic transmission, glutamatergic | biological process | GO:0051968 | 36 | 3 | 18204 | 47 |
GRIN1,GRIN2B,NRXN1 |
1.097e-04 | -9.12 | muscle system process | biological process | GO:0003012 | 297 | 6 | 18204 | 47 |
FGF12,KCNIP2,SCN8A,CACNA1G,CACNA1H,KCNMA1 |
1.131e-04 | -9.09 | soft_tissue-striated_muscle-rhabdoid_tumour | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdoid_tumour | 168 | 5 | 16828 | 48 |
ALK,DPP10,GABRB2,NTRK3,GRIA3 |
1.131e-04 | -9.09 | rhabdoid_tumour | COSMIC cancer mutations | rhabdoid_tumour | 168 | 5 | 16828 | 48 |
GRIA3,GABRB2,NTRK3,DPP10,ALK |
1.141e-04 | -9.08 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 18 | 16828 | 48 |
GRM7,SYT1,CACNA1A,GRID2,CELF4,KCNT1,KCTD16,GRIA3,GABRB2,PDE2A,ALK,TENM1,GABRD,HCN1,FGF12,NRG3,GABBR2,MCTP1 |
1.227e-04 | -9.01 | regulation of neurotransmitter transport | biological process | GO:0051588 | 99 | 4 | 18204 | 47 |
STXBP5,RIMS2,MCTP1,SYT1 |
1.277e-04 | -8.97 | mRNA splice site recognition | biological process | GO:0006376 | 38 | 3 | 18204 | 47 |
CELF5,CELF2,CELF4 |
1.342e-04 | -8.92 | dense core granule membrane | cellular component | GO:0032127 | 7 | 2 | 19108 | 49 |
STXBP5,CADPS |
1.359e-04 | -8.90 | observational learning | biological process | GO:0098597 | 7 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
1.359e-04 | -8.90 | spontaneous neurotransmitter secretion | biological process | GO:0061669 | 7 | 2 | 18204 | 47 |
RIMS2,SYT1 |
1.362e-04 | -8.90 | regulation of monoatomic cation transmembrane transport | biological process | GO:1904062 | 309 | 6 | 18204 | 47 |
GRIN1,FGF12,KCNC1,GRIN2B,DPP10,KCNIP2 |
1.366e-04 | -8.90 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 29 | 18204 | 47 |
NRG3,SYT1,HCN1,NRXN2,GPR85,OLFM1,GRIK2,ALK,CHRM2,FGF12,GABBR2,DLG4,GRM7,CELF4,CACNA1H,GRIN1,NTRK3,KCNIP2,GRIA3,KCNC1,GRID2,RIMS2,PDE2A,GABRB2,GRIN2B,MCTP1,CACNA1A,ASIC2,TENM1 |
1.407e-04 | -8.87 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 19 | 16828 | 48 |
GRIK2,NTRK3,GRID2,GRIA3,OLFM1,CACNA1H,CSMD2,CACNA1A,NRG3,DPP10,MCTP1,PDE2A,CHRM2,ALK,TENM1,CNTN5,HCN1,SCN8A,CACNA1G |
1.407e-04 | -8.87 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 19 | 16828 | 48 |
TENM1,CNTN5,HCN1,CACNA1G,SCN8A,PDE2A,ALK,CHRM2,MCTP1,NRG3,DPP10,CSMD2,CACNA1A,OLFM1,CACNA1H,GRIA3,GRIK2,NTRK3,GRID2 |
1.418e-04 | -8.86 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 4 | 18094 | 48 |
GRIK2,GRIN2B,GRIA3,GRIN1 |
1.435e-04 | -8.85 | NMDA glutamate receptor activity | molecular function | GO:0004972 | 7 | 2 | 18094 | 48 |
GRIN1,GRIN2B |
1.468e-04 | -8.83 | Post NMDA receptor activation events | REACTOME pathways | R-HSA-438064 | 37 | 3 | 10285 | 29 |
GRIN2B,DLG4,GRIN1 |
1.490e-04 | -8.81 | calcium ion import | biological process | GO:0070509 | 40 | 3 | 18204 | 47 |
CACNA1H,CACNA1A,CACNA1G |
1.497e-04 | -8.81 | LIN7B (lin-7 homolog B, crumbs cell polarity complex component) | protein interactions | 64130 | 41 | 3 | 19454 | 49 |
GRIN2B,DLG4,GRIK2 |
1.577e-04 | -8.75 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 20 | 16828 | 48 |
MCTP1,GABBR2,NRG3,FGF12,HCN1,CNTN5,GABRD,TENM1,ALK,PDE2A,GABRB2,KCTD16,GRIA3,KCNT1,CELF4,GRID2,CACNA1A,SYT1,GRM7,CACNA1H |
1.582e-04 | -8.75 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 5 | 19454 | 49 |
NRXN1,DLG3,NRXN2,GRIK2,DLG4 |
1.598e-04 | -8.74 | NrCAM interactions | REACTOME pathways | R-HSA-447038 | 7 | 2 | 10285 | 29 |
DLG4,DLG3 |
1.620e-04 | -8.73 | cognition | biological process | GO:0050890 | 319 | 6 | 18204 | 47 |
GRIN1,CSMD1,NRXN2,DLG4,NRXN1,GRIN2B |
1.658e-04 | -8.70 | Potassium Channels | REACTOME pathways | R-HSA-1296071 | 100 | 4 | 10285 | 29 |
HCN1,GABBR2,KCNC1,KCNMA1 |
1.680e-04 | -8.69 | endocytic vesicle membrane | cellular component | GO:0030666 | 203 | 5 | 19108 | 49 |
DLG4,SYT7,GRIA3,SYT1,CHRM2 |
1.693e-04 | -8.68 | protein localization to membrane | biological process | GO:0072657 | 462 | 7 | 18204 | 47 |
GRIK2,DLG4,NRXN2,DPP10,DLG3,NRXN1,GPHN |
1.745e-04 | -8.65 | DLG3 (discs large MAGUK scaffold protein 3) | protein interactions | 1741 | 111 | 4 | 19454 | 49 |
DLG4,GRIK2,GRIN1,GRIN2B |
1.779e-04 | -8.63 | postsynapse organization | biological process | GO:0099173 | 109 | 4 | 18204 | 47 |
GPHN,NRXN1,NRXN2,DLG4 |
1.786e-04 | -8.63 | regulation of monoatomic ion transport | biological process | GO:0043269 | 466 | 7 | 18204 | 47 |
DPP10,ASIC2,GRIN1,KCNIP2,KCNC1,GRIN2B,FGF12 |
1.801e-04 | -8.62 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 5 | 18204 | 47 |
GRIN1,CACNA1H,CACNA1G,GRIN2B,CACNA1A |
1.851e-04 | -8.59 | regulation of synaptic vesicle exocytosis | biological process | GO:2000300 | 43 | 3 | 18204 | 47 |
SYT1,STXBP5,RIMS2 |
1.865e-04 | -8.59 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 18 | 16828 | 48 |
GABRA1,NRG3,NRXN2,MCTP1,PDE2A,ALK,TENM1,HCN1,CNTN5,SCN8A,GRIN1,GRIK2,NTRK3,KCTD16,GRIA3,OLFM1,CACNA1H,CACNA1A |
1.870e-04 | -8.58 | voltage-gated calcium channel activity | molecular function | GO:0005245 | 42 | 3 | 18094 | 48 |
CACNA1A,CACNA1G,CACNA1H |
1.910e-04 | -8.56 | glutamate binding | molecular function | GO:0016595 | 8 | 2 | 18094 | 48 |
GRIN1,GRIN2B |
1.927e-04 | -8.55 | regulation of heart contraction | biological process | GO:0008016 | 208 | 5 | 18204 | 47 |
CACNA1H,CHRM2,CACNA1G,CELF2,KCNIP2 |
1.934e-04 | -8.55 | axon terminus | cellular component | GO:0043679 | 112 | 4 | 19108 | 49 |
CHRM2,KCNC1,GRIK2,GRIN1 |
1.983e-04 | -8.53 | receptor localization to synapse | biological process | GO:0097120 | 44 | 3 | 18204 | 47 |
DLG4,GPHN,DLG3 |
1.993e-04 | -8.52 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 38 | 16828 | 48 |
GRID2,NTRK3,KCNT1,GRM7,STXBP5,GRIN2B,SYT1,CSMD2,CADPS,NRG3,GABRA1,MCTP1,KCNC1,ALK,PDE2A,HCN1,SCN8A,FAM131A,RALYL,CELF4,GRIN1,GRIK2,KCTD16,CELF2,OLFM1,RIMS2,DPP10,GABBR2,NRXN1,NRXN2,CHRM2,GABRB2,FGF12,CNTN5,KCNMA1,CACNA1G,GABRD,CELF5 |
2.027e-04 | -8.50 | Cocaine Action Pathway | SMPDB pathways | SMP0000395 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Procaine Action Pathway | SMPDB pathways | SMP0000402 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Remifentanil Action Pathway | SMPDB pathways | SMP0000416 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Oxymorphone Action Pathway | SMPDB pathways | SMP0000412 | 26 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.027e-04 | -8.50 | Levobupivacaine Action Pathway | SMPDB pathways | SMP0000397 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Proparacaine Action Pathway | SMPDB pathways | SMP0000403 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Hydromorphone Action Pathway | SMPDB pathways | SMP0000410 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Oxybuprocaine Action Pathway | SMPDB pathways | SMP0000400 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Chloroprocaine Action Pathway | SMPDB pathways | SMP0000394 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Methadyl Acetate Action Pathway | SMPDB pathways | SMP0000678 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Alfentanil Action Pathway | SMPDB pathways | SMP0000413 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Mepivacaine Action Pathway | SMPDB pathways | SMP0000399 | 26 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.027e-04 | -8.50 | Diphenoxylate Action Pathway | SMPDB pathways | SMP0000675 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Dimethylthiambutene Action Pathway | SMPDB pathways | SMP0000680 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Tramadol Action Action Pathway | SMPDB pathways | SMP0000671 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Levallorphan Action Pathway | SMPDB pathways | SMP0000683 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Levomethadyl Acetate Action Action Pathway | SMPDB pathways | SMP0000677 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Pentazocine Action Pathway | SMPDB pathways | SMP0000686 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Anileridine Action Pathway | SMPDB pathways | SMP0000674 | 26 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.027e-04 | -8.50 | 3-Methylthiofentanyl Action Pathway | SMPDB pathways | SMP0000679 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Hydrocodone Action Pathway | SMPDB pathways | SMP0000411 | 26 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.027e-04 | -8.50 | Dibucaine Action Pathway | SMPDB pathways | SMP0000396 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Fentanyl Action Pathway | SMPDB pathways | SMP0000415 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Naloxone Action Pathway | SMPDB pathways | SMP0000688 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Prilocaine Action Pathway | SMPDB pathways | SMP0000401 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Benzocaine Action Pathway | SMPDB pathways | SMP0000392 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Ropivacaine Action Pathway | SMPDB pathways | SMP0000404 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Sufentanil Action Pathway | SMPDB pathways | SMP0000417 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Oxycodone Action Pathway | SMPDB pathways | SMP0000409 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Bupivacaine Action Pathway | SMPDB pathways | SMP0000393 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Carfentanil Action Pathway | SMPDB pathways | SMP0000414 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Ketobemidone Action Pathway | SMPDB pathways | SMP0000690 | 26 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.027e-04 | -8.50 | Dezocine Action Pathway | SMPDB pathways | SMP0000676 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Naltrexone Action Pathway | SMPDB pathways | SMP0000687 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Dihydromorphine Action Pathway | SMPDB pathways | SMP0000689 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Escitalopram Action Pathway | SMPDB pathways | SMP0000425 | 26 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.027e-04 | -8.50 | Buprenorphine Action Pathway | SMPDB pathways | SMP0000684 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Propoxyphene Action Pathway | SMPDB pathways | SMP0000672 | 26 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.027e-04 | -8.50 | Ethylmorphine Action Pathway | SMPDB pathways | SMP0000681 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.027e-04 | -8.50 | Alvimopan Action Pathway | SMPDB pathways | SMP0000685 | 26 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
2.027e-04 | -8.50 | Levorphanol Action Pathway | SMPDB pathways | SMP0000673 | 26 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.044e-04 | -8.50 | regulation of regulated secretory pathway | biological process | GO:1903305 | 113 | 4 | 18204 | 47 |
RIMS2,STXBP5,SYT7,SYT1 |
2.085e-04 | -8.48 | voltage-gated calcium channel complex | cellular component | GO:0005891 | 45 | 3 | 19108 | 49 |
CACNA1A,CACNA1G,CACNA1H |
2.117e-04 | -8.46 | Neurotransmitter_ion_chnl_CS | interpro domains | IPR018000 | 43 | 3 | 18521 | 50 |
GABRD,GABRB2,GABRA1 |
2.121e-04 | -8.46 | cardiac muscle cell action potential involved in contraction | biological process | GO:0086002 | 45 | 3 | 18204 | 47 |
SCN8A,CACNA1G,FGF12 |
2.212e-04 | -8.42 | NETO1 (neuropilin and tolloid like 1) | protein interactions | 81832 | 9 | 2 | 19454 | 49 |
GRIN2B,GRIN1 |
2.215e-04 | -8.42 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 15 | 16828 | 48 |
GRIK2,NTRK3,GRID2,GRIN2B,RIMS2,CSMD2,GRM7,STXBP5,NRXN1,NRXN2,CNTN5,FGF12,HCN1,KCNMA1,PDE2A |
2.241e-04 | -8.40 | larynx | COSMIC cancer mutations | larynx | 1948 | 15 | 16828 | 48 |
HCN1,CNTN5,FGF12,KCNMA1,PDE2A,NRXN1,NRXN2,RIMS2,GRIN2B,CSMD2,GRM7,STXBP5,GRIK2,NTRK3,GRID2 |
2.252e-04 | -8.40 | GRIA1 (glutamate ionotropic receptor AMPA type subunit 1) | protein interactions | 2890 | 47 | 3 | 19454 | 49 |
GRIK2,GRIA3,GRID2 |
2.268e-04 | -8.39 | Neurotrans-gated_channel_TM | interpro domains | IPR006029 | 44 | 3 | 18521 | 50 |
GABRD,GABRA1,GABRB2 |
2.275e-04 | -8.39 | Nalbuphine Action Pathway | SMPDB pathways | SMP0000691 | 27 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.275e-04 | -8.39 | Desipramine Action Pathway | SMPDB pathways | SMP0000423 | 27 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
2.293e-04 | -8.38 | NMDA selective glutamate receptor complex | cellular component | GO:0017146 | 9 | 2 | 19108 | 49 |
GRIN1,GRIN2B |
2.322e-04 | -8.37 | spontaneous synaptic transmission | biological process | GO:0098814 | 9 | 2 | 18204 | 47 |
SYT1,RIMS2 |
2.322e-04 | -8.37 | receptor diffusion trapping | biological process | GO:0098953 | 9 | 2 | 18204 | 47 |
GPHN,DLG4 |
2.322e-04 | -8.37 | postsynaptic neurotransmitter receptor diffusion trapping | biological process | GO:0098970 | 9 | 2 | 18204 | 47 |
DLG4,GPHN |
2.322e-04 | -8.37 | neurotransmitter receptor diffusion trapping | biological process | GO:0099628 | 9 | 2 | 18204 | 47 |
DLG4,GPHN |
2.400e-04 | -8.33 | Neur_chan_memb | pfam domains | PF02932 | 44 | 3 | 17795 | 49 |
GABRB2,GABRD,GABRA1 |
2.425e-04 | -8.32 | Neuro_actylchol_rec | interpro domains | IPR038050 | 45 | 3 | 18521 | 50 |
GABRB2,GABRA1,GABRD |
2.425e-04 | -8.32 | Neuro-gated_channel_TM_sf | interpro domains | IPR036719 | 45 | 3 | 18521 | 50 |
GABRB2,GABRA1,GABRD |
2.425e-04 | -8.32 | Neur_chan_lig-bd_sf | interpro domains | IPR036734 | 45 | 3 | 18521 | 50 |
GABRD,GABRA1,GABRB2 |
2.425e-04 | -8.32 | Neur_chan_lig-bd | interpro domains | IPR006202 | 45 | 3 | 18521 | 50 |
GABRB2,GABRA1,GABRD |
2.425e-04 | -8.32 | Neur_channel | interpro domains | IPR006201 | 45 | 3 | 18521 | 50 |
GABRD,GABRA1,GABRB2 |
2.442e-04 | -8.32 | GABAARECEPTR | prints domains | PR00253 | 22 | 3 | 5227 | 30 |
GABRB2,GABRD,GABRA1 |
2.455e-04 | -8.31 | pre-mRNA binding | molecular function | GO:0036002 | 46 | 3 | 18094 | 48 |
CELF2,CELF4,CELF5 |
2.500e-04 | -8.29 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 5 | 18204 | 47 |
NRXN2,ASIC2,PDE2A,NRXN1,KCNC1 |
2.540e-04 | -8.28 | VDCCAlpha1 | interpro domains | IPR002077 | 9 | 2 | 18521 | 50 |
CACNA1G,CACNA1A |
2.543e-04 | -8.28 | Lidocaine (Local Anaesthetic) Action Pathway | SMPDB pathways | SMP0000398 | 28 | 3 | 1369 | 7 |
CACNA1A,KCNIP2,GRIN1 |
2.567e-04 | -8.27 | Neur_chan_LBD | pfam domains | PF02931 | 45 | 3 | 17795 | 49 |
GABRB2,GABRD,GABRA1 |
2.641e-04 | -8.24 | positive regulation of transport | biological process | GO:0051050 | 844 | 9 | 18204 | 47 |
SYT7,GRIN1,STXBP5,TENM1,FGF12,SYT1,KCNIP2,CADPS,KCNC1 |
2.653e-04 | -8.23 | Taste transduction | KEGG pathways | hsa04742 | 82 | 4 | 7161 | 28 |
GABRA1,ASIC2,CACNA1A,GABBR2 |
2.653e-04 | -8.23 | Taste transduction | KEGG pathways | ko04742 | 82 | 4 | 7161 | 28 |
CACNA1A,GABBR2,GABRA1,ASIC2 |
2.694e-04 | -8.22 | NEUROTR_ION_CHANNEL | prosite domains | PS00236 | 43 | 3 | 12186 | 36 |
GABRA1,GABRB2,GABRD |
2.728e-04 | -8.21 | regulation of cellular component organization | biological process | GO:0051128 | 2455 | 16 | 18204 | 47 |
GRID2,NRG3,NRXN1,NTRK3,SYT1,PDE2A,OLFM1,RIMS2,STXBP5,GRIN2B,ALK,DLG4,MCTP1,TENM1,ASIC2,SYT7 |
2.745e-04 | -8.20 | regulation of biological process | biological process | GO:0050789 | 12079 | 42 | 18204 | 47 |
MCTP1,CACNA1G,GRIN2B,GABRD,ASIC2,CACNA1A,CELF2,TENM1,KCNIP2,NTRK3,GRID2,KCNC1,GRIA3,GABRB2,GABRA1,DLG3,RIMS2,STXBP5,PDE2A,GABBR2,FGF12,DLG4,ALK,CHRM2,CADPS,CACNA1H,GRIN1,SYT7,GRM7,DPP10,CELF4,SYT1,NRXN2,HCN1,CELF5,NRG3,NRXN1,GRIK2,KCNMA1,KCTD16,OLFM1,GPR85 |
2.761e-04 | -8.19 | human chrXq25 | chromosome location | human chrXq25 | 13 | 2 | 26134 | 50 |
TENM1,GRIA3 |
2.761e-04 | -8.19 | ASIC3 (acid sensing ion channel subunit 3) | protein interactions | 9311 | 10 | 2 | 19454 | 49 |
DLG4,ASIC2 |
2.797e-04 | -8.18 | C2DOMAIN | prints domains | PR00360 | 23 | 3 | 5227 | 30 |
MCTP1,SYT1,SYT7 |
2.830e-04 | -8.17 | Codeine Action Pathway | SMPDB pathways | SMP0000405 | 29 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
2.851e-04 | -8.16 | Phenytoin (Antiarrhythmic) Action Pathway | SMPDB pathways | SMP0000327 | 77 | 4 | 1369 | 7 |
KCNIP2,CACNA1H,CHRM2,CACNA1G |
2.856e-04 | -8.16 | Guanylate Kinase phosphate binding domain | gene3d domains | 3.30.63.10 | 8 | 2 | 14470 | 47 |
DLG4,DLG3 |
2.898e-04 | -8.15 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
2.898e-04 | -8.15 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
2.898e-04 | -8.15 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
2.903e-04 | -8.14 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 41 | 16828 | 48 |
DLG3,SYT7,GABBR2,KCNIP2,NRXN2,NRXN1,CHRM2,GABRB2,GPR85,KCNMA1,CACNA1G,CNTN5,CELF5,GABRD,DLG4,RALYL,GRIN1,GRIK2,CELF4,GRIA3,KCTD16,CACNA1H,OLFM1,RIMS2,NRG3,CADPS,GABRA1,MCTP1,KCNC1,ALK,PDE2A,SCN8A,HCN1,NTRK3,GRID2,KCNT1,GRM7,STXBP5,GRIN2B,CACNA1A,CSMD2 |
2.903e-04 | -8.14 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 41 | 16828 | 48 |
GRIK2,CELF4,GRIN1,DLG4,RALYL,KCTD16,GRIA3,CACNA1H,OLFM1,RIMS2,SYT7,DLG3,NRXN2,NRXN1,GABBR2,KCNIP2,GABRB2,CHRM2,CELF5,GABRD,KCNMA1,GPR85,CACNA1G,CNTN5,NTRK3,GRID2,KCNT1,STXBP5,GRM7,CSMD2,GRIN2B,CACNA1A,NRG3,CADPS,GABRA1,KCNC1,MCTP1,PDE2A,ALK,SCN8A,HCN1 |
3.008e-04 | -8.11 | neuron development | biological process | GO:0048666 | 859 | 9 | 18204 | 47 |
NRXN1,KCNIP2,ALK,HCN1,DLG4,CNTN5,TENM1,GRM7,GABRB2 |
3.024e-04 | -8.10 | protein-containing complex | cellular component | GO:0032991 | 6542 | 29 | 19108 | 49 |
GABRA1,STXBP5,CACNA1H,CACNA1G,GABBR2,GRID2,ALK,CELF4,NRXN2,CELF2,KCNIP2,GRIK2,GRIN1,SCN8A,KCNMA1,KCTD16,DLG4,GRIN2B,HCN1,NTRK3,GABRD,DPP10,GRIA3,KCNC1,GRM7,CACNA1A,DLG3,GABRB2,CELF5 |
3.032e-04 | -8.10 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 44 | 16828 | 48 |
GRM7,STXBP5,CACNA1A,GRIN2B,SYT1,CSMD2,NTRK3,GRID2,KCNT1,ALK,PDE2A,HCN1,SCN8A,TENM1,CADPS,GABRA1,NRG3,MCTP1,KCNC1,CELF2,CACNA1H,RIMS2,RALYL,FAM131A,DLG4,GRIN1,CELF4,KCTD16,GRIA3,CHRM2,GABRB2,CNTN5,FGF12,GPR85,CACNA1G,KCNMA1,GABRD,CELF5,DPP10,DLG3,SYT7,GABBR2,NRXN1,NRXN2 |
3.069e-04 | -8.09 | cervix | COSMIC cancer mutations | cervix | 11793 | 44 | 16828 | 48 |
CACNA1A,CSMD2,GRM7,SCN8A,TENM1,ALK,PDE2A,MCTP1,CADPS,GABRA1,RIMS2,GRIA3,FAM131A,GRIN1,CELF4,KCNMA1,GPR85,CACNA1G,GABRD,GABBR2,NRXN2,NRXN1,GRIN2B,SYT1,STXBP5,KCNT1,GRID2,NTRK3,HCN1,KCNC1,NRG3,CACNA1H,CELF2,KCTD16,RALYL,DLG4,FGF12,CNTN5,CELF5,CHRM2,GABRB2,DPP10,SYT7,DLG3 |
3.079e-04 | -8.09 | cardiac muscle cell contraction | biological process | GO:0086003 | 51 | 3 | 18204 | 47 |
FGF12,CACNA1G,SCN8A |
3.137e-04 | -8.07 | Imipramine Action Pathway | SMPDB pathways | SMP0000422 | 30 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
3.169e-04 | -8.06 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 5 | 19454 | 49 |
DLG3,KCNC1,RALYL,GRIN2B,GRIN1 |
3.219e-04 | -8.04 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 48 |
GRM7,CACNA1A,CSMD2,CADPS,GABRA1,MCTP1,ALK,PDE2A,SCN8A,TENM1,FAM131A,GRIK2,CELF4,GRIN1,GRIA3,OLFM1,RIMS2,GABBR2,NRXN2,NRXN1,GPR85,KCNMA1,CACNA1G,GABRD,GRID2,NTRK3,KCNT1,STXBP5,GRIN2B,SYT1,GPHN,NRG3,KCNC1,HCN1,DLG4,RALYL,KCTD16,CACNA1H,CELF2,DPP10,DLG3,SYT7,KCNIP2,CHRM2,GABRB2,FGF12,CNTN5,CELF5 |
3.220e-04 | -8.04 | LIN7A (lin-7 homolog A, crumbs cell polarity complex component) | protein interactions | 8825 | 53 | 3 | 19454 | 49 |
DLG3,DLG4,GRIN2B |
3.322e-04 | -8.01 | regulation of vesicle-mediated transport | biological process | GO:0060627 | 516 | 7 | 18204 | 47 |
SYT7,DLG4,MCTP1,SYT1,CADPS,STXBP5,RIMS2 |
3.337e-04 | -8.01 | amino acid binding | molecular function | GO:0016597 | 51 | 3 | 18094 | 48 |
GRM7,GRIN2B,GRIN1 |
3.342e-04 | -8.00 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 16 | 16828 | 48 |
NRG3,GABRA1,MCTP1,NRXN2,ALK,HCN1,SCN8A,TENM1,GRIK2,GRIN1,NTRK3,GRIA3,KCTD16,OLFM1,CACNA1H,CACNA1A |
3.352e-04 | -8.00 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 48 |
STXBP5,GRIN2B,SYT1,GRID2,NTRK3,KCNT1,HCN1,NRG3,GPHN,KCNC1,CACNA1H,CELF2,RALYL,DLG4,KCTD16,GABRB2,CHRM2,CELF5,FGF12,CNTN5,DLG3,SYT7,DPP10,KCNIP2,GRM7,CSMD2,CACNA1A,PDE2A,ALK,TENM1,SCN8A,CADPS,GABRA1,MCTP1,OLFM1,RIMS2,GRIK2,CELF4,GRIN1,FAM131A,GRIA3,GABRD,KCNMA1,CACNA1G,GPR85,NRXN2,NRXN1,GABBR2 |
3.369e-04 | -8.00 | Caskin1 (CASK interacting protein 1) | protein interactions | 140722 | 11 | 2 | 19454 | 49 |
SYT1,NRXN2 |
3.369e-04 | -8.00 | KCTD16 (potassium channel tetramerization domain containing 16) | protein interactions | 57528 | 11 | 2 | 19454 | 49 |
KCTD16,GABBR2 |
3.390e-04 | -7.99 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 32 | 16828 | 48 |
KCNT1,NTRK3,GRID2,GRIN2B,CSMD2,GRM7,KCNC1,GABRA1,NRG3,CADPS,SCN8A,HCN1,ALK,PDE2A,KCTD16,GRIA3,FAM131A,DLG4,GRIK2,GRIN1,RIMS2,CELF2,KCNIP2,NRXN2,NRXN1,SYT7,KCNMA1,CACNA1G,CNTN5,GABRD,CHRM2,GABRB2 |
3.451e-04 | -7.97 | social behavior | biological process | GO:0035176 | 53 | 3 | 18204 | 47 |
NRXN1,NRXN2,DLG4 |
3.451e-04 | -7.97 | biological process involved in intraspecies interaction between organisms | biological process | GO:0051703 | 53 | 3 | 18204 | 47 |
NRXN1,DLG4,NRXN2 |
3.466e-04 | -7.97 | Fluoxetine Action Pathway | SMPDB pathways | SMP0000426 | 31 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
3.591e-04 | -7.93 | adenylate cyclase-modulating G protein-coupled receptor signaling pathway | biological process | GO:0007188 | 238 | 5 | 18204 | 47 |
CHRM2,PDE2A,GRM7,RIMS2,GABBR2 |
3.611e-04 | -7.93 | neuron differentiation | biological process | GO:0030182 | 1081 | 10 | 18204 | 47 |
HCN1,DLG4,CNTN5,GRID2,NRXN1,ALK,KCNIP2,GABRB2,TENM1,GRM7 |
3.621e-04 | -7.92 | C2 | pfam domains | PF00168 | 123 | 4 | 17795 | 49 |
MCTP1,SYT7,RIMS2,SYT1 |
3.733e-04 | -7.89 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 2 | 18094 | 48 |
NRXN1,DLG4 |
3.733e-04 | -7.89 | glycine binding | molecular function | GO:0016594 | 11 | 2 | 18094 | 48 |
GRIN2B,GRIN1 |
3.740e-04 | -7.89 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 7 | 16828 | 48 |
CELF4,CADPS,NRG3,GRID2,RALYL,GABBR2,CSMD2 |
3.803e-04 | -7.87 | exocytosis | biological process | GO:0006887 | 241 | 5 | 18204 | 47 |
CADPS,STXBP5,RIMS2,SYT7,SYT1 |
3.816e-04 | -7.87 | Nicotine Action Pathway | SMPDB pathways | SMP0000431 | 32 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
3.816e-04 | -7.87 | Methadone Action Pathway | SMPDB pathways | SMP0000408 | 32 | 3 | 1369 | 7 |
KCNIP2,CACNA1A,GRIN1 |
3.816e-04 | -7.87 | Citalopram Action Pathway | SMPDB pathways | SMP0000424 | 32 | 3 | 1369 | 7 |
GRIN1,KCNIP2,CACNA1A |
3.851e-04 | -7.86 | regulation of alternative mRNA splicing, via spliceosome | biological process | GO:0000381 | 55 | 3 | 18204 | 47 |
CELF4,CELF2,CELF5 |
3.868e-04 | -7.86 | Tyr_kinase_rcpt_2_CS | interpro domains | IPR002011 | 11 | 2 | 18521 | 50 |
ALK,NTRK3 |
3.992e-04 | -7.83 | chloride channel complex | cellular component | GO:0034707 | 56 | 3 | 19108 | 49 |
GABRD,GABRB2,GABRA1 |
4.142e-04 | -7.79 | Neurotransmitter-gated ion-channel ligand-binding domain | gene3d domains | 2.70.170.10 | 45 | 3 | 14470 | 47 |
GABRB2,GABRA1,GABRD |
4.142e-04 | -7.79 | Neurotransmitter-gated ion-channel transmembrane domain | gene3d domains | 1.20.58.390 | 45 | 3 | 14470 | 47 |
GABRB2,GABRD,GABRA1 |
4.177e-04 | -7.78 | secretion | biological process | GO:0046903 | 536 | 7 | 18204 | 47 |
SYT1,NRXN2,NRXN1,CADPS,SYT7,STXBP5,RIMS2 |
4.236e-04 | -7.77 | auditory behavior | biological process | GO:0031223 | 12 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
4.236e-04 | -7.77 | neurotransmitter-gated ion channel clustering | biological process | GO:0072578 | 12 | 2 | 18204 | 47 |
GPHN,DLG4 |
4.236e-04 | -7.77 | excitatory chemical synaptic transmission | biological process | GO:0098976 | 12 | 2 | 18204 | 47 |
GRIN1,GRIN2B |
4.350e-04 | -7.74 | ARHGAP32 (Rho GTPase activating protein 32) | protein interactions | 9743 | 141 | 4 | 19454 | 49 |
GPHN,DLG4,NTRK3,GRIN2B |
4.400e-04 | -7.73 | calcium-dependent phospholipid binding | molecular function | GO:0005544 | 56 | 3 | 18094 | 48 |
SYT7,SYT1,MCTP1 |
4.454e-04 | -7.72 | signal transduction | biological process | GO:0007165 | 4637 | 23 | 18204 | 47 |
PDE2A,RIMS2,GRID2,GRIA3,KCNIP2,NTRK3,TENM1,ASIC2,GRIN2B,MCTP1,OLFM1,GPR85,GRIK2,NRG3,NRXN2,CELF4,GRM7,GRIN1,CHRM2,ALK,DLG4,GABBR2,FGF12 |
4.579e-04 | -7.69 | calcium ion transport | biological process | GO:0006816 | 251 | 5 | 18204 | 47 |
CACNA1A,GRIN2B,CACNA1G,CACNA1H,GRIN1 |
4.590e-04 | -7.69 | RECEPTOR_TYR_KIN_II | prosite domains | PS00239 | 11 | 2 | 12186 | 36 |
ALK,NTRK3 |
4.590e-04 | -7.69 | G_PROTEIN_RECEP_F3_3 | prosite domains | PS00981 | 11 | 2 | 12186 | 36 |
GABBR2,GRM7 |
4.666e-04 | -7.67 | cell-cell adhesion | biological process | GO:0098609 | 546 | 7 | 18204 | 47 |
TENM1,DLG3,GRID2,NRXN1,NRXN2,DLG4,CNTN5 |
4.927e-04 | -7.62 | regulation of secretion by cell | biological process | GO:1903530 | 551 | 7 | 18204 | 47 |
MCTP1,SYT1,CADPS,SYT7,STXBP5,GRM7,RIMS2 |
4.978e-04 | -7.61 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 3 | 18204 | 47 |
GRIK2,HCN1,SCN8A |
4.998e-04 | -7.60 | detection of calcium ion | biological process | GO:0005513 | 13 | 2 | 18204 | 47 |
KCNIP2,SYT1 |
4.998e-04 | -7.60 | positive regulation of calcium ion-dependent exocytosis | biological process | GO:0045956 | 13 | 2 | 18204 | 47 |
SYT7,SYT1 |
4.998e-04 | -7.60 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
4.998e-04 | -7.60 | cellular response to potassium ion | biological process | GO:0035865 | 13 | 2 | 18204 | 47 |
CACNA1H,DLG4 |
5.053e-04 | -7.59 | GABA receptor activation | REACTOME pathways | R-HSA-977443 | 56 | 3 | 10285 | 29 |
GABRA1,GABBR2,GABRB2 |
5.143e-04 | -7.57 | synaptic vesicle cycle | biological process | GO:0099504 | 144 | 4 | 18204 | 47 |
SYT7,SYT1,CADPS,RIMS2 |
5.143e-04 | -7.57 | regulated exocytosis | biological process | GO:0045055 | 144 | 4 | 18204 | 47 |
RIMS2,CADPS,SYT1,SYT7 |
5.276e-04 | -7.55 | GABA-gated chloride ion channel activity | molecular function | GO:0022851 | 13 | 2 | 18094 | 48 |
GABRB2,GABRA1 |
5.368e-04 | -7.53 | scalp | COSMIC cancer mutations | scalp | 2110 | 15 | 16828 | 48 |
NRXN1,GABBR2,ALK,CHRM2,GPR85,GRIK2,GRID2,NTRK3,KCNT1,KCTD16,OLFM1,STXBP5,CSMD2,RIMS2,SYT1 |
5.418e-04 | -7.52 | adult behavior | biological process | GO:0030534 | 146 | 4 | 18204 | 47 |
ALK,NRXN1,FGF12,NRXN2 |
5.482e-04 | -7.51 | regulation of postsynaptic membrane neurotransmitter receptor levels | biological process | GO:0099072 | 62 | 3 | 18204 | 47 |
DLG4,DLG3,GPHN |
5.547e-04 | -7.50 | GUCY1A2 (guanylate cyclase 1 soluble subunit alpha 2) | protein interactions | 2977 | 14 | 2 | 19454 | 49 |
DLG4,DLG3 |
5.547e-04 | -7.50 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 2 | 19454 | 49 |
SYT1,NRXN1 |
5.619e-04 | -7.48 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 15 | 16828 | 48 |
CELF4,GRID2,RALYL,CSMD2,GRIN2B,SYT1,OLFM1,GRM7,NRXN2,MCTP1,GABBR2,NRG3,FGF12,HCN1,ALK |
5.619e-04 | -7.48 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 15 | 16828 | 48 |
HCN1,FGF12,ALK,GABBR2,MCTP1,NRXN2,NRG3,SYT1,GRIN2B,CSMD2,GRM7,OLFM1,RALYL,GRID2,CELF4 |
5.821e-04 | -7.45 | mechanosensory behavior | biological process | GO:0007638 | 14 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
5.874e-04 | -7.44 | GABA A receptor activation | REACTOME pathways | R-HSA-977441 | 13 | 2 | 10285 | 29 |
GABRB2,GABRA1 |
5.885e-04 | -7.44 | peptide binding | molecular function | GO:0042277 | 258 | 5 | 18094 | 48 |
KCNIP2,GRIN1,CACNA1A,GRIN2B,GRIA3 |
5.980e-04 | -7.42 | Calcium signaling pathway | KEGG pathways | ko04020 | 181 | 5 | 7161 | 28 |
CACNA1G,GRIN1,CACNA1H,CACNA1A,CHRM2 |
5.980e-04 | -7.42 | Calcium signaling pathway | KEGG pathways | hsa04020 | 181 | 5 | 7161 | 28 |
CACNA1A,CHRM2,CACNA1H,CACNA1G,GRIN1 |
6.100e-04 | -7.40 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 20 | 16828 | 48 |
CACNA1A,SYT1,RIMS2,CSMD2,GRIK2,CELF4,GRIN1,GRID2,GRIA3,ALK,CNTN5,KCNMA1,CELF5,GABRA1,CADPS,NRG3,MCTP1,NRXN1,KCNC1,NRXN2 |
6.107e-04 | -7.40 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 23 | 16828 | 48 |
NTRK3,CACNA1A,GRIN2B,CSMD2,GRM7,MCTP1,GABRA1,CADPS,NRG3,HCN1,TENM1,DLG4,FAM131A,GRIK2,RIMS2,CACNA1H,DPP10,DLG3,FGF12,CNTN5,CACNA1G,KCNMA1,CHRM2 |
6.146e-04 | -7.39 | GNG2 (G protein subunit gamma 2) | protein interactions | 54331 | 66 | 3 | 19454 | 49 |
KCTD16,CACNA1H,CHRM2 |
6.216e-04 | -7.38 | generation of neurons | biological process | GO:0048699 | 1158 | 10 | 18204 | 47 |
TENM1,GRM7,GABRB2,GRID2,NRXN1,KCNIP2,ALK,DLG4,HCN1,CNTN5 |
6.298e-04 | -7.37 | positive regulation of synapse assembly | biological process | GO:0051965 | 65 | 3 | 18204 | 47 |
ASIC2,GRID2,NRXN1 |
6.366e-04 | -7.36 | GPCR_3 | interpro domains | IPR000337 | 14 | 2 | 18521 | 50 |
GABBR2,GRM7 |
6.366e-04 | -7.36 | Neurexin-like | interpro domains | IPR003585 | 14 | 2 | 18521 | 50 |
NRXN2,NRXN1 |
6.366e-04 | -7.36 | GPCR_3_CS | interpro domains | IPR017979 | 14 | 2 | 18521 | 50 |
GABBR2,GRM7 |
6.388e-04 | -7.36 | SDCBP (syndecan binding protein) | protein interactions | 6386 | 422 | 6 | 19454 | 49 |
NRXN1,CADPS,GRM7,GRIA3,GRIK2,PDE2A |
6.547e-04 | -7.33 | distal axon | cellular component | GO:0150034 | 273 | 5 | 19108 | 49 |
CHRM2,KCNC1,OLFM1,GRIK2,GRIN1 |
6.557e-04 | -7.33 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 28 | 16828 | 48 |
DPP10,NRXN2,GABBR2,GABRB2,FGF12,CACNA1G,GRIK2,CELF4,RALYL,DLG4,GRIA3,KCTD16,CACNA1H,RIMS2,NRG3,CADPS,MCTP1,ALK,TENM1,HCN1,GRID2,NTRK3,KCNT1,STXBP5,GRM7,CSMD2,CACNA1A,GRIN2B |
6.621e-04 | -7.32 | vesicle-mediated transport in synapse | biological process | GO:0099003 | 154 | 4 | 18204 | 47 |
CADPS,RIMS2,SYT7,SYT1 |
6.706e-04 | -7.31 | protein heterotetramerization | biological process | GO:0051290 | 15 | 2 | 18204 | 47 |
GRIN1,GRIN2B |
6.846e-04 | -7.29 | blood circulation | biological process | GO:0008015 | 418 | 6 | 18204 | 47 |
SCN8A,CACNA1G,FGF12,KCNMA1,ASIC2,PDE2A |
7.064e-04 | -7.26 | main axon | cellular component | GO:0044304 | 68 | 3 | 19108 | 49 |
KCNC1,SCN8A,DLG4 |
7.292e-04 | -7.22 | TAMALIN (trafficking regulator and scaffold protein tamalin) | protein interactions | 160622 | 16 | 2 | 19454 | 49 |
GABBR2,DLG4 |
7.292e-04 | -7.22 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 2 | 19454 | 49 |
NRXN1,SYT1 |
7.301e-04 | -7.22 | DLGAP4 (DLG associated protein 4) | protein interactions | 22839 | 70 | 3 | 19454 | 49 |
GRIN1,DLG4,DLG3 |
7.466e-04 | -7.20 | Morphine Action Pathway | SMPDB pathways | SMP0000406 | 40 | 3 | 1369 | 7 |
GRIN1,CACNA1A,KCNIP2 |
7.565e-04 | -7.19 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 41 | 16828 | 48 |
HCN1,SCN8A,TENM1,ALK,PDE2A,MCTP1,KCNC1,GPHN,NRG3,GABRA1,CADPS,CACNA1A,SYT1,GRIN2B,CSMD2,GRM7,KCNT1,GRID2,NTRK3,FGF12,CNTN5,KCNMA1,CACNA1G,GPR85,GABRD,CELF5,CHRM2,GABBR2,NRXN1,NRXN2,DPP10,SYT7,DLG3,RIMS2,OLFM1,GRIA3,KCTD16,DLG4,RALYL,CELF4,GRIK2 |
7.651e-04 | -7.18 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
7.688e-04 | -7.17 | calcium channel complex | cellular component | GO:0034704 | 70 | 3 | 19108 | 49 |
CACNA1H,CACNA1A,CACNA1G |
7.937e-04 | -7.14 | Nitric Oxide Signaling Pathway | SMPDB pathways | SMP0063777 | 9 | 2 | 1369 | 7 |
GRIN1,DLG4 |
8.077e-04 | -7.12 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 48 |
GRIK2,ASIC2,SCN8A,HCN1 |
8.322e-04 | -7.09 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 11 | 16828 | 48 |
GABBR2,GABRA1,HCN1,CELF5,KCNT1,GRIK2,NTRK3,GRID2,GRIN2B,CSMD2,GRM7 |
8.366e-04 | -7.09 | Guanylate_kinase_CS | interpro domains | IPR020590 | 16 | 2 | 18521 | 50 |
DLG4,DLG3 |
8.412e-04 | -7.08 | transport vesicle | cellular component | GO:0030133 | 437 | 6 | 19108 | 49 |
STXBP5,MCTP1,SYT7,GRIN1,DLG4,SYT1 |
8.566e-04 | -7.06 | regulation of secretion | biological process | GO:0051046 | 605 | 7 | 18204 | 47 |
SYT7,SYT1,MCTP1,CADPS,RIMS2,GRM7,STXBP5 |
8.585e-04 | -7.06 | ADGRL1 (adhesion G protein-coupled receptor L1) | protein interactions | 22859 | 74 | 3 | 19454 | 49 |
CACNA1A,DLG3,DLG4 |
8.746e-04 | -7.04 | Cocaine addiction | KEGG pathways | ko05030 | 49 | 3 | 7161 | 28 |
GRIN1,DLG4,GRIN2B |
8.746e-04 | -7.04 | Cocaine addiction | KEGG pathways | hsa05030 | 49 | 3 | 7161 | 28 |
GRIN2B,DLG4,GRIN1 |
8.991e-04 | -7.01 | cAMP signaling pathway | KEGG pathways | hsa04024 | 198 | 5 | 7161 | 28 |
GRIN1,GRIA3,GRIN2B,CHRM2,GABBR2 |
8.991e-04 | -7.01 | cAMP signaling pathway | KEGG pathways | ko04024 | 198 | 5 | 7161 | 28 |
GRIN1,GABBR2,GRIN2B,CHRM2,GRIA3 |
9.137e-04 | -7.00 | ligand-gated sodium channel activity | molecular function | GO:0015280 | 17 | 2 | 18094 | 48 |
GRIK2,ASIC2 |
9.267e-04 | -6.98 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 2 | 19454 | 49 |
CACNA1A,CACNA1H |
9.466e-04 | -6.96 | Synaptotagmin | interpro domains | IPR001565 | 17 | 2 | 18521 | 50 |
SYT1,SYT7 |
9.635e-04 | -6.94 | cytoplasmic vesicle membrane | cellular component | GO:0030659 | 1230 | 10 | 19108 | 49 |
CADPS,CHRM2,MCTP1,GABRB2,SYT7,SYT1,GRIA3,GABRA1,STXBP5,DLG4 |
9.687e-04 | -6.94 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 32 | 16828 | 48 |
GABBR2,KCNIP2,NRXN2,DPP10,SYT7,CACNA1G,CNTN5,FGF12,CELF5,GRIA3,KCTD16,RALYL,GRIK2,CELF4,GRIN1,OLFM1,MCTP1,NRG3,GABRA1,CADPS,SCN8A,HCN1,ALK,PDE2A,KCNT1,GRID2,NTRK3,SYT1,GRIN2B,CACNA1A,CSMD2,GRM7 |
9.921e-04 | -6.92 | GUANYLATE_KINASE_1 | prosite domains | PS00856 | 16 | 2 | 12186 | 36 |
DLG4,DLG3 |
9.936e-04 | -6.91 | actin-mediated cell contraction | biological process | GO:0070252 | 76 | 3 | 18204 | 47 |
FGF12,CACNA1G,SCN8A |
1.000e-03 | -6.91 | NBEA (neurobeachin) | protein interactions | 26960 | 78 | 3 | 19454 | 49 |
ALK,DLG3,NTRK3 |
1.018e-03 | -6.89 | trunk | COSMIC cancer mutations | trunk | 3554 | 20 | 16828 | 48 |
KCNT1,FAM131A,GRIK2,GRID2,NTRK3,RIMS2,GRIN2B,CSMD2,GRM7,MCTP1,GABBR2,NRXN1,NRXN2,DPP10,NRG3,GABRA1,HCN1,CNTN5,FGF12,CELF5 |
1.019e-03 | -6.89 | protein localization | biological process | GO:0008104 | 1954 | 13 | 18204 | 47 |
CADPS,DLG4,DPP10,ASIC2,NRXN1,GRID2,HCN1,NRXN2,STXBP5,RIMS2,DLG3,GPHN,GRIK2 |
1.021e-03 | -6.89 | C2 | smart domains | SM00239 | 122 | 4 | 9717 | 36 |
MCTP1,SYT1,SYT7,RIMS2 |
1.034e-03 | -6.87 | DRD1 (dopamine receptor D1) | protein interactions | 1812 | 19 | 2 | 19454 | 49 |
DLG4,GRIN1 |
1.034e-03 | -6.87 | ANKRD13C (ankyrin repeat domain 13C) | protein interactions | 81573 | 19 | 2 | 19454 | 49 |
GRIN1,NTRK3 |
1.046e-03 | -6.86 | human chr5q34 | chromosome location | human chr5q34 | 25 | 2 | 26134 | 50 |
GABRB2,GABRA1 |
1.048e-03 | -6.86 | skin-head_neck-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-head_neck-malignant_melanoma-superficial_spreading | 923 | 9 | 16828 | 48 |
GABRA1,GRIK2,NTRK3,GRID2,CHRM2,GABRD,CSMD2,SYT1,GPR85 |
1.054e-03 | -6.86 | positive regulation of kinase activity | biological process | GO:0033674 | 302 | 5 | 18204 | 47 |
DLG4,NTRK3,DLG3,ALK,TENM1 |
1.058e-03 | -6.85 | cellular macromolecule localization | biological process | GO:0070727 | 1962 | 13 | 18204 | 47 |
STXBP5,DLG3,RIMS2,GPHN,GRIK2,NRXN1,GRID2,HCN1,NRXN2,DPP10,ASIC2,CADPS,DLG4 |
1.097e-03 | -6.82 | vesicle membrane | cellular component | GO:0012506 | 1251 | 10 | 19108 | 49 |
SYT1,GABRA1,GRIA3,STXBP5,DLG4,CHRM2,CADPS,SYT7,GABRB2,MCTP1 |
1.118e-03 | -6.80 | CACHANNEL | prints domains | PR00167 | 9 | 2 | 5227 | 30 |
CACNA1G,CACNA1A |
1.142e-03 | -6.77 | cGMP effects | REACTOME pathways | R-HSA-418457 | 18 | 2 | 10285 | 29 |
KCNMA1,PDE2A |
1.145e-03 | -6.77 | syntaxin-1 binding | molecular function | GO:0017075 | 19 | 2 | 18094 | 48 |
SYT1,STXBP5 |
1.156e-03 | -6.76 | CCPG1 (cell cycle progression 1) | protein interactions | 9236 | 82 | 3 | 19454 | 49 |
GRIA3,GABRD,NTRK3 |
1.160e-03 | -6.76 | C2_domain_sf | interpro domains | IPR035892 | 171 | 4 | 18521 | 50 |
SYT1,SYT7,MCTP1,RIMS2 |
1.181e-03 | -6.74 | 4.1m | smart domains | SM00294 | 14 | 2 | 9717 | 36 |
NRXN1,NRXN2 |
1.198e-03 | -6.73 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 3 | 19454 | 49 |
SYT1,NRXN1,CACNA1A |
1.208e-03 | -6.72 | cellular process | biological process | GO:0009987 | 14996 | 46 | 18204 | 47 |
SYT7,FGF12,CADPS,KCNMA1,OLFM1,GPR85,HCN1,NRXN2,NRG3,CACNA1A,TENM1,CNTN5,GRIN2B,CACNA1G,STXBP5,DLG3,PDE2A,NTRK3,KCNIP2,KCNC1,GRIA3,CACNA1H,GRIN1,DPP10,GRM7,CELF4,GABBR2,DLG4,ALK,CHRM2,GRIK2,KCNT1,GPHN,KCTD16,SYT1,CELF5,NRXN1,GABRD,ASIC2,CELF2,MCTP1,SCN8A,GABRA1,GABRB2,RIMS2,GRID2 |
1.235e-03 | -6.70 | cellular component organization | biological process | GO:0016043 | 5636 | 25 | 18204 | 47 |
GABRA1,GABRB2,KCNC1,GRID2,KCNIP2,TENM1,CELF2,ASIC2,CNTN5,GRIN2B,OLFM1,GPHN,KCTD16,KCNMA1,HCN1,NRXN2,SYT1,NRXN1,NRG3,CELF5,SYT7,GRIN1,CELF4,GRM7,DLG4 |
1.266e-03 | -6.67 | HTR2A (5-hydroxytryptamine receptor 2A) | protein interactions | 3356 | 21 | 2 | 19454 | 49 |
NTRK3,DLG4 |
1.282e-03 | -6.66 | spliceosomal complex assembly | biological process | GO:0000245 | 83 | 3 | 18204 | 47 |
CELF2,CELF4,CELF5 |
1.282e-03 | -6.66 | cardiac muscle contraction | biological process | GO:0060048 | 83 | 3 | 18204 | 47 |
FGF12,CACNA1G,SCN8A |
1.293e-03 | -6.65 | chloride channel activity | molecular function | GO:0005254 | 81 | 3 | 18094 | 48 |
GABRD,GABRA1,GABRB2 |
1.328e-03 | -6.62 | optic nerve development | biological process | GO:0021554 | 21 | 2 | 18204 | 47 |
KCNC1,SCN8A |
1.329e-03 | -6.62 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 17 | 18204 | 47 |
CELF2,CELF4,ASIC2,GRIN1,SYT7,CACNA1H,CACNA1G,CHRM2,GRIN2B,DLG4,FGF12,OLFM1,RIMS2,GRIK2,GRID2,NRXN1,KCNIP2 |
1.336e-03 | -6.62 | protein-containing complex assembly | biological process | GO:0065003 | 1279 | 10 | 18204 | 47 |
GRIN1,CELF4,KCTD16,CELF2,SYT1,HCN1,DLG4,CELF5,KCNC1,GRIN2B |
1.421e-03 | -6.56 | regulation of potassium ion transmembrane transport | biological process | GO:1901379 | 86 | 3 | 18204 | 47 |
KCNC1,DPP10,KCNIP2 |
1.438e-03 | -6.54 | animal organ development | biological process | GO:0048513 | 2846 | 16 | 18204 | 47 |
CSMD1,GRIN1,CACNA1H,GRIN2B,CACNA1G,ALK,FGF12,CNTN5,OLFM1,PDE2A,GABRB2,KCNC1,GRID2,NRG3,NTRK3,HCN1 |
1.453e-03 | -6.53 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 22 | 16828 | 48 |
STXBP5,CACNA1H,GRM7,CSMD2,CACNA1A,RIMS2,GRIK2,GRID2,NTRK3,DLG4,KCNT1,KCTD16,GRIA3,GABRB2,ALK,TENM1,HCN1,CADPS,DPP10,NRXN2,MCTP1,GABBR2 |
1.456e-03 | -6.53 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 11 | 16828 | 48 |
HCN1,CNTN5,ALK,PDE2A,KCNC1,CSMD2,KCTD16,KCNT1,GRIN1,GRIK2,NTRK3 |
1.458e-03 | -6.53 | postsynapse assembly | biological process | GO:0099068 | 22 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
1.478e-03 | -6.52 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 4 | 18094 | 48 |
GRIA3,GRIN2B,GRIK2,GRIN1 |
1.507e-03 | -6.50 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 4 | 18094 | 48 |
GRIN1,GRIA3,GRIN2B,GRIK2 |
1.520e-03 | -6.49 | GLS2 (glutaminase 2) | protein interactions | 27165 | 23 | 2 | 19454 | 49 |
DLG3,DLG4 |
1.536e-03 | -6.48 | PDZ domain binding | molecular function | GO:0030165 | 86 | 3 | 18094 | 48 |
DLG4,GRIK2,GRID2 |
1.559e-03 | -6.46 | G_PROTEIN_RECEP_F3_4 | prosite domains | PS50259 | 20 | 2 | 12186 | 36 |
GRM7,GABBR2 |
1.561e-03 | -6.46 | MAP1A (microtubule associated protein 1A) | protein interactions | 4130 | 91 | 3 | 19454 | 49 |
DLG4,GRIN2B,KCNMA1 |
1.567e-03 | -6.46 | GPCRs, Class C Metabotropic glutamate, pheromone | WikiPathways | WP501 | 16 | 2 | 5310 | 20 |
GRM7,GABBR2 |
1.568e-03 | -6.46 | multicellular organismal response to stress | biological process | GO:0033555 | 89 | 3 | 18204 | 47 |
GRM7,GRIK2,HCN1 |
1.578e-03 | -6.45 | Long-term depression | KEGG pathways | hsa04730 | 60 | 3 | 7161 | 28 |
GRID2,GRIA3,CACNA1A |
1.578e-03 | -6.45 | Long-term depression | KEGG pathways | ko04730 | 60 | 3 | 7161 | 28 |
GRID2,CACNA1A,GRIA3 |
1.594e-03 | -6.44 | GPCR_3_C | interpro domains | IPR017978 | 22 | 2 | 18521 | 50 |
GABBR2,GRM7 |
1.594e-03 | -6.44 | Guanylate_kin-like_dom | interpro domains | IPR008144 | 22 | 2 | 18521 | 50 |
DLG4,DLG3 |
1.595e-03 | -6.44 | inhibitory synapse assembly | biological process | GO:1904862 | 23 | 2 | 18204 | 47 |
GABRA1,GABRB2 |
1.603e-03 | -6.44 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 41 | 16828 | 48 |
GABRD,CELF5,CNTN5,FGF12,KCNMA1,GPR85,CACNA1G,CHRM2,NRXN1,NRXN2,GABBR2,SYT7,DLG3,DPP10,RIMS2,OLFM1,GRIA3,KCTD16,CELF4,GRIK2,RALYL,DLG4,TENM1,HCN1,SCN8A,PDE2A,ALK,KCNC1,MCTP1,NRG3,CADPS,GABRA1,GPHN,CSMD2,CACNA1A,GRIN2B,SYT1,GRM7,KCNT1,NTRK3,GRID2 |
1.611e-03 | -6.43 | KDM5B (lysine demethylase 5B) | protein interactions | 10765 | 92 | 3 | 19454 | 49 |
GRIN2B,CACNA1H,CACNA1A |
1.617e-03 | -6.43 | C2 domain | gene3d domains | 2.60.40.150 | 156 | 4 | 14470 | 47 |
SYT7,RIMS2,SYT1,MCTP1 |
1.656e-03 | -6.40 | CNKSR2 (connector enhancer of kinase suppressor of Ras 2) | protein interactions | 22866 | 24 | 2 | 19454 | 49 |
DLG3,DLG4 |
1.656e-03 | -6.40 | KCNMA1 (potassium calcium-activated channel subfamily M alpha 1) | protein interactions | 3778 | 24 | 2 | 19454 | 49 |
KCNMA1,CACNA1H |
1.656e-03 | -6.40 | RASGRF1 (Ras protein specific guanine nucleotide releasing factor 1) | protein interactions | 5923 | 24 | 2 | 19454 | 49 |
NTRK3,GRIN2B |
1.657e-03 | -6.40 | 7tm_3 | pfam domains | PF00003 | 22 | 2 | 17795 | 49 |
GRM7,GABBR2 |
1.701e-03 | -6.38 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 17 | 16828 | 48 |
PDE2A,GABRB2,ALK,KCNMA1,HCN1,CNTN5,CADPS,GABBR2,STXBP5,OLFM1,GRM7,CSMD2,RIMS2,SYT1,GRID2,GRIN1,GRIK2 |
1.715e-03 | -6.37 | sodium channel complex | cellular component | GO:0034706 | 24 | 2 | 19108 | 49 |
SCN8A,GRIK2 |
1.737e-03 | -6.36 | postsynaptic density organization | biological process | GO:0097106 | 24 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
1.737e-03 | -6.36 | positive regulation of dendrite extension | biological process | GO:1903861 | 24 | 2 | 18204 | 47 |
SYT1,RIMS2 |
1.792e-03 | -6.32 | Brain-Derived Neurotrophic Factor (BDNF) signaling pathway | WikiPathways | WP2380 | 144 | 4 | 5310 | 20 |
GRIN2B,NTRK3,GRIN1,GRIA3 |
1.797e-03 | -6.32 | CRIPT (CXXC repeat containing interactor of PDZ3 domain) | protein interactions | 9419 | 25 | 2 | 19454 | 49 |
DLG3,DLG4 |
1.800e-03 | -6.32 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 47 | 16828 | 48 |
CACNA1A,CSMD2,GRM7,MCTP1,CADPS,GABRA1,SCN8A,TENM1,ALK,PDE2A,GRIA3,FAM131A,GRIK2,GRIN1,CELF4,RIMS2,GABBR2,NRXN2,NRXN1,KCNMA1,GPR85,CACNA1G,GABRD,KCNT1,NTRK3,GRID2,SYT1,GRIN2B,STXBP5,KCNC1,GPHN,NRG3,HCN1,KCTD16,RALYL,DLG4,CACNA1H,CELF2,KCNIP2,DPP10,SYT7,DLG3,CNTN5,FGF12,CELF5,CHRM2,GABRB2 |
1.804e-03 | -6.32 | NRIONCHANNEL | prints domains | PR00252 | 43 | 3 | 5227 | 30 |
GABRB2,GABRA1,GABRD |
1.818e-03 | -6.31 | human chr9q34.3 | chromosome location | human chr9q34.3 | 126 | 3 | 26134 | 50 |
KCNT1,OLFM1,GRIN1 |
1.832e-03 | -6.30 | cAMP binding | molecular function | GO:0030552 | 24 | 2 | 18094 | 48 |
HCN1,PDE2A |
1.833e-03 | -6.30 | neurogenesis | biological process | GO:0022008 | 1334 | 10 | 18204 | 47 |
GRM7,TENM1,GABRB2,KCNIP2,ALK,NRXN1,GRID2,CNTN5,HCN1,DLG4 |
1.861e-03 | -6.29 | neuronal dense core vesicle | cellular component | GO:0098992 | 25 | 2 | 19108 | 49 |
CADPS,STXBP5 |
1.865e-03 | -6.28 | circulatory system process | biological process | GO:0003013 | 508 | 6 | 18204 | 47 |
KCNMA1,ASIC2,PDE2A,FGF12,CACNA1G,SCN8A |
1.868e-03 | -6.28 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 10 | 16828 | 48 |
DPP10,GRID2,NRG3,GRM7,CACNA1H,GABRB2,GRIN2B,RIMS2,SYT1,CACNA1A |
1.885e-03 | -6.27 | regulation of long-term neuronal synaptic plasticity | biological process | GO:0048169 | 25 | 2 | 18204 | 47 |
GRIK2,DLG4 |
1.889e-03 | -6.27 | GUANYLATE_KINASE_2 | prosite domains | PS50052 | 22 | 2 | 12186 | 36 |
DLG3,DLG4 |
1.913e-03 | -6.26 | human chr17q11.2-q12 | chromosome location | human chr17q11.2-q12 | 1 | 1 | 26134 | 50 |
ASIC2 |
1.913e-03 | -6.26 | human chr2p23.2-p23.1 | chromosome location | human chr2p23.2-p23.1 | 1 | 1 | 26134 | 50 |
ALK |
1.913e-03 | -6.26 | human chr3q28-q29 | chromosome location | human chr3q28-q29 | 1 | 1 | 26134 | 50 |
FGF12 |
1.913e-03 | -6.26 | human chr4q22.1-q22.2 | chromosome location | human chr4q22.1-q22.2 | 1 | 1 | 26134 | 50 |
GRID2 |
1.943e-03 | -6.24 | TSPAN7 (tetraspanin 7) | protein interactions | 7102 | 26 | 2 | 19454 | 49 |
CACNA1A,CHRM2 |
1.943e-03 | -6.24 | DLGAP2 (DLG associated protein 2) | protein interactions | 9228 | 26 | 2 | 19454 | 49 |
DLG3,DLG4 |
1.949e-03 | -6.24 | endocytic vesicle | cellular component | GO:0030139 | 349 | 5 | 19108 | 49 |
SYT7,DLG4,CHRM2,SYT1,GRIA3 |
2.007e-03 | -6.21 | nerve development | biological process | GO:0021675 | 97 | 3 | 18204 | 47 |
GABRB2,KCNC1,SCN8A |
2.034e-03 | -6.20 | macromolecule localization | biological process | GO:0033036 | 2376 | 14 | 18204 | 47 |
NRXN1,GRID2,HCN1,NRXN2,STXBP5,RIMS2,DLG3,GPHN,GRIK2,CADPS,DLG4,DPP10,ASIC2,SYT7 |
2.039e-03 | -6.20 | Nitric oxide stimulates guanylate cyclase | REACTOME pathways | R-HSA-392154 | 24 | 2 | 10285 | 29 |
KCNMA1,PDE2A |
2.059e-03 | -6.19 | GK/Ca_channel_bsu | interpro domains | IPR008145 | 25 | 2 | 18521 | 50 |
DLG4,DLG3 |
2.082e-03 | -6.17 | cellular localization | biological process | GO:0051641 | 2660 | 15 | 18204 | 47 |
CADPS,DLG4,ASIC2,DPP10,SYT7,GRID2,NRXN1,SYT1,NRXN2,HCN1,DLG3,RIMS2,STXBP5,GPHN,GRIK2 |
2.095e-03 | -6.17 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 49 |
DLG3,DLG4 |
2.095e-03 | -6.17 | DLGAP3 (DLG associated protein 3) | protein interactions | 58512 | 27 | 2 | 19454 | 49 |
DLG3,DLG4 |
2.095e-03 | -6.17 | DLGAP1 (DLG associated protein 1) | protein interactions | 9229 | 27 | 2 | 19454 | 49 |
DLG3,DLG4 |
2.104e-03 | -6.16 | PRKCG (protein kinase C gamma) | protein interactions | 5582 | 101 | 3 | 19454 | 49 |
GRIN1,GRIN2B,GABRA1 |
2.106e-03 | -6.16 | monoatomic anion channel activity | molecular function | GO:0005253 | 96 | 3 | 18094 | 48 |
GABRB2,GABRA1,GABRD |
2.127e-03 | -6.15 | heart contraction | biological process | GO:0060047 | 99 | 3 | 18204 | 47 |
FGF12,CACNA1G,SCN8A |
2.140e-03 | -6.15 | Guanylate_kin | pfam domains | PF00625 | 25 | 2 | 17795 | 49 |
DLG4,DLG3 |
2.141e-03 | -6.15 | lung-carcinoid-endocrine_tumour-typical | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour-typical | 321 | 5 | 16828 | 48 |
TENM1,DPP10,ALK,NTRK3,DLG3 |
2.141e-03 | -6.15 | typical | COSMIC cancer mutations | typical | 321 | 5 | 16828 | 48 |
DPP10,ALK,NTRK3,DLG3,TENM1 |
2.150e-03 | -6.14 | ionotropic glutamate receptor binding | molecular function | GO:0035255 | 26 | 2 | 18094 | 48 |
DLG4,DLG3 |
2.155e-03 | -6.14 | positive regulation of monoatomic ion transport | biological process | GO:0043270 | 212 | 4 | 18204 | 47 |
KCNC1,KCNIP2,GRIN1,FGF12 |
2.158e-03 | -6.14 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 31 | 16828 | 48 |
OLFM1,CACNA1H,GRIN1,CELF4,RALYL,KCTD16,GRIA3,GABRB2,CHRM2,CELF5,FGF12,SYT7,DPP10,NRXN2,GABBR2,GRM7,CSMD2,CACNA1A,SYT1,GRIN2B,NTRK3,GRID2,KCNT1,PDE2A,ALK,TENM1,HCN1,SCN8A,GABRA1,NRG3,MCTP1 |
2.170e-03 | -6.13 | RRM_1 | pfam domains | PF00076 | 199 | 4 | 17795 | 49 |
CELF4,CELF5,RALYL,CELF2 |
2.170e-03 | -6.13 | dendrite cytoplasm | cellular component | GO:0032839 | 27 | 2 | 19108 | 49 |
GRIK2,DLG4 |
2.171e-03 | -6.13 | bladder | COSMIC cancer mutations | bladder | 14112 | 47 | 16828 | 48 |
NRXN1,NRXN2,GABBR2,GABRD,KCNMA1,GPR85,CACNA1G,CELF4,GRIK2,GRIN1,FAM131A,GRIA3,RIMS2,GABRA1,CADPS,MCTP1,PDE2A,ALK,TENM1,SCN8A,GRM7,CSMD2,CACNA1A,SYT7,DLG3,DPP10,KCNIP2,GABRB2,CHRM2,CELF5,CNTN5,FGF12,RALYL,DLG4,KCTD16,CELF2,CACNA1H,NRG3,GPHN,KCNC1,HCN1,NTRK3,GRID2,KCNT1,STXBP5,SYT1,GRIN2B |
2.171e-03 | -6.13 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 47 | 16828 | 48 |
GRM7,CSMD2,CACNA1A,CADPS,GABRA1,MCTP1,PDE2A,ALK,TENM1,SCN8A,GRIK2,CELF4,GRIN1,FAM131A,GRIA3,RIMS2,NRXN2,NRXN1,GABBR2,GABRD,KCNMA1,GPR85,CACNA1G,GRID2,NTRK3,KCNT1,STXBP5,GRIN2B,SYT1,NRG3,GPHN,KCNC1,HCN1,DLG4,RALYL,KCTD16,CACNA1H,CELF2,SYT7,DLG3,DPP10,KCNIP2,GABRB2,CHRM2,CELF5,FGF12,CNTN5 |
2.198e-03 | -6.12 | positive regulation of protein tyrosine kinase activity | biological process | GO:0061098 | 27 | 2 | 18204 | 47 |
DLG3,DLG4 |
2.198e-03 | -6.12 | regulation of dendrite extension | biological process | GO:1903859 | 27 | 2 | 18204 | 47 |
RIMS2,SYT1 |
2.198e-03 | -6.12 | postsynaptic specialization organization | biological process | GO:0099084 | 27 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
2.219e-03 | -6.11 | cellular component organization or biogenesis | biological process | GO:0071840 | 5850 | 25 | 18204 | 47 |
ASIC2,CELF2,TENM1,GRIN2B,CNTN5,GABRB2,GABRA1,KCNIP2,GRID2,KCNC1,GRM7,CELF4,GRIN1,SYT7,DLG4,KCNMA1,KCTD16,GPHN,OLFM1,CELF5,NRG3,NRXN1,SYT1,NRXN2,HCN1 |
2.232e-03 | -6.10 | thyroid | COSMIC cancer mutations | thyroid | 9867 | 38 | 16828 | 48 |
RIMS2,CACNA1H,CELF2,OLFM1,GRIA3,CELF4,GRIN1,GRIK2,RALYL,DLG4,CELF5,GABRD,CACNA1G,KCNMA1,CNTN5,NRXN2,NRXN1,GABBR2,KCNIP2,DLG3,SYT7,DPP10,CSMD2,GRIN2B,SYT1,CACNA1A,KCNT1,NTRK3,GRID2,TENM1,SCN8A,HCN1,PDE2A,ALK,KCNC1,CADPS,GABRA1,NRG3 |
2.252e-03 | -6.10 | actin filament-based movement | biological process | GO:0030048 | 101 | 3 | 18204 | 47 |
SCN8A,CACNA1G,FGF12 |
2.252e-03 | -6.10 | regulation of potassium ion transport | biological process | GO:0043266 | 101 | 3 | 18204 | 47 |
DPP10,KCNIP2,KCNC1 |
2.264e-03 | -6.09 | Amphetamine addiction | KEGG pathways | ko05031 | 68 | 3 | 7161 | 28 |
GRIN1,GRIN2B,GRIA3 |
2.264e-03 | -6.09 | Amphetamine addiction | KEGG pathways | hsa05031 | 68 | 3 | 7161 | 28 |
GRIN2B,GRIA3,GRIN1 |
2.319e-03 | -6.07 | outward rectifier potassium channel activity | molecular function | GO:0015271 | 27 | 2 | 18094 | 48 |
KCNT1,KCNIP2 |
2.363e-03 | -6.05 | regulation of calcium ion-dependent exocytosis | biological process | GO:0017158 | 28 | 2 | 18204 | 47 |
SYT1,SYT7 |
2.363e-03 | -6.05 | startle response | biological process | GO:0001964 | 28 | 2 | 18204 | 47 |
CSMD1,GRID2 |
2.392e-03 | -6.04 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 16 | 16828 | 48 |
DPP10,NRG3,KCNIP2,NRXN2,ALK,CHRM2,HCN1,SCN8A,GPR85,GABRD,TENM1,CACNA1H,STXBP5,CACNA1A,GRIN2B,CSMD2 |
2.392e-03 | -6.04 | Ligand-gated ion channel transport | REACTOME pathways | R-HSA-975298 | 26 | 2 | 10285 | 29 |
GABRB2,GABRA1 |
2.393e-03 | -6.04 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 22 | 16828 | 48 |
RIMS2,OLFM1,CACNA1H,GRIA3,KCTD16,CNTN5,CACNA1G,NRXN2,GABBR2,DPP10,CSMD2,CACNA1A,STXBP5,KCNT1,NTRK3,GRID2,TENM1,HCN1,ALK,KCNC1,CADPS,NRG3 |
2.393e-03 | -6.04 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 22 | 16828 | 48 |
GABBR2,NRXN2,DPP10,CACNA1G,CNTN5,KCTD16,GRIA3,RIMS2,CACNA1H,OLFM1,KCNC1,CADPS,NRG3,HCN1,TENM1,ALK,KCNT1,NTRK3,GRID2,CACNA1A,CSMD2,STXBP5 |
2.403e-03 | -6.03 | brain development | biological process | GO:0007420 | 724 | 7 | 18204 | 47 |
GRIN1,ALK,NRG3,GRID2,KCNC1,GRIN2B,CNTN5 |
2.447e-03 | -6.01 | inorganic cation import across plasma membrane | biological process | GO:0098659 | 104 | 3 | 18204 | 47 |
CACNA1A,CACNA1G,CACNA1H |
2.447e-03 | -6.01 | inorganic ion import across plasma membrane | biological process | GO:0099587 | 104 | 3 | 18204 | 47 |
CACNA1G,CACNA1A,CACNA1H |
2.519e-03 | -5.98 | Apob (apolipoprotein B) | protein interactions | 54225 | 1 | 1 | 19454 | 49 |
CELF2 |
2.519e-03 | -5.98 | KCNC2 (potassium voltage-gated channel subfamily C member 2) | protein interactions | 3747 | 1 | 1 | 19454 | 49 |
KCNC1 |
2.519e-03 | -5.98 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 49 |
NRXN1 |
2.519e-03 | -5.98 | Kcna4 (potassium voltage-gated channel subfamily A member 4) | protein interactions | 25469 | 1 | 1 | 19454 | 49 |
DLG4 |
2.519e-03 | -5.98 | Shank1 (SH3 and multiple ankyrin repeat domains 1) | protein interactions | 78957 | 1 | 1 | 19454 | 49 |
DLG4 |
2.519e-03 | -5.98 | Cript (CXXC repeat containing interactor of PDZ3 domain) | protein interactions | 56725 | 1 | 1 | 19454 | 49 |
DLG4 |
2.519e-03 | -5.98 | Setsip (SET like protein) | protein interactions | 307947 | 1 | 1 | 19454 | 49 |
CHRM2 |
2.519e-03 | -5.98 | Rnf138 (ring finger protein 138) | protein interactions | 94196 | 1 | 1 | 19454 | 49 |
CACNA1A |
2.519e-03 | -5.98 | Pick1 (protein interacting with C kinase 1) | protein interactions | 18693 | 1 | 1 | 19454 | 49 |
ASIC2 |
2.543e-03 | -5.97 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 19 | 16828 | 48 |
CNTN5,HCN1,SCN8A,CACNA1G,ALK,GABBR2,DPP10,NRG3,CACNA1A,RIMS2,CSMD2,GRM7,OLFM1,CELF2,STXBP5,KCNT1,DLG4,NTRK3,GRID2 |
2.556e-03 | -5.97 | EGF_3 | prosite domains | PS50026 | 196 | 4 | 12186 | 36 |
NRG3,TENM1,NRXN1,NRXN2 |
2.561e-03 | -5.97 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 19 | 16828 | 48 |
CNTN5,HCN1,CACNA1G,SCN8A,ALK,GABBR2,DPP10,NRG3,CACNA1A,RIMS2,CSMD2,GRM7,CELF2,OLFM1,STXBP5,KCNT1,DLG4,NTRK3,GRID2 |
2.563e-03 | -5.97 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 8 | 16828 | 48 |
GRID2,CADPS,KCTD16,GRIA3,GRM7,GABRB2,RIMS2,GABRD |
2.564e-03 | -5.97 | extrinsic component of dense core granule membrane | cellular component | GO:0098922 | 1 | 1 | 19108 | 49 |
STXBP5 |
2.564e-03 | -5.97 | mossy fiber rosette | cellular component | GO:0097471 | 1 | 1 | 19108 | 49 |
GRIK2 |
2.564e-03 | -5.97 | extrinsic component of neuronal dense core vesicle membrane | cellular component | GO:0098674 | 1 | 1 | 19108 | 49 |
STXBP5 |
2.582e-03 | -5.96 | sensory perception of cold stimulus | biological process | GO:0062035 | 1 | 1 | 18204 | 47 |
GRIK2 |
2.582e-03 | -5.96 | positive regulation of calcium ion-dependent exocytosis of neurotransmitter | biological process | GO:1903235 | 1 | 1 | 18204 | 47 |
SYT1 |
2.582e-03 | -5.96 | regulation of retina development in camera-type eye | biological process | GO:1902866 | 1 | 1 | 18204 | 47 |
CELF4 |
2.582e-03 | -5.96 | regulation of systemic arterial blood pressure by aortic arch baroreceptor feedback | biological process | GO:0003026 | 1 | 1 | 18204 | 47 |
ASIC2 |
2.582e-03 | -5.96 | response to environmental enrichment | biological process | GO:0090648 | 1 | 1 | 18204 | 47 |
ALK |
2.582e-03 | -5.96 | synchronous neurotransmitter secretion | biological process | GO:0071911 | 1 | 1 | 18204 | 47 |
SYT1 |
2.582e-03 | -5.96 | propylene metabolic process | biological process | GO:0018964 | 1 | 1 | 18204 | 47 |
GRIN1 |
2.582e-03 | -5.96 | directional guidance of interneurons involved in migration from the subpallium to the cortex | biological process | GO:0021840 | 1 | 1 | 18204 | 47 |
NRG3 |
2.582e-03 | -5.96 | chemorepulsion involved in interneuron migration from the subpallium to the cortex | biological process | GO:0021842 | 1 | 1 | 18204 | 47 |
NRG3 |
2.582e-03 | -5.96 | detection of cold stimulus involved in thermoception | biological process | GO:0120169 | 1 | 1 | 18204 | 47 |
GRIK2 |
2.582e-03 | -5.96 | glycine receptor clustering | biological process | GO:0072579 | 1 | 1 | 18204 | 47 |
GPHN |
2.582e-03 | -5.96 | fast, calcium ion-dependent exocytosis of neurotransmitter | biological process | GO:0098746 | 1 | 1 | 18204 | 47 |
SYT1 |
2.584e-03 | -5.96 | GRIN3B (glutamate ionotropic receptor NMDA type subunit 3B) | protein interactions | 116444 | 30 | 2 | 19454 | 49 |
GRIN1,DLG4 |
2.653e-03 | -5.93 | P2Y1 nucleotide receptor binding | molecular function | GO:0031812 | 1 | 1 | 18094 | 48 |
DLG4 |
2.653e-03 | -5.93 | molybdopterin molybdotransferase activity | molecular function | GO:0061599 | 1 | 1 | 18094 | 48 |
GPHN |
2.653e-03 | -5.93 | intracellular cAMP-activated cation channel activity involved in regulation of presynaptic membrane potential | molecular function | GO:0140232 | 1 | 1 | 18094 | 48 |
HCN1 |
2.653e-03 | -5.93 | molybdopterin adenylyltransferase activity | molecular function | GO:0061598 | 1 | 1 | 18094 | 48 |
GPHN |
2.653e-03 | -5.93 | G protein-coupled nucleotide receptor binding | molecular function | GO:0031811 | 1 | 1 | 18094 | 48 |
DLG4 |
2.673e-03 | -5.92 | ligand-gated calcium channel activity | molecular function | GO:0099604 | 29 | 2 | 18094 | 48 |
GRIN1,GRIN2B |
2.678e-03 | -5.92 | RRM_dom | interpro domains | IPR000504 | 215 | 4 | 18521 | 50 |
CELF4,CELF5,CELF2,RALYL |
2.700e-03 | -5.91 | C2A_Synaptotagmin-7 | interpro domains | IPR037732 | 1 | 1 | 18521 | 50 |
SYT7 |
2.700e-03 | -5.91 | GABRA1_ECD | interpro domains | IPR047079 | 1 | 1 | 18521 | 50 |
GABRA1 |
2.700e-03 | -5.91 | MoCF_biosynth_CS | interpro domains | IPR008284 | 1 | 1 | 18521 | 50 |
GPHN |
2.700e-03 | -5.91 | GBR2_CC | interpro domains | IPR041689 | 1 | 1 | 18521 | 50 |
GABBR2 |
2.700e-03 | -5.91 | C2B_Synaptotagmin-7 | interpro domains | IPR037741 | 1 | 1 | 18521 | 50 |
SYT7 |
2.700e-03 | -5.91 | GPCR_3_mGluR7 | interpro domains | IPR001883 | 1 | 1 | 18521 | 50 |
GRM7 |
2.700e-03 | -5.91 | MoeA_linker/N_sf | interpro domains | IPR036135 | 1 | 1 | 18521 | 50 |
GPHN |
2.700e-03 | -5.91 | MoeA_C_domain_IV_sf | interpro domains | IPR036688 | 1 | 1 | 18521 | 50 |
GPHN |
2.700e-03 | -5.91 | DLG3_SH3 | interpro domains | IPR035763 | 1 | 1 | 18521 | 50 |
DLG3 |
2.700e-03 | -5.91 | GABBAa1_rcpt | interpro domains | IPR005431 | 1 | 1 | 18521 | 50 |
GABRA1 |
2.700e-03 | -5.91 | CACNA1A | interpro domains | IPR005448 | 1 | 1 | 18521 | 50 |
CACNA1A |
2.700e-03 | -5.91 | GPCR_3_GABA_rcpt_B2 | interpro domains | IPR002457 | 1 | 1 | 18521 | 50 |
GABBR2 |
2.700e-03 | -5.91 | MoeA-like | interpro domains | IPR038987 | 1 | 1 | 18521 | 50 |
GPHN |
2.700e-03 | -5.91 | Na_channel_a8su | interpro domains | IPR008054 | 1 | 1 | 18521 | 50 |
SCN8A |
2.700e-03 | -5.91 | MoeA_linker/N | interpro domains | IPR005110 | 1 | 1 | 18521 | 50 |
GPHN |
2.700e-03 | -5.91 | K_chnl_volt-dep_Kv3 | interpro domains | IPR005403 | 1 | 1 | 18521 | 50 |
KCNC1 |
2.700e-03 | -5.91 | MoeA_C_domain_IV | interpro domains | IPR005111 | 1 | 1 | 18521 | 50 |
GPHN |
2.700e-03 | -5.91 | Musac_Ach_M2_rcpt | interpro domains | IPR001065 | 1 | 1 | 18521 | 50 |
CHRM2 |
2.700e-03 | -5.91 | NTRK3 | interpro domains | IPR020446 | 1 | 1 | 18521 | 50 |
NTRK3 |
2.700e-03 | -5.91 | GABAAd_rcpt | interpro domains | IPR008098 | 1 | 1 | 18521 | 50 |
GABRD |
2.751e-03 | -5.90 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 47 | 16828 | 48 |
HCN1,NRG3,KCNC1,STXBP5,GRIN2B,SYT1,NTRK3,GRID2,KCNT1,GABRB2,CHRM2,CELF5,FGF12,CNTN5,SYT7,DLG3,DPP10,KCNIP2,CELF2,CACNA1H,RALYL,DLG4,KCTD16,PDE2A,ALK,TENM1,SCN8A,GABRA1,CADPS,MCTP1,GRM7,CSMD2,CACNA1A,GABRD,KCNMA1,GPR85,CACNA1G,NRXN1,NRXN2,GABBR2,OLFM1,RIMS2,CELF4,GRIN1,GRIK2,FAM131A,GRIA3 |
2.754e-03 | -5.89 | MoeA_C | pfam domains | PF03454 | 1 | 1 | 17795 | 49 |
GPHN |
2.754e-03 | -5.89 | GBR2_CC | pfam domains | PF18455 | 1 | 1 | 17795 | 49 |
GABBR2 |
2.754e-03 | -5.89 | MoeA_N | pfam domains | PF03453 | 1 | 1 | 17795 | 49 |
GPHN |
2.758e-03 | -5.89 | HECTD4 (HECT domain E3 ubiquitin protein ligase 4) | protein interactions | 283450 | 31 | 2 | 19454 | 49 |
GRIA3,GRIN2B |
2.777e-03 | -5.89 | GPCRMGR | prints domains | PR00248 | 14 | 2 | 5227 | 30 |
GRM7,GABBR2 |
2.790e-03 | -5.88 | L1CAM interactions | REACTOME pathways | R-HSA-373760 | 101 | 3 | 10285 | 29 |
DLG3,SCN8A,DLG4 |
2.869e-03 | -5.85 | chloride transmembrane transport | biological process | GO:1902476 | 110 | 3 | 18204 | 47 |
GABRD,GABRB2,GABRA1 |
2.869e-03 | -5.85 | positive regulation of cell junction assembly | biological process | GO:1901890 | 110 | 3 | 18204 | 47 |
ASIC2,NRXN1,GRID2 |
2.916e-03 | -5.84 | positive regulation of transferase activity | biological process | GO:0051347 | 381 | 5 | 18204 | 47 |
NTRK3,DLG3,ALK,TENM1,DLG4 |
2.944e-03 | -5.83 | regulation of mRNA splicing, via spliceosome | biological process | GO:0048024 | 111 | 3 | 18204 | 47 |
CELF2,CELF4,CELF5 |
2.954e-03 | -5.82 | MOCF_BIOSYNTHESIS_1 | prosite domains | PS01078 | 1 | 1 | 12186 | 36 |
GPHN |
2.954e-03 | -5.82 | MOCF_BIOSYNTHESIS_2 | prosite domains | PS01079 | 1 | 1 | 12186 | 36 |
GPHN |
3.024e-03 | -5.80 | nodular | COSMIC cancer mutations | nodular | 1515 | 11 | 16828 | 48 |
KCNT1,GRID2,NTRK3,GRIK2,GRIN2B,CSMD2,GRM7,GABBR2,GABRA1,HCN1,CELF5 |
3.028e-03 | -5.80 | large_intestine-colon | COSMIC cancer mutations | large_intestine-colon | 1291 | 10 | 16828 | 48 |
CACNA1H,ALK,CACNA1A,CNTN5,CACNA1G,RIMS2,CADPS,DPP10,KCNT1,KCTD16 |
3.042e-03 | -5.80 | CDH2 (cadherin 2) | protein interactions | 1000 | 115 | 3 | 19454 | 49 |
NTRK3,GRIN1,GRIK2 |
3.042e-03 | -5.80 | presynaptic active zone membrane | cellular component | GO:0048787 | 32 | 2 | 19108 | 49 |
HCN1,SCN8A |
3.096e-03 | -5.78 | heart process | biological process | GO:0003015 | 113 | 3 | 18204 | 47 |
SCN8A,CACNA1G,FGF12 |
3.175e-03 | -5.75 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 8 | 16828 | 48 |
CADPS,GRID2,KCTD16,GRIA3,GRM7,GABRB2,RIMS2,GABRD |
3.180e-03 | -5.75 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 32 | 16828 | 48 |
KCNT1,NTRK3,GRID2,CACNA1A,SYT1,GRIN2B,CSMD2,GRM7,MCTP1,NRG3,GABRA1,HCN1,SCN8A,TENM1,ALK,PDE2A,KCTD16,GRIA3,RALYL,GRIN1,CELF4,OLFM1,CACNA1H,GABBR2,NRXN2,DPP10,SYT7,DLG3,FGF12,CELF5,CHRM2,GABRB2 |
3.222e-03 | -5.74 | RRM | prosite domains | PS50102 | 209 | 4 | 12186 | 36 |
RALYL,CELF2,CELF4,CELF5 |
3.248e-03 | -5.73 | Molybdopterin biosynthesis moea protein, domain 2 | gene3d domains | 3.90.105.10 | 1 | 1 | 14470 | 47 |
GPHN |
3.248e-03 | -5.73 | MoeA, C-terminal, domain IV | gene3d domains | 2.40.340.10 | 1 | 1 | 14470 | 47 |
GPHN |
3.248e-03 | -5.73 | Molybdopterin biosynthesis moea protein, domain 3 | gene3d domains | 2.170.190.11 | 1 | 1 | 14470 | 47 |
GPHN |
3.249e-03 | -5.73 | protein tyrosine kinase activator activity | molecular function | GO:0030296 | 32 | 2 | 18094 | 48 |
ALK,NRG3 |
3.294e-03 | -5.72 | breast-other-papilloma | COSMIC cancer mutations | breast-other-papilloma | 30 | 2 | 16828 | 48 |
NTRK3,ALK |
3.294e-03 | -5.72 | adenosis | COSMIC cancer mutations | adenosis | 30 | 2 | 16828 | 48 |
ALK,NTRK3 |
3.294e-03 | -5.72 | breast-other-adenosis | COSMIC cancer mutations | breast-other-adenosis | 30 | 2 | 16828 | 48 |
NTRK3,ALK |
3.312e-03 | -5.71 | SEMA4F (ssemaphorin 4F) | protein interactions | 10505 | 34 | 2 | 19454 | 49 |
GRIA3,DLG4 |
3.330e-03 | -5.70 | regulation of metal ion transport | biological process | GO:0010959 | 393 | 5 | 18204 | 47 |
FGF12,GRIN1,DPP10,KCNIP2,KCNC1 |
3.415e-03 | -5.68 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 3 | 18204 | 47 |
GRID2,NRXN1,ASIC2 |
3.430e-03 | -5.68 | ZDHHC15 (zinc finger DHHC-type palmitoyltransferase 15) | protein interactions | 158866 | 120 | 3 | 19454 | 49 |
RIMS2,MCTP1,NRXN1 |
3.487e-03 | -5.66 | head development | biological process | GO:0060322 | 774 | 7 | 18204 | 47 |
GRID2,NRG3,GRIN2B,KCNC1,ALK,CNTN5,GRIN1 |
3.507e-03 | -5.65 | NRXN1 (neurexin 1) | protein interactions | 9378 | 35 | 2 | 19454 | 49 |
SYT1,SYT7 |
3.507e-03 | -5.65 | GRIK1 (glutamate ionotropic receptor kainate type subunit 1) | protein interactions | 2897 | 35 | 2 | 19454 | 49 |
DLG4,GRIK2 |
3.519e-03 | -5.65 | EGF-like_dom | interpro domains | IPR000742 | 232 | 4 | 18521 | 50 |
NRG3,TENM1,NRXN2,NRXN1 |
3.567e-03 | -5.64 | bone | COSMIC cancer mutations | bone | 8157 | 33 | 16828 | 48 |
CSMD2,CACNA1A,GRIN2B,SYT1,STXBP5,GRM7,KCNT1,NTRK3,GRID2,TENM1,HCN1,SCN8A,ALK,KCNC1,NRG3,CADPS,CELF2,OLFM1,CACNA1H,GRIA3,GRIK2,GRIN1,CELF4,FAM131A,DLG4,GABRD,CNTN5,FGF12,CACNA1G,GABRB2,NRXN1,NRXN2,GABBR2 |
3.607e-03 | -5.62 | cellular response to nitrogen compound | biological process | GO:1901699 | 580 | 6 | 18204 | 47 |
CACNA1A,PDE2A,CHRM2,GABRB2,GRIN1,HCN1 |
3.613e-03 | -5.62 | Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | REACTOME pathways | R-HSA-399721 | 32 | 2 | 10285 | 29 |
GRIA3,DLG4 |
3.613e-03 | -5.62 | Trafficking of AMPA receptors | REACTOME pathways | R-HSA-399719 | 32 | 2 | 10285 | 29 |
GRIA3,DLG4 |
3.638e-03 | -5.62 | central nervous system development | biological process | GO:0007417 | 995 | 8 | 18204 | 47 |
ASIC2,GRIN1,ALK,KCNC1,GRIN2B,GRID2,NRG3,CNTN5 |
3.667e-03 | -5.61 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 47 |
FGF12,CACNA1G,SCN8A |
3.677e-03 | -5.61 | behavioral fear response | biological process | GO:0001662 | 35 | 2 | 18204 | 47 |
GRM7,GRIK2 |
3.677e-03 | -5.61 | presynaptic modulation of chemical synaptic transmission | biological process | GO:0099171 | 35 | 2 | 18204 | 47 |
CHRM2,GRIK2 |
3.681e-03 | -5.60 | regulation of synapse organization | biological process | GO:0050807 | 246 | 4 | 18204 | 47 |
ASIC2,NRXN1,GRIN2B,GRID2 |
3.714e-03 | -5.60 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 9 | 16828 | 48 |
GRID2,NTRK3,GRIK2,GABRA1,SYT1,GPR85,CSMD2,GABRD,CHRM2 |
3.754e-03 | -5.59 | chloride transport | biological process | GO:0006821 | 121 | 3 | 18204 | 47 |
GABRA1,GABRB2,GABRD |
3.795e-03 | -5.57 | GuKc | smart domains | SM00072 | 25 | 2 | 9717 | 36 |
DLG4,DLG3 |
3.823e-03 | -5.57 | human chr8p23.2 | chromosome location | human chr8p23.2 | 2 | 1 | 26134 | 50 |
CSMD1 |
3.823e-03 | -5.57 | human chr14q23.3-q24.1 | chromosome location | human chr14q23.3-q24.1 | 2 | 1 | 26134 | 50 |
GPHN |
3.857e-03 | -5.56 | Aldosterone synthesis and secretion | KEGG pathways | ko04925 | 82 | 3 | 7161 | 28 |
PDE2A,CACNA1G,CACNA1H |
3.857e-03 | -5.56 | Aldosterone synthesis and secretion | KEGG pathways | hsa04925 | 82 | 3 | 7161 | 28 |
CACNA1G,CACNA1H,PDE2A |
3.867e-03 | -5.56 | chloride transmembrane transporter activity | molecular function | GO:0015108 | 119 | 3 | 18094 | 48 |
GABRD,GABRB2,GABRA1 |
3.872e-03 | -5.55 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 9 | 16828 | 48 |
HCN1,FGF12,CNTN5,GRM7,ALK,KCNT1,NRG3,CELF4,GRID2 |
3.887e-03 | -5.55 | behavioral defense response | biological process | GO:0002209 | 36 | 2 | 18204 | 47 |
GRIK2,GRM7 |
3.913e-03 | -5.54 | GRIN2D (glutamate ionotropic receptor NMDA type subunit 2D) | protein interactions | 2906 | 37 | 2 | 19454 | 49 |
GRIN1,DLG4 |
3.931e-03 | -5.54 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 6 | 16828 | 48 |
NRG3,GRID2,GRM7,FGF12,HCN1,SYT1 |
4.010e-03 | -5.52 | PLCG1 (phospholipase C gamma 1) | protein interactions | 5335 | 258 | 4 | 19454 | 49 |
ALK,NTRK3,GRIN1,GRIN2B |
4.010e-03 | -5.52 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 4 | 18204 | 47 |
GRIN2B,NRXN1,GRID2,ASIC2 |
4.068e-03 | -5.50 | large_intestine-caecum-adenoma | COSMIC cancer mutations | large_intestine-caecum-adenoma | 229 | 4 | 16828 | 48 |
OLFM1,CSMD2,RIMS2,HCN1 |
4.089e-03 | -5.50 | RBD_domain_sf | interpro domains | IPR035979 | 242 | 4 | 18521 | 50 |
RALYL,CELF2,CELF4,CELF5 |
4.102e-03 | -5.50 | positive regulation of potassium ion transmembrane transport | biological process | GO:1901381 | 37 | 2 | 18204 | 47 |
KCNIP2,KCNC1 |
4.106e-03 | -5.50 | SYNAPTOTAGMN | prints domains | PR00399 | 17 | 2 | 5227 | 30 |
SYT1,SYT7 |
4.123e-03 | -5.49 | GABBR1 (gamma-aminobutyric acid type B receptor subunit 1) | protein interactions | 2550 | 38 | 2 | 19454 | 49 |
KCTD16,GABBR2 |
4.241e-03 | -5.46 | positive regulation of protein kinase activity | biological process | GO:0045860 | 256 | 4 | 18204 | 47 |
DLG4,TENM1,NTRK3,DLG3 |
4.272e-03 | -5.46 | Nucleotide-bd_a/b_plait_sf | interpro domains | IPR012677 | 245 | 4 | 18521 | 50 |
RALYL,CELF2,CELF5,CELF4 |
4.339e-03 | -5.44 | GLRB (glycine receptor beta) | protein interactions | 2743 | 39 | 2 | 19454 | 49 |
GPHN,GRIA3 |
4.408e-03 | -5.42 | Laminin_G_2 | pfam domains | PF02210 | 36 | 2 | 17795 | 49 |
NRXN1,NRXN2 |
4.435e-03 | -5.42 | molybdenum cofactor biosynthesis | BIOCYC pathways | HUMAN_PWY-6823 | 4 | 1 | 902 | 1 |
GPHN |
4.435e-03 | -5.42 | molybdenum cofactor biosynthesis | BIOCYC pathways | META_PWY-6823 | 4 | 1 | 902 | 1 |
GPHN |
4.464e-03 | -5.41 | papilloma | COSMIC cancer mutations | papilloma | 35 | 2 | 16828 | 48 |
NTRK3,ALK |
4.464e-03 | -5.41 | columnar_cell_lesion | COSMIC cancer mutations | columnar_cell_lesion | 35 | 2 | 16828 | 48 |
NTRK3,ALK |
4.464e-03 | -5.41 | ductal_epithelial_hyperplasia-hyperplasia_of_usual_type | COSMIC cancer mutations | ductal_epithelial_hyperplasia-hyperplasia_of_usual_type | 35 | 2 | 16828 | 48 |
NTRK3,ALK |
4.464e-03 | -5.41 | breast-hyperplasia-columnar_cell_lesion | COSMIC cancer mutations | breast-hyperplasia-columnar_cell_lesion | 35 | 2 | 16828 | 48 |
ALK,NTRK3 |
4.464e-03 | -5.41 | breast-hyperplasia-ductal_epithelial_hyperplasia-hyperplasia_of_usual_type | COSMIC cancer mutations | breast-hyperplasia-ductal_epithelial_hyperplasia-hyperplasia_of_usual_type | 35 | 2 | 16828 | 48 |
NTRK3,ALK |
4.519e-03 | -5.40 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 11 | 16828 | 48 |
KCTD16,KCNT1,NRXN1,GRIK2,SYT1,GPR85,RIMS2,CSMD2,ALK,CHRM2,OLFM1 |
4.547e-03 | -5.39 | amide binding | molecular function | GO:0033218 | 254 | 4 | 18094 | 48 |
GRIN2B,GRIA3,CACNA1A,GRIN1 |
4.558e-03 | -5.39 | cyclic nucleotide binding | molecular function | GO:0030551 | 38 | 2 | 18094 | 48 |
HCN1,PDE2A |
4.590e-03 | -5.38 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 10 | 16828 | 48 |
CSMD2,HCN1,CNTN5,PDE2A,KCNC1,KCNT1,KCTD16,NTRK3,GRIN1,GRIK2 |
4.604e-03 | -5.38 | PDZ | pfam domains | PF00595 | 122 | 3 | 17795 | 49 |
RIMS2,DLG4,DLG3 |
4.671e-03 | -5.37 | RAF/MAP kinase cascade | REACTOME pathways | R-HSA-5673001 | 245 | 4 | 10285 | 29 |
NRG3,GRIN2B,DLG4,GRIN1 |
4.671e-03 | -5.37 | SOS-mediated signalling | REACTOME pathways | R-HSA-112412 | 245 | 4 | 10285 | 29 |
GRIN1,NRG3,GRIN2B,DLG4 |
4.671e-03 | -5.37 | SHC1 events in EGFR signaling | REACTOME pathways | R-HSA-180336 | 245 | 4 | 10285 | 29 |
DLG4,GRIN2B,NRG3,GRIN1 |
4.671e-03 | -5.37 | GRB2 events in EGFR signaling | REACTOME pathways | R-HSA-179812 | 245 | 4 | 10285 | 29 |
NRG3,GRIN2B,DLG4,GRIN1 |
4.687e-03 | -5.36 | response to calcium ion | biological process | GO:0051592 | 131 | 3 | 18204 | 47 |
KCNMA1,KCNIP2,SYT1 |
4.708e-03 | -5.36 | synaptic vesicle membrane | cellular component | GO:0030672 | 132 | 3 | 19108 | 49 |
MCTP1,SYT7,SYT1 |
4.708e-03 | -5.36 | exocytic vesicle membrane | cellular component | GO:0099501 | 132 | 3 | 19108 | 49 |
SYT1,MCTP1,SYT7 |
4.718e-03 | -5.36 | breast-carcinoma_in_situ-lobular_carcinoma_in_situ | COSMIC cancer mutations | breast-carcinoma_in_situ-lobular_carcinoma_in_situ | 36 | 2 | 16828 | 48 |
NTRK3,ALK |
4.718e-03 | -5.36 | lobular_carcinoma_in_situ | COSMIC cancer mutations | lobular_carcinoma_in_situ | 36 | 2 | 16828 | 48 |
ALK,NTRK3 |
4.722e-03 | -5.36 | dendrite membrane | cellular component | GO:0032590 | 40 | 2 | 19108 | 49 |
KCNC1,GABRA1 |
4.749e-03 | -5.35 | LAM_G_DOMAIN | prosite domains | PS50025 | 35 | 2 | 12186 | 36 |
NRXN2,NRXN1 |
4.781e-03 | -5.34 | fear response | biological process | GO:0042596 | 40 | 2 | 18204 | 47 |
GRIK2,GRM7 |
4.783e-03 | -5.34 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 6 | 16828 | 48 |
ALK,SYT7,GRIA3,CACNA1A,CNTN5,CSMD2 |
4.787e-03 | -5.34 | WBP1 (WW domain binding protein 1) | protein interactions | 23559 | 41 | 2 | 19454 | 49 |
CACNA1A,KCNIP2 |
4.787e-03 | -5.34 | KCNJ2 (potassium inwardly rectifying channel subfamily J member 2) | protein interactions | 3759 | 41 | 2 | 19454 | 49 |
DLG3,DLG4 |
4.788e-03 | -5.34 | regulation of mRNA processing | biological process | GO:0050684 | 132 | 3 | 18204 | 47 |
CELF5,CELF2,CELF4 |
4.788e-03 | -5.34 | inorganic anion transmembrane transport | biological process | GO:0098661 | 132 | 3 | 18204 | 47 |
GABRA1,GABRD,GABRB2 |
4.810e-03 | -5.34 | NCAM1 interactions | REACTOME pathways | R-HSA-419037 | 37 | 2 | 10285 | 29 |
CACNA1G,CACNA1H |
4.867e-03 | -5.33 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 6 | 16828 | 48 |
ALK,CSMD2,CACNA1A,CNTN5,SYT7,GRIA3 |
4.947e-03 | -5.31 | Signalling to p38 via RIT and RIN | REACTOME pathways | R-HSA-187706 | 249 | 4 | 10285 | 29 |
DLG4,GRIN2B,NRG3,GRIN1 |
4.947e-03 | -5.31 | ARMS-mediated activation | REACTOME pathways | R-HSA-170984 | 249 | 4 | 10285 | 29 |
GRIN2B,NRG3,DLG4,GRIN1 |
5.009e-03 | -5.30 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 7 | 16828 | 48 |
GRIN2B,RIMS2,CSMD2,CACNA1H,DPP10,GRID2,CADPS |
5.018e-03 | -5.29 | Frs2-mediated activation | REACTOME pathways | R-HSA-170968 | 250 | 4 | 10285 | 29 |
DLG4,NRG3,GRIN2B,GRIN1 |
5.018e-03 | -5.29 | KCND3 (potassium voltage-gated channel subfamily D member 3) | protein interactions | 3752 | 42 | 2 | 19454 | 49 |
DPP10,KCNIP2 |
5.031e-03 | -5.29 | C17orf67 (chromosome 17 open reading frame 67) | protein interactions | 339210 | 2 | 1 | 19454 | 49 |
CADPS |
5.031e-03 | -5.29 | ZNF233 (zinc finger protein 233) | protein interactions | 353355 | 2 | 1 | 19454 | 49 |
CACNA1A |
5.031e-03 | -5.29 | Dlgap1 (DLG associated protein 1) | protein interactions | 65040 | 2 | 1 | 19454 | 49 |
DLG4 |
5.031e-03 | -5.29 | AOAH (acyloxyacyl hydrolase) | protein interactions | 313 | 2 | 1 | 19454 | 49 |
DLG3 |
5.031e-03 | -5.29 | Grin2b (glutamate ionotropic receptor NMDA type subunit 2B) | protein interactions | 24410 | 2 | 1 | 19454 | 49 |
DLG4 |
5.080e-03 | -5.28 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 8 | 16828 | 48 |
NTRK3,DPP10,KCNT1,GABBR2,CELF2,CSMD2,RIMS2,FGF12 |
5.080e-03 | -5.28 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 8 | 16828 | 48 |
FGF12,RIMS2,CSMD2,CELF2,GABBR2,KCNT1,DPP10,NTRK3 |
5.089e-03 | -5.28 | MAPK1/MAPK3 signaling | REACTOME pathways | R-HSA-5684996 | 251 | 4 | 10285 | 29 |
DLG4,GRIN2B,NRG3,GRIN1 |
5.122e-03 | -5.27 | Kv4.2-KChIP2 channel complex | cellular component | GO:0071193 | 2 | 1 | 19108 | 49 |
KCNIP2 |
5.122e-03 | -5.27 | G protein-coupled GABA receptor complex | cellular component | GO:1902712 | 2 | 1 | 19108 | 49 |
GABBR2 |
5.157e-03 | -5.27 | establishment of synaptic specificity at neuromuscular junction | biological process | GO:0007529 | 2 | 1 | 18204 | 47 |
GPHN |
5.157e-03 | -5.27 | olefin metabolic process | biological process | GO:1900673 | 2 | 1 | 18204 | 47 |
GRIN1 |
5.157e-03 | -5.27 | swimming behavior | biological process | GO:0036269 | 2 | 1 | 18204 | 47 |
ALK |
5.157e-03 | -5.27 | cellular alkene metabolic process | biological process | GO:0043449 | 2 | 1 | 18204 | 47 |
GRIN1 |
5.157e-03 | -5.27 | response to nickel cation | biological process | GO:0010045 | 2 | 1 | 18204 | 47 |
CACNA1G |
5.157e-03 | -5.27 | response to carbon monoxide | biological process | GO:0034465 | 2 | 1 | 18204 | 47 |
KCNMA1 |
5.161e-03 | -5.27 | Prolonged ERK activation events | REACTOME pathways | R-HSA-169893 | 252 | 4 | 10285 | 29 |
NRG3,GRIN2B,DLG4,GRIN1 |
5.234e-03 | -5.25 | Signaling by Leptin | REACTOME pathways | R-HSA-2586552 | 253 | 4 | 10285 | 29 |
GRIN1,GRIN2B,NRG3,DLG4 |
5.260e-03 | -5.25 | positive regulation of regulated secretory pathway | biological process | GO:1903307 | 42 | 2 | 18204 | 47 |
SYT7,SYT1 |
5.299e-03 | -5.24 | voltage-gated calcium channel activity involved SA node cell action potential | molecular function | GO:0086059 | 2 | 1 | 18094 | 48 |
CACNA1G |
5.299e-03 | -5.24 | syntaxin-3 binding | molecular function | GO:0030348 | 2 | 1 | 18094 | 48 |
SYT1 |
5.299e-03 | -5.24 | group III metabotropic glutamate receptor activity | molecular function | GO:0001642 | 2 | 1 | 18094 | 48 |
GRM7 |
5.299e-03 | -5.24 | intracellular sodium-activated potassium channel activity | molecular function | GO:0005228 | 2 | 1 | 18094 | 48 |
KCNT1 |
5.299e-03 | -5.24 | BRE binding | molecular function | GO:0042835 | 2 | 1 | 18094 | 48 |
CELF4 |
5.299e-03 | -5.24 | extracellularly glutamate-gated ion channel activity | molecular function | GO:0005234 | 2 | 1 | 18094 | 48 |
GRIK2 |
5.299e-03 | -5.24 | large conductance calcium-activated potassium channel activity | molecular function | GO:0060072 | 2 | 1 | 18094 | 48 |
KCNMA1 |
5.332e-03 | -5.23 | Class C/3 (Metabotropic glutamate/pheromone receptors) | REACTOME pathways | R-HSA-420499 | 39 | 2 | 10285 | 29 |
GRM7,GABBR2 |
5.366e-03 | -5.23 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 12 | 16828 | 48 |
PDE2A,GRM7,CSMD2,GRIN2B,KCNMA1,SYT1,HCN1,CNTN5,GRID2,NTRK3,GRIA3,MCTP1 |
5.378e-03 | -5.23 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 15 | 16828 | 48 |
KCNT1,FAM131A,GRID2,GRIK2,RIMS2,GRIN2B,CSMD2,MCTP1,NRXN2,NRXN1,DPP10,NRG3,CNTN5,FGF12,HCN1 |
5.381e-03 | -5.22 | Interleukin receptor SHC signaling | REACTOME pathways | R-HSA-912526 | 255 | 4 | 10285 | 29 |
GRIN1,GRIN2B,NRG3,DLG4 |
5.390e-03 | -5.22 | extremity | COSMIC cancer mutations | extremity | 1876 | 12 | 16828 | 48 |
GRIA3,NTRK3,GRID2,CSMD2,GRIN2B,SYT1,GRM7,MCTP1,CNTN5,HCN1,KCNMA1,PDE2A |
5.392e-03 | -5.22 | CELF1/2_RRM1 | interpro domains | IPR034196 | 2 | 1 | 18521 | 50 |
CELF2 |
5.392e-03 | -5.22 | CELF1/2_RRM2 | interpro domains | IPR034198 | 2 | 1 | 18521 | 50 |
CELF2 |
5.392e-03 | -5.22 | Slowpoke-like_C | interpro domains | IPR048735 | 2 | 1 | 18521 | 50 |
KCNMA1 |
5.392e-03 | -5.22 | MoaB/Mog-like_dom_sf | interpro domains | IPR036425 | 2 | 1 | 18521 | 50 |
GPHN |
5.392e-03 | -5.22 | MCTP_C | interpro domains | IPR013583 | 2 | 1 | 18521 | 50 |
MCTP1 |
5.392e-03 | -5.22 | RHS_repeat | interpro domains | IPR031325 | 2 | 1 | 18521 | 50 |
TENM1 |
5.392e-03 | -5.22 | CELF1/2_RRM3 | interpro domains | IPR034199 | 2 | 1 | 18521 | 50 |
CELF2 |
5.392e-03 | -5.22 | CAPS | interpro domains | IPR033227 | 2 | 1 | 18521 | 50 |
CADPS |
5.392e-03 | -5.22 | Lgl_C_dom | interpro domains | IPR013905 | 2 | 1 | 18521 | 50 |
STXBP5 |
5.392e-03 | -5.22 | MoaB/Mog_dom | interpro domains | IPR001453 | 2 | 1 | 18521 | 50 |
GPHN |
5.418e-03 | -5.22 | sodium ion transmembrane transport | biological process | GO:0035725 | 138 | 3 | 18204 | 47 |
HCN1,ASIC2,SCN8A |
5.456e-03 | -5.21 | Signalling to RAS | REACTOME pathways | R-HSA-167044 | 256 | 4 | 10285 | 29 |
GRIN1,DLG4,GRIN2B,NRG3 |
5.476e-03 | -5.21 | Laminin_G | interpro domains | IPR001791 | 41 | 2 | 18521 | 50 |
NRXN2,NRXN1 |
5.492e-03 | -5.20 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 4 | 18094 | 48 |
GRIN1,GRIN2B,GRIK2,GRIA3 |
5.500e-03 | -5.20 | Slowpoke_C | pfam domains | PF21014 | 2 | 1 | 17795 | 49 |
KCNMA1 |
5.500e-03 | -5.20 | RHS_repeat | pfam domains | PF05593 | 2 | 1 | 17795 | 49 |
TENM1 |
5.500e-03 | -5.20 | Gly_rich | pfam domains | PF12810 | 2 | 1 | 17795 | 49 |
ALK |
5.500e-03 | -5.20 | PRT_C | pfam domains | PF08372 | 2 | 1 | 17795 | 49 |
MCTP1 |
5.500e-03 | -5.20 | MoCF_biosynth | pfam domains | PF00994 | 2 | 1 | 17795 | 49 |
GPHN |
5.500e-03 | -5.20 | Lgl_C | pfam domains | PF08596 | 2 | 1 | 17795 | 49 |
STXBP5 |
5.527e-03 | -5.20 | positive regulation of cation transmembrane transport | biological process | GO:1904064 | 139 | 3 | 18204 | 47 |
KCNC1,KCNIP2,GRIN1 |
5.545e-03 | -5.19 | ligand-gated monoatomic anion channel activity | molecular function | GO:0099095 | 42 | 2 | 18094 | 48 |
GABRB2,GABRA1 |
5.608e-03 | -5.18 | VEGFR2 mediated cell proliferation | REACTOME pathways | R-HSA-5218921 | 258 | 4 | 10285 | 29 |
GRIN1,DLG4,NRG3,GRIN2B |
5.632e-03 | -5.18 | Activation of Na-permeable Kainate Receptors | REACTOME pathways | R-HSA-451307 | 2 | 1 | 10285 | 29 |
GRIK2 |
5.699e-03 | -5.17 | thyroid-other-neoplasm | COSMIC cancer mutations | thyroid-other-neoplasm | 7637 | 31 | 16828 | 48 |
DPP10,SYT7,KCNIP2,GABBR2,NRXN2,CNTN5,CACNA1G,KCNMA1,GABRD,CELF5,DLG4,GRIN1,CELF4,GRIA3,OLFM1,CELF2,CACNA1H,RIMS2,GABRA1,NRG3,CADPS,KCNC1,ALK,PDE2A,SCN8A,TENM1,NTRK3,CACNA1A,SYT1,GRIN2B,CSMD2 |
5.739e-03 | -5.16 | MUSCRINICM2R | prints domains | PR00539 | 1 | 1 | 5227 | 30 |
CHRM2 |
5.739e-03 | -5.16 | NACHANNEL8 | prints domains | PR01667 | 1 | 1 | 5227 | 30 |
SCN8A |
5.739e-03 | -5.16 | PQVDCCALPHA1 | prints domains | PR01632 | 1 | 1 | 5227 | 30 |
CACNA1A |
5.739e-03 | -5.16 | MTABOTROPC7R | prints domains | PR01057 | 1 | 1 | 5227 | 30 |
GRM7 |
5.739e-03 | -5.16 | GABAARALPHA1 | prints domains | PR01614 | 1 | 1 | 5227 | 30 |
GABRA1 |
5.739e-03 | -5.16 | KV31CHANNEL | prints domains | PR01581 | 1 | 1 | 5227 | 30 |
KCNC1 |
5.739e-03 | -5.16 | NTKRECEPTOR3 | prints domains | PR01942 | 1 | 1 | 5227 | 30 |
NTRK3 |
5.739e-03 | -5.16 | GABAARDELTA | prints domains | PR01722 | 1 | 1 | 5227 | 30 |
GABRD |
5.739e-03 | -5.16 | GABAB2RECPTR | prints domains | PR01178 | 1 | 1 | 5227 | 30 |
GABBR2 |
5.760e-03 | -5.16 | mammary gland morphogenesis | biological process | GO:0060443 | 44 | 2 | 18204 | 47 |
CSMD1,NRG3 |
5.760e-03 | -5.16 | cellular response to amyloid-beta | biological process | GO:1904646 | 44 | 2 | 18204 | 47 |
CACNA1A,GRIN1 |
5.864e-03 | -5.14 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 47 |
GABRA1,GABRD,GABRB2 |
5.920e-03 | -5.13 | Interleukin-2 signaling | REACTOME pathways | R-HSA-451927 | 262 | 4 | 10285 | 29 |
GRIN1,DLG4,GRIN2B,NRG3 |
5.999e-03 | -5.12 | Signalling to ERKs | REACTOME pathways | R-HSA-187687 | 263 | 4 | 10285 | 29 |
DLG4,NRG3,GRIN2B,GRIN1 |
6.018e-03 | -5.11 | positive regulation of potassium ion transport | biological process | GO:0043268 | 45 | 2 | 18204 | 47 |
KCNC1,KCNIP2 |
6.087e-03 | -5.10 | femur | COSMIC cancer mutations | femur | 1197 | 9 | 16828 | 48 |
DLG4,NRG3,GRID2,GABBR2,CACNA1H,FGF12,HCN1,SYT1,GABRD |
6.110e-03 | -5.10 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 8 | 16828 | 48 |
GRIN2B,SYT1,CACNA1A,GRM7,CACNA1H,GABRB2,GRID2,NRG3 |
6.111e-03 | -5.10 | Laminin | gene3d domains | 2.10.25.10 | 226 | 4 | 14470 | 47 |
NRG3,NRXN2,TENM1,NRXN1 |
6.117e-03 | -5.10 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 10 | 16828 | 48 |
GABRD,TENM1,CSMD2,CACNA1A,GRIN2B,CACNA1H,ALK,NRXN2,KCNIP2,DPP10 |
6.117e-03 | -5.10 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 10 | 16828 | 48 |
NRXN2,KCNIP2,DPP10,GABRD,CSMD2,TENM1,CACNA1A,GRIN2B,CACNA1H,ALK |
6.155e-03 | -5.09 | LRP2 (LDL receptor related protein 2) | protein interactions | 4036 | 148 | 3 | 19454 | 49 |
DLG3,DLG4,SYT1 |
6.161e-03 | -5.09 | FCERI mediated MAPK activation | REACTOME pathways | R-HSA-2871796 | 265 | 4 | 10285 | 29 |
GRIN2B,NRG3,DLG4,GRIN1 |
6.164e-03 | -5.09 | EPHB-mediated forward signaling | REACTOME pathways | R-HSA-3928662 | 42 | 2 | 10285 | 29 |
GRIN1,GRIN2B |
6.205e-03 | -5.08 | terminal bouton | cellular component | GO:0043195 | 46 | 2 | 19108 | 49 |
GRIK2,GRIN1 |
6.324e-03 | -5.06 | monoatomic anion transmembrane transporter activity | molecular function | GO:0008509 | 142 | 3 | 18094 | 48 |
GABRD,GABRA1,GABRB2 |
6.346e-03 | -5.06 | RRM | smart domains | SM00360 | 202 | 4 | 9717 | 36 |
RALYL,CELF5,CELF2,CELF4 |
6.387e-03 | -5.05 | ACTN2 (actinin alpha 2) | protein interactions | 88 | 150 | 3 | 19454 | 49 |
DLG4,GRIN2B,GRIN1 |
6.398e-03 | -5.05 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 37 | 16828 | 48 |
HCN1,SCN8A,ALK,PDE2A,MCTP1,GPHN,NRG3,CADPS,GABRA1,GRIN2B,SYT1,CSMD2,GRM7,STXBP5,KCNT1,GRID2,NTRK3,CNTN5,FGF12,CACNA1G,GABRD,CELF5,CHRM2,GABBR2,NRXN1,NRXN2,DPP10,DLG3,RIMS2,CELF2,OLFM1,CACNA1H,GRIA3,KCTD16,DLG4,GRIK2,CELF4 |
6.412e-03 | -5.05 | stomach-carcinoma-adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-adenocarcinoma | 15150 | 48 | 16828 | 48 |
KCNIP2,DLG3,SYT7,DPP10,CELF5,FGF12,CNTN5,GABRB2,CHRM2,KCTD16,RALYL,DLG4,CELF2,CACNA1H,KCNC1,NRG3,GPHN,HCN1,KCNT1,NTRK3,GRID2,SYT1,GRIN2B,STXBP5,NRXN1,NRXN2,GABBR2,GABRD,KCNMA1,GPR85,CACNA1G,GRIA3,GRIN1,CELF4,GRIK2,FAM131A,RIMS2,OLFM1,MCTP1,GABRA1,CADPS,TENM1,SCN8A,PDE2A,ALK,CSMD2,CACNA1A,GRM7 |
6.472e-03 | -5.04 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 37 | 16828 | 48 |
RIMS2,CACNA1H,OLFM1,CELF2,KCTD16,GRIA3,GRIK2,CELF4,DLG4,CELF5,GABRD,CACNA1G,FGF12,CNTN5,CHRM2,NRXN2,NRXN1,GABBR2,DLG3,DPP10,CSMD2,GRIN2B,SYT1,STXBP5,GRM7,KCNT1,NTRK3,GRID2,SCN8A,HCN1,PDE2A,ALK,MCTP1,NRG3,CADPS,GABRA1,GPHN |
6.486e-03 | -5.04 | MoaB/Mog-like domain | gene3d domains | 3.40.980.10 | 2 | 1 | 14470 | 47 |
GPHN |
6.492e-03 | -5.04 | positive regulation of secretion by cell | biological process | GO:1903532 | 289 | 4 | 18204 | 47 |
SYT7,SYT1,CADPS,STXBP5 |
6.560e-03 | -5.03 | regulation of cellular process | biological process | GO:0050794 | 11468 | 38 | 18204 | 47 |
DPP10,GRM7,CELF4,SYT7,GRIN1,ALK,CHRM2,CADPS,FGF12,GABBR2,DLG4,KCNMA1,GPR85,OLFM1,KCTD16,GRIK2,CELF5,NRXN1,NRG3,SYT1,HCN1,NRXN2,ASIC2,CACNA1A,TENM1,CELF2,GRIN2B,CACNA1G,MCTP1,STXBP5,RIMS2,DLG3,PDE2A,NTRK3,KCNIP2,KCNC1,GRIA3,GRID2 |
6.578e-03 | -5.02 | RET signaling | REACTOME pathways | R-HSA-8853659 | 270 | 4 | 10285 | 29 |
GRIN1,DLG4,NRG3,GRIN2B |
6.590e-03 | -5.02 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 20 | 16828 | 48 |
CACNA1A,SYT1,GRIN2B,RIMS2,CSMD2,CELF2,GRIA3,RALYL,GRIK2,GRID2,NTRK3,HCN1,KCNMA1,CACNA1G,CELF5,TENM1,ALK,KCNIP2,NRXN1,NRXN2 |
6.636e-03 | -5.02 | response to abiotic stimulus | biological process | GO:0009628 | 1100 | 8 | 18204 | 47 |
PDE2A,ASIC2,KCNMA1,GRIN1,GRIK2,KCNC1,NRXN1,NRXN2 |
6.636e-03 | -5.02 | BDNF-TrkB Signaling | WikiPathways | WP3676 | 33 | 2 | 5310 | 20 |
GRIN1,DLG4 |
6.663e-03 | -5.01 | Interleukin-3, 5 and GM-CSF signaling | REACTOME pathways | R-HSA-512988 | 271 | 4 | 10285 | 29 |
DLG4,NRG3,GRIN2B,GRIN1 |
6.702e-03 | -5.01 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 48 |
GRIN2B,SYT1,STXBP5,KCNT1,GRID2,NTRK3,HCN1,KCNC1,GPHN,NRG3,CACNA1H,CELF2,KCTD16,DLG4,RALYL,FGF12,CNTN5,CELF5,CHRM2,DPP10,DLG3,SYT7,CACNA1A,CSMD2,GRM7,SCN8A,TENM1,ALK,PDE2A,MCTP1,GABRA1,CADPS,RIMS2,OLFM1,GRIA3,FAM131A,CELF4,GRIK2,GRIN1,GPR85,KCNMA1,CACNA1G,GABRD,GABBR2,NRXN2,NRXN1 |
6.702e-03 | -5.01 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 48 |
KCNC1,GPHN,NRG3,HCN1,KCNT1,NTRK3,GRID2,SYT1,GRIN2B,STXBP5,DPP10,DLG3,SYT7,FGF12,CNTN5,CELF5,CHRM2,KCTD16,DLG4,RALYL,CELF2,CACNA1H,MCTP1,GABRA1,CADPS,SCN8A,TENM1,ALK,PDE2A,CACNA1A,CSMD2,GRM7,GABBR2,NRXN1,NRXN2,CACNA1G,GPR85,KCNMA1,GABRD,GRIA3,FAM131A,GRIN1,GRIK2,CELF4,RIMS2,OLFM1 |
6.815e-03 | -4.99 | PICK1 (protein interacting with PRKCA 1) | protein interactions | 9463 | 477 | 5 | 19454 | 49 |
GRIK2,DLG4,GRM7,ASIC2,GRIA3 |
6.824e-03 | -4.99 | regulation of membrane depolarization | biological process | GO:0003254 | 48 | 2 | 18204 | 47 |
HCN1,CACNA1G |
6.904e-03 | -4.98 | glutamate receptor binding | molecular function | GO:0035254 | 47 | 2 | 18094 | 48 |
DLG3,DLG4 |
7.076e-03 | -4.95 | - | gene3d domains | 2.60.120.200 | 121 | 3 | 14470 | 47 |
ALK,NRXN1,NRXN2 |
7.139e-03 | -4.94 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 25 | 18204 | 47 |
TENM1,ASIC2,GRIN2B,PDE2A,STXBP5,DLG3,RIMS2,KCNC1,GRID2,NTRK3,KCNIP2,CELF4,DPP10,SYT7,GRIN1,CACNA1H,CADPS,ALK,DLG4,FGF12,OLFM1,KCNMA1,GRIK2,NRXN1,SYT1 |
7.175e-03 | -4.94 | PDZ | interpro domains | IPR001478 | 146 | 3 | 18521 | 50 |
DLG3,RIMS2,DLG4 |
7.192e-03 | -4.93 | potassium channel regulator activity | molecular function | GO:0015459 | 48 | 2 | 18094 | 48 |
DPP10,KCNIP2 |
7.240e-03 | -4.93 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 29 |
KCNIP2,FGF12,SCN8A |
7.302e-03 | -4.92 | response to external stimulus | biological process | GO:0009605 | 1882 | 11 | 18204 | 47 |
CSMD1,ASIC2,CHRM2,ALK,GRIK2,PDE2A,NRXN2,NRG3,GRID2,NRXN1,KCNC1 |
7.325e-03 | -4.92 | APLP1 (amyloid beta precursor like protein 1) | protein interactions | 333 | 51 | 2 | 19454 | 49 |
GRIN2B,GRIN1 |
7.333e-03 | -4.92 | calcium-mediated signaling | biological process | GO:0019722 | 154 | 3 | 18204 | 47 |
MCTP1,GRIN1,GRIN2B |
7.368e-03 | -4.91 | DPM1 (dolichyl-phosphate mannosyltransferase subunit 1, catalytic) | protein interactions | 8813 | 158 | 3 | 19454 | 49 |
NTRK3,GABRA1,ALK |
7.384e-03 | -4.91 | cell differentiation | biological process | GO:0030154 | 3645 | 17 | 18204 | 47 |
PDE2A,OLFM1,RIMS2,GABRB2,GRID2,NRXN1,KCNIP2,NTRK3,HCN1,SYT1,CELF4,TENM1,GRM7,CACNA1H,ALK,DLG4,CNTN5 |
7.386e-03 | -4.91 | cellular response to cAMP | biological process | GO:0071320 | 50 | 2 | 18204 | 47 |
HCN1,PDE2A |
7.396e-03 | -4.91 | MoCF_biosynth | smart domains | SM00852 | 2 | 1 | 9717 | 36 |
GPHN |
7.420e-03 | -4.90 | CUB | pfam domains | PF00431 | 47 | 2 | 17795 | 49 |
CSMD1,CSMD2 |
7.447e-03 | -4.90 | cellular developmental process | biological process | GO:0048869 | 3648 | 17 | 18204 | 47 |
RIMS2,OLFM1,PDE2A,GABRB2,NTRK3,KCNIP2,NRXN1,GRID2,SYT1,HCN1,GRM7,TENM1,CELF4,CACNA1H,ALK,CNTN5,DLG4 |
7.453e-03 | -4.90 | positive regulation of cellular component organization | biological process | GO:0051130 | 1122 | 8 | 18204 | 47 |
TENM1,ASIC2,DLG4,SYT1,NRXN1,GRID2,NTRK3,ALK |
7.464e-03 | -4.90 | positive regulation of monoatomic ion transmembrane transport | biological process | GO:0034767 | 155 | 3 | 18204 | 47 |
GRIN1,KCNIP2,KCNC1 |
7.485e-03 | -4.89 | calcium channel regulator activity | molecular function | GO:0005246 | 49 | 2 | 18094 | 48 |
NRXN2,NRXN1 |
7.538e-03 | -4.89 | GOLGA6L5P (golgin A6 family like 5, pseudogene) | protein interactions | 374650 | 3 | 1 | 19454 | 49 |
CACNA1A |
7.538e-03 | -4.89 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 49 |
NRXN1 |
7.538e-03 | -4.89 | ARSH (arylsulfatase family member H) | protein interactions | 347527 | 3 | 1 | 19454 | 49 |
GPHN |
7.538e-03 | -4.89 | NAB2 (mRNA-binding protein NAB2) | protein interactions | 852755 | 3 | 1 | 19454 | 49 |
RALYL |
7.538e-03 | -4.89 | Dlgap2 (DLG associated protein 2) | protein interactions | 116681 | 3 | 1 | 19454 | 49 |
GRIN2B |
7.587e-03 | -4.88 | PDZ_sf | interpro domains | IPR036034 | 149 | 3 | 18521 | 50 |
RIMS2,DLG4,DLG3 |
7.605e-03 | -4.88 | ABCA1 (ATP binding cassette subfamily A member 1) | protein interactions | 19 | 52 | 2 | 19454 | 49 |
DLG3,RIMS2 |
7.672e-03 | -4.87 | Phase 0 - rapid depolarisation | REACTOME pathways | R-HSA-5576892 | 47 | 2 | 10285 | 29 |
SCN8A,FGF12 |
7.674e-03 | -4.87 | G protein-coupled receptor heterodimeric complex | cellular component | GO:0038039 | 3 | 1 | 19108 | 49 |
GABBR2 |
7.674e-03 | -4.87 | clathrin-sculpted acetylcholine transport vesicle membrane | cellular component | GO:0060201 | 3 | 1 | 19108 | 49 |
SYT1 |
7.674e-03 | -4.87 | clathrin-sculpted acetylcholine transport vesicle | cellular component | GO:0060200 | 3 | 1 | 19108 | 49 |
SYT1 |
7.675e-03 | -4.87 | regulation of protein tyrosine kinase activity | biological process | GO:0061097 | 51 | 2 | 18204 | 47 |
DLG4,DLG3 |
7.675e-03 | -4.87 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 47 |
DLG4,NRXN1 |
7.726e-03 | -4.86 | short-term synaptic potentiation | biological process | GO:1990926 | 3 | 1 | 18204 | 47 |
SYT7 |
7.726e-03 | -4.86 | cellular response to 2,3,7,8-tetrachlorodibenzodioxine | biological process | GO:1904613 | 3 | 1 | 18204 | 47 |
PDE2A |
7.726e-03 | -4.86 | tertiary alcohol biosynthetic process | biological process | GO:1902645 | 3 | 1 | 18204 | 47 |
CACNA1H |
7.726e-03 | -4.86 | smooth muscle contraction involved in micturition | biological process | GO:0060083 | 3 | 1 | 18204 | 47 |
KCNMA1 |
7.726e-03 | -4.86 | response to glycine | biological process | GO:1905429 | 3 | 1 | 18204 | 47 |
GRIN1 |
7.726e-03 | -4.86 | calcium ion regulated lysosome exocytosis | biological process | GO:1990927 | 3 | 1 | 18204 | 47 |
SYT7 |
7.726e-03 | -4.86 | cortisol biosynthetic process | biological process | GO:0034651 | 3 | 1 | 18204 | 47 |
CACNA1H |
7.726e-03 | -4.86 | aldosterone biosynthetic process | biological process | GO:0032342 | 3 | 1 | 18204 | 47 |
CACNA1H |
7.726e-03 | -4.86 | mammary placode formation | biological process | GO:0060596 | 3 | 1 | 18204 | 47 |
NRG3 |
7.726e-03 | -4.86 | positive regulation of synaptic vesicle exocytosis | biological process | GO:2000302 | 3 | 1 | 18204 | 47 |
SYT1 |
7.731e-03 | -4.86 | protein-containing complex localization | biological process | GO:0031503 | 157 | 3 | 18204 | 47 |
GPHN,DLG3,DLG4 |
7.747e-03 | -4.86 | CUB_dom | interpro domains | IPR000859 | 49 | 2 | 18521 | 50 |
CSMD2,CSMD1 |
7.914e-03 | -4.84 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 6 | 18204 | 47 |
DLG4,NTRK3,ALK,GRIN2B,GRID2,TENM1 |
7.938e-03 | -4.84 | serine binding | molecular function | GO:0070905 | 3 | 1 | 18094 | 48 |
GRM7 |
7.938e-03 | -4.84 | cGMP-stimulated cyclic-nucleotide phosphodiesterase activity | molecular function | GO:0004118 | 3 | 1 | 18094 | 48 |
PDE2A |
7.938e-03 | -4.84 | G protein-coupled GABA receptor activity | molecular function | GO:0004965 | 3 | 1 | 18094 | 48 |
GABBR2 |
7.938e-03 | -4.84 | voltage-gated calcium channel activity involved in AV node cell action potential | molecular function | GO:0086056 | 3 | 1 | 18094 | 48 |
CACNA1G |
7.938e-03 | -4.84 | nitrate reductase activity | molecular function | GO:0008940 | 3 | 1 | 18094 | 48 |
GPHN |
7.938e-03 | -4.84 | beta-1 adrenergic receptor binding | molecular function | GO:0031697 | 3 | 1 | 18094 | 48 |
DLG4 |
7.969e-03 | -4.83 | response to nerve growth factor | biological process | GO:1990089 | 52 | 2 | 18204 | 47 |
NTRK3,KCNC1 |
8.003e-03 | -4.83 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 47 |
GABRA1,GABRD,GABRB2 |
8.024e-03 | -4.83 | ANK3 (ankyrin 3) | protein interactions | 288 | 163 | 3 | 19454 | 49 |
KCNC1,FGF12,NTRK3 |
8.042e-03 | -4.82 | Developmental Biology | REACTOME pathways | R-HSA-1266738 | 1075 | 8 | 10285 | 29 |
GRIN2B,CACNA1H,CACNA1G,DLG3,DLG4,NRG3,SCN8A,GRIN1 |
8.078e-03 | -4.82 | Neuregulin | interpro domains | IPR040180 | 3 | 1 | 18521 | 50 |
NRG3 |
8.078e-03 | -4.82 | GPCR3_GABA-B | interpro domains | IPR002455 | 3 | 1 | 18521 | 50 |
GABBR2 |
8.078e-03 | -4.82 | FAM131 | interpro domains | IPR026782 | 3 | 1 | 18521 | 50 |
FAM131A |
8.078e-03 | -4.82 | Noelin_dom | interpro domains | IPR022082 | 3 | 1 | 18521 | 50 |
OLFM1 |
8.078e-03 | -4.82 | NTRK | interpro domains | IPR020777 | 3 | 1 | 18521 | 50 |
NTRK3 |
8.078e-03 | -4.82 | GABAAb_rcpt | interpro domains | IPR002289 | 3 | 1 | 18521 | 50 |
GABRB2 |
8.078e-03 | -4.82 | NTRK_LRRCT | interpro domains | IPR031635 | 3 | 1 | 18521 | 50 |
NTRK3 |
8.078e-03 | -4.82 | NMDAR2_C | interpro domains | IPR018884 | 3 | 1 | 18521 | 50 |
GRIN2B |
8.088e-03 | -4.82 | - | gene3d domains | 3.30.70.330 | 245 | 4 | 14470 | 47 |
CELF2,CELF5,CELF4,RALYL |
8.165e-03 | -4.81 | spinal_cord | COSMIC cancer mutations | spinal_cord | 145 | 3 | 16828 | 48 |
NTRK3,ALK,GRIA3 |
8.238e-03 | -4.80 | NMDAR2_C | pfam domains | PF10565 | 3 | 1 | 17795 | 49 |
GRIN2B |
8.238e-03 | -4.80 | FAM131 | pfam domains | PF15010 | 3 | 1 | 17795 | 49 |
FAM131A |
8.238e-03 | -4.80 | MAGUK_N_PEST | pfam domains | PF10608 | 3 | 1 | 17795 | 49 |
DLG4 |
8.238e-03 | -4.80 | Noelin-1 | pfam domains | PF12308 | 3 | 1 | 17795 | 49 |
OLFM1 |
8.238e-03 | -4.80 | LRRCT_2 | pfam domains | PF16920 | 3 | 1 | 17795 | 49 |
NTRK3 |
8.268e-03 | -4.80 | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules | biological process | GO:0007157 | 53 | 2 | 18204 | 47 |
GRID2,TENM1 |
8.281e-03 | -4.79 | sensory perception of sound | biological process | GO:0007605 | 161 | 3 | 18204 | 47 |
CNTN5,ASIC2,GRM7 |
8.281e-03 | -4.79 | inorganic anion transport | biological process | GO:0015698 | 161 | 3 | 18204 | 47 |
GABRD,GABRB2,GABRA1 |
8.368e-03 | -4.78 | positive regulation of secretion | biological process | GO:0051047 | 311 | 4 | 18204 | 47 |
STXBP5,CADPS,SYT1,SYT7 |
8.370e-03 | -4.78 | T1-type_BTB | interpro domains | IPR003131 | 51 | 2 | 18521 | 50 |
KCNC1,KCTD16 |
8.434e-03 | -4.78 | MAPK family signaling cascades | REACTOME pathways | R-HSA-5683057 | 290 | 4 | 10285 | 29 |
DLG4,GRIN2B,NRG3,GRIN1 |
8.436e-03 | -4.78 | Toxicity of botulinum toxin type G (BoNT/G) | REACTOME pathways | R-HSA-5250989 | 3 | 1 | 10285 | 29 |
SYT1 |
8.436e-03 | -4.78 | Toxicity of botulinum toxin type B (BoNT/B) | REACTOME pathways | R-HSA-5250958 | 3 | 1 | 10285 | 29 |
SYT1 |
8.477e-03 | -4.77 | AP4M1 (adaptor related protein complex 4 subunit mu 1) | protein interactions | 9179 | 55 | 2 | 19454 | 49 |
GRID2,GRIN2B |
8.513e-03 | -4.77 | PDZ | prosite domains | PS50106 | 143 | 3 | 12186 | 36 |
DLG3,DLG4,RIMS2 |
8.533e-03 | -4.76 | lung-right_upper_lobe-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-non_small_cell_carcinoma | 3 | 1 | 16828 | 48 |
ALK |
8.533e-03 | -4.76 | cervical | COSMIC cancer mutations | cervical | 3 | 1 | 16828 | 48 |
ALK |
8.565e-03 | -4.76 | positive regulation of cytosolic calcium ion concentration | biological process | GO:0007204 | 163 | 3 | 18204 | 47 |
DLG4,GRIN1,CACNA1A |
8.624e-03 | -4.75 | inorganic anion transmembrane transporter activity | molecular function | GO:0015103 | 159 | 3 | 18094 | 48 |
GABRD,GABRA1,GABRB2 |
8.690e-03 | -4.75 | Sperma_CUB_dom_sf | interpro domains | IPR035914 | 52 | 2 | 18521 | 50 |
CSMD2,CSMD1 |
8.690e-03 | -4.75 | Sushi | pfam domains | PF00084 | 51 | 2 | 17795 | 49 |
CSMD2,CSMD1 |
8.690e-03 | -4.75 | BTB_2 | pfam domains | PF02214 | 51 | 2 | 17795 | 49 |
KCNC1,KCTD16 |
8.842e-03 | -4.73 | IRS-mediated signalling | REACTOME pathways | R-HSA-112399 | 294 | 4 | 10285 | 29 |
DLG4,GRIN2B,NRG3,GRIN1 |
8.854e-03 | -4.73 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 47 |
CACNA1H,CACNA1A,CACNA1G |
8.881e-03 | -4.72 | establishment or maintenance of epithelial cell apical/basal polarity | biological process | GO:0045197 | 55 | 2 | 18204 | 47 |
DLG4,DLG3 |
9.001e-03 | -4.71 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 23 | 18204 | 47 |
SYT7,GRIN1,TENM1,CELF4,DPP10,ASIC2,DLG4,GRIN2B,CADPS,ALK,GRIK2,OLFM1,PDE2A,STXBP5,DLG3,RIMS2,KCNMA1,SYT1,KCNC1,NRXN1,GRID2,NTRK3,KCNIP2 |
9.015e-03 | -4.71 | calcium ion binding | molecular function | GO:0005509 | 683 | 6 | 18094 | 48 |
NRXN1,SYT1,MCTP1,KCNIP2,GRIN1,SYT7 |
9.120e-03 | -4.70 | islet_cell | COSMIC cancer mutations | islet_cell | 151 | 3 | 16828 | 48 |
ALK,NTRK3,FGF12 |
9.120e-03 | -4.70 | pancreas-carcinoid-endocrine_tumour-islet_cell | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour-islet_cell | 151 | 3 | 16828 | 48 |
FGF12,NTRK3,ALK |
9.146e-03 | -4.69 | CUB | prosite domains | PS01180 | 49 | 2 | 12186 | 36 |
CSMD1,CSMD2 |
9.157e-03 | -4.69 | Insulin receptor signalling cascade | REACTOME pathways | R-HSA-74751 | 297 | 4 | 10285 | 29 |
GRIN1,DLG4,NRG3,GRIN2B |
9.195e-03 | -4.69 | response to amyloid-beta | biological process | GO:1904645 | 56 | 2 | 18204 | 47 |
CACNA1A,GRIN1 |
9.264e-03 | -4.68 | IGF1R signaling cascade | REACTOME pathways | R-HSA-2428924 | 298 | 4 | 10285 | 29 |
GRIN1,DLG4,NRG3,GRIN2B |
9.264e-03 | -4.68 | IRS-related events triggered by IGF1R | REACTOME pathways | R-HSA-2428928 | 298 | 4 | 10285 | 29 |
NRG3,GRIN2B,DLG4,GRIN1 |
9.328e-03 | -4.67 | cytoplasmic vesicle | cellular component | GO:0031410 | 2521 | 13 | 19108 | 49 |
SCN8A,GRIN1,GABRB2,CHRM2,CADPS,GRIA3,SYT7,MCTP1,GRIN2B,DLG4,STXBP5,GABRA1,SYT1 |
9.371e-03 | -4.67 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | REACTOME pathways | R-HSA-2404192 | 299 | 4 | 10285 | 29 |
GRIN2B,NRG3,DLG4,GRIN1 |
9.390e-03 | -4.67 | MAP3K11 (mitogen-activated protein kinase kinase kinase 11) | protein interactions | 4296 | 58 | 2 | 19454 | 49 |
GRIK2,DLG4 |
9.390e-03 | -4.67 | MANEA (mannosidase endo-alpha) | protein interactions | 79694 | 58 | 2 | 19454 | 49 |
OLFM1,GRIN1 |
9.472e-03 | -4.66 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 5 | 18204 | 47 |
GABRB2,GRIN1,HCN1,CACNA1A,PDE2A |
9.512e-03 | -4.66 | intracellular vesicle | cellular component | GO:0097708 | 2527 | 13 | 19108 | 49 |
GRIA3,GABRB2,SCN8A,GRIN1,CHRM2,CADPS,STXBP5,DLG4,SYT1,GABRA1,SYT7,MCTP1,GRIN2B |
9.529e-03 | -4.65 | LamG | smart domains | SM00282 | 40 | 2 | 9717 | 36 |
NRXN1,NRXN2 |
9.530e-03 | -4.65 | human chr6q16.3 | chromosome location | human chr6q16.3 | 5 | 1 | 26134 | 50 |
GRIK2 |
9.586e-03 | -4.65 | SLC1A1 (solute carrier family 1 member 1) | protein interactions | 6505 | 174 | 3 | 19454 | 49 |
DLG4,GRIN2B,GRIN1 |
9.647e-03 | -4.64 | hyperplasia | COSMIC cancer mutations | hyperplasia | 52 | 2 | 16828 | 48 |
NTRK3,ALK |
9.673e-03 | -4.64 | response to chemical | biological process | GO:0042221 | 3743 | 17 | 18204 | 47 |
CACNA1G,GRIN2B,CHRM2,DLG4,CACNA1A,ASIC2,CACNA1H,GRIN1,KCNIP2,NRG3,KCNC1,SYT1,HCN1,KCNMA1,GPHN,PDE2A,GABRB2 |
9.682e-03 | -4.64 | Sushi_SCR_CCP_dom | interpro domains | IPR000436 | 55 | 2 | 18521 | 50 |
CSMD1,CSMD2 |
9.713e-03 | -4.63 | Acid-sensing ion channel domain | gene3d domains | 1.10.287.820 | 3 | 1 | 14470 | 47 |
ASIC2 |
9.713e-03 | -4.63 | acid-sensing ion channel 1 domain | gene3d domains | 1.10.3590.10 | 3 | 1 | 14470 | 47 |
ASIC2 |
9.853e-03 | -4.62 | CALM3 (calmodulin 3) | protein interactions | 808 | 334 | 4 | 19454 | 49 |
NTRK3,CACNA1A,ALK,GRM7 |
9.999e-03 | -4.61 | cell adhesion | biological process | GO:0007155 | 942 | 7 | 18204 | 47 |
DLG4,NRXN2,CNTN5,TENM1,NRXN1,GRID2,DLG3 |
1.002e-02 | -4.60 | clathrin binding | molecular function | GO:0030276 | 57 | 2 | 18094 | 48 |
SYT7,SYT1 |
1.004e-02 | -4.60 | Sstr2 (somatostatin receptor 2) | protein interactions | 54305 | 4 | 1 | 19454 | 49 |
DLG3 |
1.004e-02 | -4.60 | HCN4 (hyperpolarization activated cyclic nucleotide gated potassium channel 4) | protein interactions | 10021 | 4 | 1 | 19454 | 49 |
HCN1 |
1.004e-02 | -4.60 | Ngfr (nerve growth factor receptor) | protein interactions | 24596 | 4 | 1 | 19454 | 49 |
NTRK3 |
1.017e-02 | -4.59 | establishment or maintenance of apical/basal cell polarity | biological process | GO:0035088 | 59 | 2 | 18204 | 47 |
DLG3,DLG4 |
1.017e-02 | -4.59 | establishment or maintenance of bipolar cell polarity | biological process | GO:0061245 | 59 | 2 | 18204 | 47 |
DLG4,DLG3 |
1.019e-02 | -4.59 | ERBB4 (erb-b2 receptor tyrosine kinase 4) | protein interactions | 2066 | 178 | 3 | 19454 | 49 |
DLG4,DLG3,NRG3 |
1.022e-02 | -4.58 | HCN channel complex | cellular component | GO:0098855 | 4 | 1 | 19108 | 49 |
HCN1 |
1.022e-02 | -4.58 | clathrin-sculpted glutamate transport vesicle | cellular component | GO:0060199 | 4 | 1 | 19108 | 49 |
SYT1 |
1.022e-02 | -4.58 | clathrin-sculpted glutamate transport vesicle membrane | cellular component | GO:0060203 | 4 | 1 | 19108 | 49 |
SYT1 |
1.029e-02 | -4.58 | gamma-aminobutyric acid receptor clustering | biological process | GO:0097112 | 4 | 1 | 18204 | 47 |
GPHN |
1.029e-02 | -4.58 | positive regulation of synaptic vesicle fusion to presynaptic active zone membrane | biological process | GO:0031632 | 4 | 1 | 18204 | 47 |
SYT1 |
1.029e-02 | -4.58 | calcium-dependent activation of synaptic vesicle fusion | biological process | GO:0099502 | 4 | 1 | 18204 | 47 |
SYT1 |
1.029e-02 | -4.58 | negative regulation of dendritic spine maintenance | biological process | GO:1902951 | 4 | 1 | 18204 | 47 |
GRIN2B |
1.029e-02 | -4.58 | oviduct epithelium development | biological process | GO:0035846 | 4 | 1 | 18204 | 47 |
CSMD1 |
1.029e-02 | -4.58 | clustering of voltage-gated potassium channels | biological process | GO:0045163 | 4 | 1 | 18204 | 47 |
KCNIP2 |
1.029e-02 | -4.58 | globus pallidus development | biological process | GO:0021759 | 4 | 1 | 18204 | 47 |
KCNC1 |
1.029e-02 | -4.58 | positive regulation of potassium ion export across plasma membrane | biological process | GO:1903766 | 4 | 1 | 18204 | 47 |
KCNIP2 |
1.029e-02 | -4.58 | positive regulation of synaptic vesicle membrane organization | biological process | GO:1901634 | 4 | 1 | 18204 | 47 |
SYT1 |
1.029e-02 | -4.58 | regulation of calcium ion-dependent exocytosis of neurotransmitter | biological process | GO:1903233 | 4 | 1 | 18204 | 47 |
SYT1 |
1.029e-02 | -4.58 | regulation of systemic arterial blood pressure by baroreceptor feedback | biological process | GO:0003025 | 4 | 1 | 18204 | 47 |
ASIC2 |
1.029e-02 | -4.58 | regulation of grooming behavior | biological process | GO:2000821 | 4 | 1 | 18204 | 47 |
DLG4 |
1.029e-02 | -4.58 | mineralocorticoid biosynthetic process | biological process | GO:0006705 | 4 | 1 | 18204 | 47 |
CACNA1H |
1.029e-02 | -4.58 | primary alcohol biosynthetic process | biological process | GO:0034309 | 4 | 1 | 18204 | 47 |
CACNA1H |
1.035e-02 | -4.57 | PCDH10 (protocadherin 10) | protein interactions | 57575 | 61 | 2 | 19454 | 49 |
DLG4,CACNA1H |
1.035e-02 | -4.57 | GDA (guanine deaminase) | protein interactions | 9615 | 61 | 2 | 19454 | 49 |
DLG4,DLG3 |
1.037e-02 | -4.57 | Sushi/SCR/CCP_sf | interpro domains | IPR035976 | 57 | 2 | 18521 | 50 |
CSMD1,CSMD2 |
1.037e-02 | -4.57 | neuron projection membrane | cellular component | GO:0032589 | 60 | 2 | 19108 | 49 |
KCNC1,GABRA1 |
1.050e-02 | -4.56 | membrane assembly | biological process | GO:0071709 | 60 | 2 | 18204 | 47 |
NRXN1,NRXN2 |
1.053e-02 | -4.55 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 4 | 16828 | 48 |
GRID2,GRM7,FGF12,HCN1 |
1.057e-02 | -4.55 | adenylate cyclase inhibitor activity | molecular function | GO:0010855 | 4 | 1 | 18094 | 48 |
GRM7 |
1.057e-02 | -4.55 | AMPA glutamate receptor activity | molecular function | GO:0004971 | 4 | 1 | 18094 | 48 |
GRIA3 |
1.057e-02 | -4.55 | A-type (transient outward) potassium channel activity | molecular function | GO:0005250 | 4 | 1 | 18094 | 48 |
KCNIP2 |
1.057e-02 | -4.55 | calcium ion sensor activity | molecular function | GO:0061891 | 4 | 1 | 18094 | 48 |
SYT1 |
1.060e-02 | -4.55 | Common Pathways Underlying Drug Addiction | WikiPathways | WP2636 | 42 | 2 | 5310 | 20 |
GRIN1,GRIA3 |
1.075e-02 | -4.53 | salivary_gland-maxilla-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-maxilla-carcinoma-adenoid_cystic_carcinoma | 55 | 2 | 16828 | 48 |
CSMD2,CADPS |
1.076e-02 | -4.53 | LLGL2 | interpro domains | IPR013577 | 4 | 1 | 18521 | 50 |
STXBP5 |
1.076e-02 | -4.53 | Lethal2_giant | interpro domains | IPR000664 | 4 | 1 | 18521 | 50 |
STXBP5 |
1.076e-02 | -4.53 | Ion_trans_N | interpro domains | IPR013621 | 4 | 1 | 18521 | 50 |
HCN1 |
1.076e-02 | -4.53 | Ten_N | interpro domains | IPR009471 | 4 | 1 | 18521 | 50 |
TENM1 |
1.076e-02 | -4.53 | K_chnl_volt-dep_Kv3 | interpro domains | IPR003974 | 4 | 1 | 18521 | 50 |
KCNC1 |
1.076e-02 | -4.53 | YD | interpro domains | IPR006530 | 4 | 1 | 18521 | 50 |
TENM1 |
1.076e-02 | -4.53 | Rim-like | interpro domains | IPR039032 | 4 | 1 | 18521 | 50 |
RIMS2 |
1.076e-02 | -4.53 | Tox-GHH_dom | interpro domains | IPR028916 | 4 | 1 | 18521 | 50 |
TENM1 |
1.079e-02 | -4.53 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 19 | 16828 | 48 |
CSMD2,RIMS2,GRIN2B,CACNA1A,CACNA1H,KCNT1,NTRK3,GRID2,GRIK2,FAM131A,SCN8A,CNTN5,HCN1,PDE2A,GABRB2,ALK,KCNIP2,GABRA1,DPP10 |
1.095e-02 | -4.51 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 44 | 16828 | 48 |
GRID2,NTRK3,KCNT1,STXBP5,SYT1,GRIN2B,NRG3,KCNC1,HCN1,RALYL,KCTD16,CACNA1H,CELF2,SYT7,DPP10,KCNIP2,GABRB2,CHRM2,CELF5,FGF12,CNTN5,GRM7,CSMD2,CACNA1A,CADPS,GABRA1,MCTP1,PDE2A,ALK,SCN8A,GRIN1,CELF4,GRIK2,FAM131A,GRIA3,OLFM1,RIMS2,NRXN2,NRXN1,GABBR2,GABRD,CACNA1G,GPR85,KCNMA1 |
1.097e-02 | -4.51 | Tox-GHH | pfam domains | PF15636 | 4 | 1 | 17795 | 49 |
TENM1 |
1.097e-02 | -4.51 | Ion_trans_N | pfam domains | PF08412 | 4 | 1 | 17795 | 49 |
HCN1 |
1.097e-02 | -4.51 | Ten_N | pfam domains | PF06484 | 4 | 1 | 17795 | 49 |
TENM1 |
1.097e-02 | -4.51 | LLGL | pfam domains | PF08366 | 4 | 1 | 17795 | 49 |
STXBP5 |
1.101e-02 | -4.51 | KCNA4 (potassium voltage-gated channel subfamily A member 4) | protein interactions | 3739 | 63 | 2 | 19454 | 49 |
DLG4,DLG3 |
1.123e-02 | -4.49 | HCN channels | REACTOME pathways | R-HSA-1296061 | 4 | 1 | 10285 | 29 |
HCN1 |
1.123e-02 | -4.49 | Activation of AMPA receptors | REACTOME pathways | R-HSA-399710 | 4 | 1 | 10285 | 29 |
GRIA3 |
1.138e-02 | -4.48 | sodium ion transport | biological process | GO:0006814 | 181 | 3 | 18204 | 47 |
ASIC2,SCN8A,HCN1 |
1.142e-02 | -4.47 | SUSHI | prosite domains | PS50923 | 55 | 2 | 12186 | 36 |
CSMD1,CSMD2 |
1.145e-02 | -4.47 | BKCHANNELA | prints domains | PR01449 | 2 | 1 | 5227 | 30 |
KCNMA1 |
1.146e-02 | -4.47 | Spermadhesin, CUB domain | gene3d domains | 2.60.120.290 | 50 | 2 | 14470 | 47 |
CSMD2,CSMD1 |
1.153e-02 | -4.46 | synaptic vesicle recycling | biological process | GO:0036465 | 63 | 2 | 18204 | 47 |
SYT1,SYT7 |
1.160e-02 | -4.46 | regulation of kinase activity | biological process | GO:0043549 | 531 | 5 | 18204 | 47 |
DLG4,DLG3,ALK,NTRK3,TENM1 |
1.165e-02 | -4.45 | BAIAP2 (BAR/IMD domain containing adaptor protein 2) | protein interactions | 10458 | 187 | 3 | 19454 | 49 |
NTRK3,DLG4,PDE2A |
1.177e-02 | -4.44 | TENEURIN_N | prosite domains | PS51361 | 4 | 1 | 12186 | 36 |
TENM1 |
1.178e-02 | -4.44 | transmembrane receptor protein tyrosine kinase activity | molecular function | GO:0004714 | 62 | 2 | 18094 | 48 |
NTRK3,ALK |
1.181e-02 | -4.44 | STX1A (syntaxin 1A) | protein interactions | 6804 | 188 | 3 | 19454 | 49 |
STXBP5,SYT1,SYT7 |
1.188e-02 | -4.43 | cranial nerve development | biological process | GO:0021545 | 64 | 2 | 18204 | 47 |
KCNC1,SCN8A |
1.207e-02 | -4.42 | cellular response to metal ion | biological process | GO:0071248 | 185 | 3 | 18204 | 47 |
DLG4,CACNA1H,SYT1 |
1.207e-02 | -4.42 | regulation of RNA splicing | biological process | GO:0043484 | 185 | 3 | 18204 | 47 |
CELF5,CELF4,CELF2 |
1.207e-02 | -4.42 | sensory perception of mechanical stimulus | biological process | GO:0050954 | 185 | 3 | 18204 | 47 |
CNTN5,ASIC2,GRM7 |
1.207e-02 | -4.42 | Signaling by Insulin receptor | REACTOME pathways | R-HSA-74752 | 322 | 4 | 10285 | 29 |
GRIN2B,NRG3,DLG4,GRIN1 |
1.224e-02 | -4.40 | membrane biogenesis | biological process | GO:0044091 | 65 | 2 | 18204 | 47 |
NRXN2,NRXN1 |
1.233e-02 | -4.40 | EXOC4 (exocyst complex component 4) | protein interactions | 60412 | 191 | 3 | 19454 | 49 |
GRIN2B,DLG3,DLG4 |
1.246e-02 | -4.38 | - | gene3d domains | 2.30.42.10 | 149 | 3 | 14470 | 47 |
DLG3,DLG4,RIMS2 |
1.247e-02 | -4.38 | head_neck | COSMIC cancer mutations | head_neck | 15361 | 48 | 16828 | 48 |
CHRM2,GABRB2,CNTN5,FGF12,CELF5,DPP10,SYT7,DLG3,KCNIP2,CACNA1H,CELF2,DLG4,RALYL,KCTD16,HCN1,GPHN,NRG3,KCNC1,STXBP5,SYT1,GRIN2B,GRID2,NTRK3,KCNT1,KCNMA1,CACNA1G,GPR85,GABRD,GABBR2,NRXN2,NRXN1,OLFM1,RIMS2,FAM131A,GRIK2,CELF4,GRIN1,GRIA3,ALK,PDE2A,SCN8A,TENM1,GABRA1,CADPS,MCTP1,GRM7,CACNA1A,CSMD2 |
1.253e-02 | -4.38 | DPP10 (dipeptidyl peptidase like 10) | protein interactions | 57628 | 5 | 1 | 19454 | 49 |
DPP10 |
1.253e-02 | -4.38 | HCN3 (hyperpolarization activated cyclic nucleotide gated potassium channel 3) | protein interactions | 57657 | 5 | 1 | 19454 | 49 |
HCN1 |
1.253e-02 | -4.38 | GABRG3 (gamma-aminobutyric acid type A receptor subunit gamma3) | protein interactions | 2567 | 5 | 1 | 19454 | 49 |
GABRA1 |
1.253e-02 | -4.38 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 49 |
NRXN1 |
1.253e-02 | -4.38 | Mtor (mechanistic target of rapamycin kinase) | protein interactions | 56718 | 5 | 1 | 19454 | 49 |
GPHN |
1.259e-02 | -4.38 | primary_central_nervous_system_lymphoma | COSMIC cancer mutations | primary_central_nervous_system_lymphoma | 683 | 6 | 16828 | 48 |
CSMD2,CACNA1H,NRXN1,KCNT1,NRG3,GRIK2 |
1.259e-02 | -4.38 | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-primary_central_nervous_system_lymphoma | 683 | 6 | 16828 | 48 |
CSMD2,CACNA1H,KCNT1,NRXN1,GRIK2,NRG3 |
1.269e-02 | -4.37 | central_nervous_system-spinal_cord-atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | central_nervous_system-spinal_cord-atypical_teratoid-rhabdoid_tumour | 60 | 2 | 16828 | 48 |
ALK,NTRK3 |
1.276e-02 | -4.36 | clathrin-sculpted monoamine transport vesicle | cellular component | GO:0070081 | 5 | 1 | 19108 | 49 |
SYT1 |
1.276e-02 | -4.36 | kainate selective glutamate receptor complex | cellular component | GO:0032983 | 5 | 1 | 19108 | 49 |
GRIK2 |
1.276e-02 | -4.36 | clathrin-sculpted monoamine transport vesicle membrane | cellular component | GO:0070083 | 5 | 1 | 19108 | 49 |
SYT1 |
1.284e-02 | -4.35 | cortisol metabolic process | biological process | GO:0034650 | 5 | 1 | 18204 | 47 |
CACNA1H |
1.284e-02 | -4.35 | general adaptation syndrome, behavioral process | biological process | GO:0051867 | 5 | 1 | 18204 | 47 |
HCN1 |
1.284e-02 | -4.35 | detection of temperature stimulus involved in thermoception | biological process | GO:0050960 | 5 | 1 | 18204 | 47 |
GRIK2 |
1.284e-02 | -4.35 | AMPA glutamate receptor clustering | biological process | GO:0097113 | 5 | 1 | 18204 | 47 |
DLG4 |
1.284e-02 | -4.35 | neuron-glial cell signaling | biological process | GO:0150099 | 5 | 1 | 18204 | 47 |
GABBR2 |
1.284e-02 | -4.35 | response to 2,3,7,8-tetrachlorodibenzodioxine | biological process | GO:1904612 | 5 | 1 | 18204 | 47 |
PDE2A |
1.284e-02 | -4.35 | membrane depolarization during AV node cell action potential | biological process | GO:0086045 | 5 | 1 | 18204 | 47 |
CACNA1G |
1.284e-02 | -4.35 | aldosterone metabolic process | biological process | GO:0032341 | 5 | 1 | 18204 | 47 |
CACNA1H |
1.284e-02 | -4.35 | cGMP catabolic process | biological process | GO:0046069 | 5 | 1 | 18204 | 47 |
PDE2A |
1.284e-02 | -4.35 | conditioned place preference | biological process | GO:1990708 | 5 | 1 | 18204 | 47 |
CSMD1 |
1.284e-02 | -4.35 | negative regulation of glutamate secretion | biological process | GO:0014050 | 5 | 1 | 18204 | 47 |
GRM7 |
1.284e-02 | -4.35 | regulation of neuronal action potential | biological process | GO:0098908 | 5 | 1 | 18204 | 47 |
FGF12 |
1.284e-02 | -4.35 | negative regulation of cell volume | biological process | GO:0045794 | 5 | 1 | 18204 | 47 |
KCNMA1 |
1.284e-02 | -4.35 | glutamate receptor clustering | biological process | GO:0097688 | 5 | 1 | 18204 | 47 |
DLG4 |
1.284e-02 | -4.35 | membrane depolarization during SA node cell action potential | biological process | GO:0086046 | 5 | 1 | 18204 | 47 |
CACNA1G |
1.285e-02 | -4.35 | TUBB2B (tubulin beta 2B class IIb) | protein interactions | 347733 | 194 | 3 | 19454 | 49 |
GABRA1,DLG4,CACNA1A |
1.293e-02 | -4.35 | RHS repeat-associated core | gene3d domains | 2.180.10.10 | 4 | 1 | 14470 | 47 |
TENM1 |
1.299e-02 | -4.34 | CUB | smart domains | SM00042 | 47 | 2 | 9717 | 36 |
CSMD1,CSMD2 |
1.305e-02 | -4.34 | membrane organization | biological process | GO:0061024 | 761 | 6 | 18204 | 47 |
SYT7,GPHN,DLG4,NRXN2,KCNIP2,NRXN1 |
1.310e-02 | -4.34 | soft_tissue-striated_muscle-rhabdomyosarcoma-sclerosing | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-sclerosing | 61 | 2 | 16828 | 48 |
NTRK3,ALK |
1.312e-02 | -4.33 | VEGFA-VEGFR2 Pathway | REACTOME pathways | R-HSA-4420097 | 330 | 4 | 10285 | 29 |
GRIN1,DLG4,GRIN2B,NRG3 |
1.320e-02 | -4.33 | voltage-gated calcium channel activity involved in cardiac muscle cell action potential | molecular function | GO:0086007 | 5 | 1 | 18094 | 48 |
CACNA1G |
1.320e-02 | -4.33 | metal ion sensor activity | molecular function | GO:0140784 | 5 | 1 | 18094 | 48 |
SYT1 |
1.320e-02 | -4.33 | receptor signaling protein tyrosine kinase activator activity | molecular function | GO:0030298 | 5 | 1 | 18094 | 48 |
ALK |
1.320e-02 | -4.33 | kainate selective glutamate receptor activity | molecular function | GO:0015277 | 5 | 1 | 18094 | 48 |
GRIK2 |
1.320e-02 | -4.33 | cyclase inhibitor activity | molecular function | GO:0010852 | 5 | 1 | 18094 | 48 |
GRM7 |
1.320e-02 | -4.33 | neurotrophin receptor activity | molecular function | GO:0005030 | 5 | 1 | 18094 | 48 |
NTRK3 |
1.320e-02 | -4.33 | ER retention sequence binding | molecular function | GO:0046923 | 5 | 1 | 18094 | 48 |
KCNIP2 |
1.323e-02 | -4.33 | kidney | COSMIC cancer mutations | kidney | 15380 | 48 | 16828 | 48 |
TENM1,SCN8A,PDE2A,ALK,MCTP1,CADPS,GABRA1,CSMD2,CACNA1A,GRM7,GABRD,KCNMA1,CACNA1G,GPR85,NRXN2,NRXN1,GABBR2,RIMS2,OLFM1,GRIA3,CELF4,GRIK2,GRIN1,FAM131A,HCN1,KCNC1,NRG3,GPHN,SYT1,GRIN2B,STXBP5,KCNT1,GRID2,NTRK3,CELF5,CNTN5,FGF12,GABRB2,CHRM2,KCNIP2,DLG3,SYT7,DPP10,CACNA1H,CELF2,KCTD16,DLG4,RALYL |
1.343e-02 | -4.31 | Musac_Ach_rcpt | interpro domains | IPR000995 | 5 | 1 | 18521 | 50 |
CHRM2 |
1.351e-02 | -4.30 | sclerosing | COSMIC cancer mutations | sclerosing | 62 | 2 | 16828 | 48 |
ALK,NTRK3 |
1.351e-02 | -4.30 | cellular response to xenobiotic stimulus | biological process | GO:0071466 | 193 | 3 | 18204 | 47 |
KCNC1,ASIC2,GRIN1 |
1.370e-02 | -4.29 | protein homooligomerization | biological process | GO:0051260 | 194 | 3 | 18204 | 47 |
HCN1,KCTD16,KCNC1 |
1.372e-02 | -4.29 | Type II diabetes mellitus | KEGG pathways | hsa04930 | 46 | 2 | 7161 | 28 |
CACNA1A,CACNA1G |
1.372e-02 | -4.29 | Type II diabetes mellitus | KEGG pathways | ko04930 | 46 | 2 | 7161 | 28 |
CACNA1A,CACNA1G |
1.375e-02 | -4.29 | Dopaminergic synapse | KEGG pathways | ko04728 | 130 | 3 | 7161 | 28 |
GRIA3,GRIN2B,CACNA1A |
1.375e-02 | -4.29 | Dopaminergic synapse | KEGG pathways | hsa04728 | 130 | 3 | 7161 | 28 |
CACNA1A,GRIN2B,GRIA3 |
1.388e-02 | -4.28 | positive regulation of cell projection organization | biological process | GO:0031346 | 361 | 4 | 18204 | 47 |
DLG4,TENM1,NTRK3,ALK |
1.392e-02 | -4.27 | meninges-meningioma | COSMIC cancer mutations | meninges-meningioma | 327 | 4 | 16828 | 48 |
ALK,NTRK3,RIMS2,NRXN2 |
1.402e-02 | -4.27 | Muscarinic acetylcholine receptors | REACTOME pathways | R-HSA-390648 | 5 | 1 | 10285 | 29 |
CHRM2 |
1.408e-02 | -4.26 | Signaling by SCF-KIT | REACTOME pathways | R-HSA-1433557 | 337 | 4 | 10285 | 29 |
GRIN1,NRG3,GRIN2B,DLG4 |
1.422e-02 | -4.25 | Signaling by VEGF | REACTOME pathways | R-HSA-194138 | 338 | 4 | 10285 | 29 |
GRIN1,DLG4,GRIN2B,NRG3 |
1.427e-02 | -4.25 | locomotory behavior | biological process | GO:0007626 | 197 | 3 | 18204 | 47 |
DLG4,FGF12,ALK |
1.478e-02 | -4.21 | maxilla | COSMIC cancer mutations | maxilla | 65 | 2 | 16828 | 48 |
CSMD2,CADPS |
1.486e-02 | -4.21 | protein-RNA complex assembly | biological process | GO:0022618 | 200 | 3 | 18204 | 47 |
CELF5,CELF4,CELF2 |
1.494e-02 | -4.20 | carboxylic acid binding | molecular function | GO:0031406 | 195 | 3 | 18094 | 48 |
GRIN1,GRIN2B,GRM7 |
1.499e-02 | -4.20 | Nicotine Activity on Chromaffin Cells | WikiPathways | WP1603 | 4 | 1 | 5310 | 20 |
CACNA1G |
1.502e-02 | -4.20 | NLGN4X (neuroligin 4 X-linked) | protein interactions | 57502 | 6 | 1 | 19454 | 49 |
DLG4 |
1.502e-02 | -4.20 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 49 |
NRXN1 |
1.502e-02 | -4.20 | TMEM8B (transmembrane protein 8B) | protein interactions | 51754 | 6 | 1 | 19454 | 49 |
CHRM2 |
1.502e-02 | -4.20 | GRID2IP (Grid2 interacting protein) | protein interactions | 392862 | 6 | 1 | 19454 | 49 |
GRID2 |
1.502e-02 | -4.20 | Nos1 (nitric oxide synthase 1) | protein interactions | 24598 | 6 | 1 | 19454 | 49 |
DLG4 |
1.504e-02 | -4.20 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 25 | 16828 | 48 |
NRG3,CADPS,KCNC1,ALK,SCN8A,NTRK3,GRID2,KCNT1,STXBP5,GRM7,CSMD2,GRIN2B,CACNA1A,NRXN2,GABRB2,CACNA1G,CNTN5,CELF4,GRIK2,DLG4,FAM131A,GRIA3,CACNA1H,OLFM1,CELF2 |
1.506e-02 | -4.20 | KCHANNEL | prints domains | PR00169 | 33 | 2 | 5227 | 30 |
KCNMA1,KCNC1 |
1.509e-02 | -4.19 | response to nitrogen compound | biological process | GO:1901698 | 1021 | 7 | 18204 | 47 |
KCNC1,CHRM2,PDE2A,CACNA1A,HCN1,GRIN1,GABRB2 |
1.516e-02 | -4.19 | meningioma | COSMIC cancer mutations | meningioma | 514 | 5 | 16828 | 48 |
NTRK3,ALK,GRM7,NRXN2,RIMS2 |
1.516e-02 | -4.19 | meninges | COSMIC cancer mutations | meninges | 514 | 5 | 16828 | 48 |
GRM7,ALK,NTRK3,RIMS2,NRXN2 |
1.524e-02 | -4.18 | phosphatidylserine binding | molecular function | GO:0001786 | 71 | 2 | 18094 | 48 |
SYT7,SYT1 |
1.526e-02 | -4.18 | heart valve development | biological process | GO:0003170 | 73 | 2 | 18204 | 47 |
OLFM1,PDE2A |
1.529e-02 | -4.18 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 3 | 16828 | 48 |
SYT1,NRG3,GRID2 |
1.534e-02 | -4.18 | UNC5B (unc-5 netrin receptor B) | protein interactions | 219699 | 75 | 2 | 19454 | 49 |
ALK,NTRK3 |
1.539e-02 | -4.17 | Mo-molybdopterin cofactor biosynthetic process | biological process | GO:0006777 | 6 | 1 | 18204 | 47 |
GPHN |
1.539e-02 | -4.17 | negative regulation of cGMP-mediated signaling | biological process | GO:0010754 | 6 | 1 | 18204 | 47 |
PDE2A |
1.539e-02 | -4.17 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 1 | 18204 | 47 |
NRG3 |
1.539e-02 | -4.17 | molybdopterin cofactor biosynthetic process | biological process | GO:0032324 | 6 | 1 | 18204 | 47 |
GPHN |
1.539e-02 | -4.17 | oviduct development | biological process | GO:0060066 | 6 | 1 | 18204 | 47 |
CSMD1 |
1.539e-02 | -4.17 | Mo-molybdopterin cofactor metabolic process | biological process | GO:0019720 | 6 | 1 | 18204 | 47 |
GPHN |
1.539e-02 | -4.17 | mineralocorticoid metabolic process | biological process | GO:0008212 | 6 | 1 | 18204 | 47 |
CACNA1H |
1.539e-02 | -4.17 | positive regulation of dopamine secretion | biological process | GO:0033603 | 6 | 1 | 18204 | 47 |
SYT1 |
1.539e-02 | -4.17 | positive regulation of inhibitory postsynaptic potential | biological process | GO:0097151 | 6 | 1 | 18204 | 47 |
RIMS2 |
1.539e-02 | -4.17 | general adaptation syndrome | biological process | GO:0051866 | 6 | 1 | 18204 | 47 |
HCN1 |
1.539e-02 | -4.17 | prosthetic group metabolic process | biological process | GO:0051189 | 6 | 1 | 18204 | 47 |
GPHN |
1.539e-02 | -4.17 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 47 |
NRG3 |
1.539e-02 | -4.17 | neuronal signal transduction | biological process | GO:0023041 | 6 | 1 | 18204 | 47 |
OLFM1 |
1.539e-02 | -4.17 | molybdopterin cofactor metabolic process | biological process | GO:0043545 | 6 | 1 | 18204 | 47 |
GPHN |
1.539e-02 | -4.17 | cellular response to histamine | biological process | GO:0071420 | 6 | 1 | 18204 | 47 |
GABRB2 |
1.547e-02 | -4.17 | heart development | biological process | GO:0007507 | 571 | 5 | 18204 | 47 |
FGF12,PDE2A,CACNA1G,OLFM1,NTRK3 |
1.551e-02 | -4.17 | pancreas-carcinoma-adenocarcinoma | COSMIC cancer mutations | pancreas-carcinoma-adenocarcinoma | 517 | 5 | 16828 | 48 |
CHRM2,GRIA3,KCNT1,CSMD2,KCNC1 |
1.562e-02 | -4.16 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 25 | 16828 | 48 |
GRID2,GRM7,STXBP5,SYT1,GRIN2B,CSMD2,CADPS,NRG3,MCTP1,ALK,PDE2A,HCN1,GRIN1,GRIK2,CELF4,KCTD16,RIMS2,DPP10,SYT7,NRXN1,NRXN2,GABRB2,GPR85,KCNMA1,CELF5 |
1.563e-02 | -4.16 | PDZ | smart domains | SM00228 | 143 | 3 | 9717 | 36 |
DLG3,DLG4,RIMS2 |
1.567e-02 | -4.16 | MACF1 (microtubule actin crosslinking factor 1) | protein interactions | 23499 | 209 | 3 | 19454 | 49 |
TENM1,NRXN1,NRXN2 |
1.569e-02 | -4.16 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 25 | 16828 | 48 |
NRG3,CADPS,SYT7,DPP10,NRXN1,NRXN2,MCTP1,PDE2A,GABRB2,ALK,CELF5,HCN1,KCNMA1,GPR85,GRIN1,CELF4,GRIK2,GRID2,KCTD16,STXBP5,GRM7,CSMD2,RIMS2,SYT1,GRIN2B |
1.579e-02 | -4.15 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 19 | 16828 | 48 |
TENM1,HCN1,ALK,NRXN2,MCTP1,GABBR2,CADPS,CSMD2,CACNA1A,RIMS2,CACNA1H,STXBP5,GRM7,KCNT1,KCTD16,GRIK2,GRID2,NTRK3,DLG4 |
1.581e-02 | -4.15 | molybdopterin cofactor binding | molecular function | GO:0043546 | 6 | 1 | 18094 | 48 |
GPHN |
1.581e-02 | -4.15 | D1 dopamine receptor binding | molecular function | GO:0031748 | 6 | 1 | 18094 | 48 |
DLG4 |
1.584e-02 | -4.15 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 47 | 16828 | 48 |
GPHN,NRG3,KCNC1,HCN1,NTRK3,GRID2,KCNT1,STXBP5,SYT1,GRIN2B,DPP10,DLG3,SYT7,KCNIP2,CHRM2,GABRB2,CNTN5,FGF12,CELF5,RALYL,DLG4,KCTD16,CELF2,CACNA1H,CADPS,GABRA1,MCTP1,ALK,PDE2A,SCN8A,TENM1,GRM7,CACNA1A,CSMD2,GABBR2,NRXN1,NRXN2,CACNA1G,KCNMA1,GPR85,GABRD,CELF4,GRIN1,GRIK2,GRIA3,OLFM1,RIMS2 |
1.584e-02 | -4.15 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 47 | 16828 | 48 |
CACNA1H,CELF2,RALYL,DLG4,KCTD16,GABRB2,CHRM2,CELF5,CNTN5,FGF12,DLG3,SYT7,DPP10,KCNIP2,STXBP5,SYT1,GRIN2B,NTRK3,GRID2,KCNT1,HCN1,NRG3,GPHN,KCNC1,OLFM1,RIMS2,GRIK2,CELF4,GRIN1,GRIA3,GABRD,CACNA1G,KCNMA1,GPR85,NRXN2,NRXN1,GABBR2,GRM7,CSMD2,CACNA1A,PDE2A,ALK,TENM1,SCN8A,GABRA1,CADPS,MCTP1 |
1.587e-02 | -4.14 | clathrin-coated endocytic vesicle membrane | cellular component | GO:0030669 | 75 | 2 | 19108 | 49 |
SYT1,CHRM2 |
1.587e-02 | -4.14 | neuromuscular junction | cellular component | GO:0031594 | 75 | 2 | 19108 | 49 |
DLG3,DLG4 |
1.597e-02 | -4.14 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 20 |
CACNA1A,SYT1 |
1.607e-02 | -4.13 | EPHB2 (EPH receptor B2) | protein interactions | 2048 | 211 | 3 | 19454 | 49 |
GRIN2B,GRIN1,ALK |
1.609e-02 | -4.13 | Na_trans_cytopl | interpro domains | IPR024583 | 6 | 1 | 18521 | 50 |
SCN8A |
1.609e-02 | -4.13 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 50 |
NRXN1 |
1.609e-02 | -4.13 | hnRNP_C | interpro domains | IPR017347 | 6 | 1 | 18521 | 50 |
RALYL |
1.609e-02 | -4.13 | Gabra-1-6_TM | interpro domains | IPR047024 | 6 | 1 | 18521 | 50 |
GABRA1 |
1.609e-02 | -4.13 | Peptidase_S9B_N | interpro domains | IPR002469 | 6 | 1 | 18521 | 50 |
DPP10 |
1.609e-02 | -4.13 | GABAAa_rcpt | interpro domains | IPR001390 | 6 | 1 | 18521 | 50 |
GABRA1 |
1.629e-02 | -4.12 | Downstream signal transduction | REACTOME pathways | R-HSA-186763 | 352 | 4 | 10285 | 29 |
DLG4,GRIN2B,NRG3,GRIN1 |
1.634e-02 | -4.11 | CCP | smart domains | SM00032 | 53 | 2 | 9717 | 36 |
CSMD2,CSMD1 |
1.640e-02 | -4.11 | MAPK signaling pathway | KEGG pathways | ko04010 | 255 | 4 | 7161 | 28 |
CACNA1A,FGF12,CACNA1H,CACNA1G |
1.640e-02 | -4.11 | MAPK signaling pathway | KEGG pathways | hsa04010 | 255 | 4 | 7161 | 28 |
CACNA1A,CACNA1G,CACNA1H,FGF12 |
1.641e-02 | -4.11 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 49 |
NRXN1 |
1.641e-02 | -4.11 | DPPIV_N | pfam domains | PF00930 | 6 | 1 | 17795 | 49 |
DPP10 |
1.641e-02 | -4.11 | Na_trans_cytopl | pfam domains | PF11933 | 6 | 1 | 17795 | 49 |
SCN8A |
1.652e-02 | -4.10 | LRP8 (LDL receptor related protein 8) | protein interactions | 7804 | 78 | 2 | 19454 | 49 |
DLG4,GRIN1 |
1.670e-02 | -4.09 | Amyotrophic lateral sclerosis (ALS) | KEGG pathways | ko05014 | 51 | 2 | 7161 | 28 |
GRIN2B,GRIN1 |
1.670e-02 | -4.09 | Amyotrophic lateral sclerosis (ALS) | KEGG pathways | hsa05014 | 51 | 2 | 7161 | 28 |
GRIN1,GRIN2B |
1.680e-02 | -4.09 | Molybdenum cofactor biosynthesis | REACTOME pathways | R-HSA-947581 | 6 | 1 | 10285 | 29 |
GPHN |
1.688e-02 | -4.08 | negative regulation of endocytosis | biological process | GO:0045806 | 77 | 2 | 18204 | 47 |
MCTP1,DLG4 |
1.691e-02 | -4.08 | protein-RNA complex organization | biological process | GO:0071826 | 210 | 3 | 18204 | 47 |
CELF5,CELF4,CELF2 |
1.691e-02 | -4.08 | DAP12 signaling | REACTOME pathways | R-HSA-2424491 | 356 | 4 | 10285 | 29 |
DLG4,NRG3,GRIN2B,GRIN1 |
1.700e-02 | -4.07 | ganglioneuroma | COSMIC cancer mutations | ganglioneuroma | 6 | 1 | 16828 | 48 |
ALK |
1.700e-02 | -4.07 | genital_tract-germ_cell_tumour-teratoma | COSMIC cancer mutations | genital_tract-germ_cell_tumour-teratoma | 6 | 1 | 16828 | 48 |
ALK |
1.700e-02 | -4.07 | autonomic_ganglia-ganglioneuroma | COSMIC cancer mutations | autonomic_ganglia-ganglioneuroma | 6 | 1 | 16828 | 48 |
ALK |
1.712e-02 | -4.07 | GABAARBETA | prints domains | PR01160 | 3 | 1 | 5227 | 30 |
GABRB2 |
1.712e-02 | -4.07 | NTKRECEPTOR | prints domains | PR01939 | 3 | 1 | 5227 | 30 |
NTRK3 |
1.712e-02 | -4.07 | GABABRECEPTR | prints domains | PR01176 | 3 | 1 | 5227 | 30 |
GABBR2 |
1.715e-02 | -4.07 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 29 | 16828 | 48 |
CELF2,OLFM1,CACNA1H,GRIN1,GRIK2,CELF4,FAM131A,DLG4,GRIA3,GABRB2,CNTN5,CACNA1G,NRXN1,NRXN2,GABBR2,STXBP5,GRM7,CSMD2,CACNA1A,GRIN2B,NTRK3,GRID2,KCNT1,ALK,TENM1,SCN8A,CADPS,NRG3,KCNC1 |
1.728e-02 | -4.06 | calmodulin binding | molecular function | GO:0005516 | 206 | 3 | 18094 | 48 |
GRIN1,SYT1,SYT7 |
1.729e-02 | -4.06 | PRKCA (protein kinase C alpha) | protein interactions | 5578 | 395 | 4 | 19454 | 49 |
GRM7,DLG4,GRIN2B,GRIN1 |
1.733e-02 | -4.06 | PPP1CA (protein phosphatase 1 catalytic subunit alpha) | protein interactions | 100009298 | 80 | 2 | 19454 | 49 |
CSMD1,DLG3 |
1.733e-02 | -4.06 | STX2 (syntaxin 2) | protein interactions | 2054 | 80 | 2 | 19454 | 49 |
SYT7,SYT1 |
1.750e-02 | -4.05 | organic acid binding | molecular function | GO:0043177 | 207 | 3 | 18094 | 48 |
GRIN1,GRM7,GRIN2B |
1.750e-02 | -4.05 | Dlg4 (discs large MAGUK scaffold protein 4) | protein interactions | 13385 | 7 | 1 | 19454 | 49 |
GRIN1 |
1.750e-02 | -4.05 | HCN2 (hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2) | protein interactions | 610 | 7 | 1 | 19454 | 49 |
HCN1 |
1.750e-02 | -4.05 | KCNMB1 (potassium calcium-activated channel subfamily M regulatory beta subunit 1) | protein interactions | 3779 | 7 | 1 | 19454 | 49 |
KCNMA1 |
1.750e-02 | -4.05 | SV2B (synaptic vesicle glycoprotein 2B) | protein interactions | 9899 | 7 | 1 | 19454 | 49 |
SYT1 |
1.750e-02 | -4.05 | RIMBP2 (RIMS binding protein 2) | protein interactions | 23504 | 7 | 1 | 19454 | 49 |
CACNA1A |
1.751e-02 | -4.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_III | 1419 | 9 | 16828 | 48 |
ALK,GRM7,FGF12,HCN1,TENM1,GRID2,NRG3,GABBR2,MCTP1 |
1.752e-02 | -4.04 | central_nervous_system-brain-glioma | COSMIC cancer mutations | central_nervous_system-brain-glioma | 15470 | 48 | 16828 | 48 |
CSMD2,CACNA1A,GRM7,TENM1,SCN8A,PDE2A,ALK,MCTP1,CADPS,GABRA1,RIMS2,OLFM1,GRIA3,GRIK2,CELF4,GRIN1,FAM131A,GABRD,KCNMA1,CACNA1G,GPR85,NRXN1,NRXN2,GABBR2,SYT1,GRIN2B,STXBP5,KCNT1,NTRK3,GRID2,HCN1,KCNC1,NRG3,GPHN,CELF2,CACNA1H,KCTD16,RALYL,DLG4,CELF5,CNTN5,FGF12,GABRB2,CHRM2,KCNIP2,DLG3,SYT7,DPP10 |
1.777e-02 | -4.03 | positive regulation of transmembrane transport | biological process | GO:0034764 | 214 | 3 | 18204 | 47 |
KCNIP2,KCNC1,GRIN1 |
1.777e-02 | -4.03 | cellular response to inorganic substance | biological process | GO:0071241 | 214 | 3 | 18204 | 47 |
DLG4,SYT1,CACNA1H |
1.777e-02 | -4.03 | regulation of monoatomic ion transmembrane transporter activity | biological process | GO:0032412 | 214 | 3 | 18204 | 47 |
FGF12,DLG4,KCNIP2 |
1.782e-02 | -4.03 | G protein-coupled receptor dimeric complex | cellular component | GO:0038037 | 7 | 1 | 19108 | 49 |
GABBR2 |
1.782e-02 | -4.03 | cerebellar mossy fiber | cellular component | GO:0044300 | 7 | 1 | 19108 | 49 |
DLG4 |
1.794e-02 | -4.02 | regulation of synaptic vesicle priming | biological process | GO:0010807 | 7 | 1 | 18204 | 47 |
STXBP5 |
1.794e-02 | -4.02 | cellular response to cGMP | biological process | GO:0071321 | 7 | 1 | 18204 | 47 |
PDE2A |
1.794e-02 | -4.02 | SA node cell action potential | biological process | GO:0086015 | 7 | 1 | 18204 | 47 |
CACNA1G |
1.794e-02 | -4.02 | modulation of inhibitory postsynaptic potential | biological process | GO:0098828 | 7 | 1 | 18204 | 47 |
RIMS2 |
1.794e-02 | -4.02 | mammary gland branching involved in pregnancy | biological process | GO:0060745 | 7 | 1 | 18204 | 47 |
CSMD1 |
1.794e-02 | -4.02 | cerebellar granule cell differentiation | biological process | GO:0021707 | 7 | 1 | 18204 | 47 |
GRID2 |
1.794e-02 | -4.02 | SA node cell to atrial cardiac muscle cell signaling | biological process | GO:0086018 | 7 | 1 | 18204 | 47 |
CACNA1G |
1.794e-02 | -4.02 | AV node cell to bundle of His cell signaling | biological process | GO:0086027 | 7 | 1 | 18204 | 47 |
CACNA1G |
1.794e-02 | -4.02 | positive regulation of long-term synaptic depression | biological process | GO:1900454 | 7 | 1 | 18204 | 47 |
GRID2 |
1.794e-02 | -4.02 | interneuron migration from the subpallium to the cortex | biological process | GO:0021830 | 7 | 1 | 18204 | 47 |
NRG3 |
1.794e-02 | -4.02 | hydrocarbon metabolic process | biological process | GO:0120252 | 7 | 1 | 18204 | 47 |
GRIN1 |
1.794e-02 | -4.02 | AV node cell action potential | biological process | GO:0086016 | 7 | 1 | 18204 | 47 |
CACNA1G |
1.794e-02 | -4.02 | cerebellar granular layer formation | biological process | GO:0021684 | 7 | 1 | 18204 | 47 |
GRID2 |
1.794e-02 | -4.02 | glucocorticoid biosynthetic process | biological process | GO:0006704 | 7 | 1 | 18204 | 47 |
CACNA1H |
1.794e-02 | -4.02 | dense core granule exocytosis | biological process | GO:1990504 | 7 | 1 | 18204 | 47 |
CADPS |
1.794e-02 | -4.02 | urinary bladder smooth muscle contraction | biological process | GO:0014832 | 7 | 1 | 18204 | 47 |
KCNMA1 |
1.816e-02 | -4.01 | TUBA8 (tubulin alpha 8) | protein interactions | 51807 | 82 | 2 | 19454 | 49 |
GRM7,GABRA1 |
1.821e-02 | -4.01 | Signaling by EGFR | REACTOME pathways | R-HSA-177929 | 364 | 4 | 10285 | 29 |
GRIN1,NRG3,GRIN2B,DLG4 |
1.838e-02 | -4.00 | NSF (N-ethylmaleimide sensitive factor, vesicle fusing ATPase) | protein interactions | 4905 | 222 | 3 | 19454 | 49 |
GRIA3,NTRK3,GABBR2 |
1.839e-02 | -4.00 | DUF1041 | smart domains | SM01145 | 5 | 1 | 9717 | 36 |
CADPS |
1.843e-02 | -3.99 | TPR domain binding | molecular function | GO:0030911 | 7 | 1 | 18094 | 48 |
PDE2A |
1.843e-02 | -3.99 | G protein-coupled acetylcholine receptor activity | molecular function | GO:0016907 | 7 | 1 | 18094 | 48 |
CHRM2 |
1.844e-02 | -3.99 | regulation of cell junction assembly | biological process | GO:1901888 | 217 | 3 | 18204 | 47 |
NRXN1,GRID2,ASIC2 |
1.858e-02 | -3.99 | ARHGEF10 (Rho guanine nucleotide exchange factor 10) | protein interactions | 9639 | 83 | 2 | 19454 | 49 |
NTRK3,ALK |
1.875e-02 | -3.98 | VDCC_a1su_IQ | interpro domains | IPR014873 | 7 | 1 | 18521 | 50 |
CACNA1A |
1.875e-02 | -3.98 | Hud_Sxl_RNA | interpro domains | IPR002343 | 7 | 1 | 18521 | 50 |
CELF2 |
1.875e-02 | -3.98 | GAF | interpro domains | IPR003018 | 7 | 1 | 18521 | 50 |
PDE2A |
1.875e-02 | -3.98 | GPHH_dom | interpro domains | IPR031649 | 7 | 1 | 18521 | 50 |
CACNA1A |
1.875e-02 | -3.98 | MUN_dom | interpro domains | IPR010439 | 7 | 1 | 18521 | 50 |
CADPS |
1.875e-02 | -3.98 | ENaC_chordates | interpro domains | IPR004724 | 7 | 1 | 18521 | 50 |
ASIC2 |
1.875e-02 | -3.98 | Munc13_1 | interpro domains | IPR014770 | 7 | 1 | 18521 | 50 |
CADPS |
1.897e-02 | -3.96 | human chr11q22.1 | chromosome location | human chr11q22.1 | 10 | 1 | 26134 | 50 |
CNTN5 |
1.897e-02 | -3.96 | human chr8q21.2 | chromosome location | human chr8q21.2 | 10 | 1 | 26134 | 50 |
RALYL |
1.900e-02 | -3.96 | RAB27A (RAB27A, member RAS oncogene family) | protein interactions | 5873 | 84 | 2 | 19454 | 49 |
SYT1,RIMS2 |
1.900e-02 | -3.96 | MAPK12 (mitogen-activated protein kinase 12) | protein interactions | 6300 | 84 | 2 | 19454 | 49 |
DLG4,DLG3 |
1.910e-02 | -3.96 | hairy_cell_leukaemia | COSMIC cancer mutations | hairy_cell_leukaemia | 1440 | 9 | 16828 | 48 |
GABBR2,NRXN1,NRXN2,CADPS,NTRK3,RIMS2,CELF5,GRM7,ALK |
1.910e-02 | -3.96 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | 1440 | 9 | 16828 | 48 |
GABBR2,NRXN1,NRXN2,CADPS,NTRK3,RIMS2,CELF5,ALK,GRM7 |
1.911e-02 | -3.96 | secretory vesicle | cellular component | GO:0099503 | 1076 | 7 | 19108 | 49 |
CADPS,MCTP1,SYT7,GRIN1,SYT1,STXBP5,DLG4 |
1.912e-02 | -3.96 | MUN | pfam domains | PF06292 | 7 | 1 | 17795 | 49 |
CADPS |
1.912e-02 | -3.96 | GPHH | pfam domains | PF16905 | 7 | 1 | 17795 | 49 |
CACNA1A |
1.912e-02 | -3.96 | Ca_chan_IQ | pfam domains | PF08763 | 7 | 1 | 17795 | 49 |
CACNA1A |
1.912e-02 | -3.96 | GAF | pfam domains | PF01590 | 7 | 1 | 17795 | 49 |
PDE2A |
1.919e-02 | -3.95 | humerus | COSMIC cancer mutations | humerus | 546 | 5 | 16828 | 48 |
GRID2,GRM7,TENM1,FGF12,HCN1 |
1.923e-02 | -3.95 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 3 | 10285 | 29 |
KCNIP2,FGF12,SCN8A |
1.933e-02 | -3.95 | Dipeptidylpeptidase IV, N-terminal domain | gene3d domains | 2.140.10.30 | 6 | 1 | 14470 | 47 |
DPP10 |
1.939e-02 | -3.94 | DAP12 interactions | REACTOME pathways | R-HSA-2172127 | 371 | 4 | 10285 | 29 |
GRIN2B,NRG3,DLG4,GRIN1 |
1.944e-02 | -3.94 | regulation of amine transport | biological process | GO:0051952 | 83 | 2 | 18204 | 47 |
SYT1,GRM7 |
1.944e-02 | -3.94 | positive regulation of MAP kinase activity | biological process | GO:0043406 | 83 | 2 | 18204 | 47 |
NTRK3,TENM1 |
1.954e-02 | -3.94 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 48 |
ALK,NTRK3 |
1.956e-02 | -3.93 | Fc epsilon receptor (FCERI) signaling | REACTOME pathways | R-HSA-2454202 | 372 | 4 | 10285 | 29 |
GRIN1,DLG4,GRIN2B,NRG3 |
1.957e-02 | -3.93 | regulation of transmembrane transporter activity | biological process | GO:0022898 | 222 | 3 | 18204 | 47 |
KCNIP2,FGF12,DLG4 |
1.958e-02 | -3.93 | Phase 1 - inactivation of fast Na+ channels | REACTOME pathways | R-HSA-5576894 | 7 | 1 | 10285 | 29 |
KCNIP2 |
1.960e-02 | -3.93 | skin-leg-malignant_melanoma | COSMIC cancer mutations | skin-leg-malignant_melanoma | 549 | 5 | 16828 | 48 |
CSMD2,NTRK3,NRG3,CADPS,CELF4 |
1.964e-02 | -3.93 | regulation of cell growth | biological process | GO:0001558 | 401 | 4 | 18204 | 47 |
RIMS2,NRG3,OLFM1,SYT1 |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
NTRK3,ALK |
1.980e-02 | -3.92 | autonomic_ganglia-ganglioneuroblastoma | COSMIC cancer mutations | autonomic_ganglia-ganglioneuroblastoma | 7 | 1 | 16828 | 48 |
ALK |
1.980e-02 | -3.92 | stomach-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | stomach-carcinoma-mixed_adenosquamous_carcinoma | 7 | 1 | 16828 | 48 |
NTRK3 |
1.980e-02 | -3.92 | bone-scapula-chordoma | COSMIC cancer mutations | bone-scapula-chordoma | 7 | 1 | 16828 | 48 |
ALK |
1.980e-02 | -3.92 | bone-extraskeletal-chordoma | COSMIC cancer mutations | bone-extraskeletal-chordoma | 7 | 1 | 16828 | 48 |
ALK |
1.986e-02 | -3.92 | FAM171A1 (family with sequence similarity 171 member A1) | protein interactions | 221061 | 86 | 2 | 19454 | 49 |
ALK,NTRK3 |
1.986e-02 | -3.92 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 49 |
ALK,NTRK3 |
1.986e-02 | -3.92 | HLA-F (major histocompatibility complex, class I, F) | protein interactions | 3134 | 86 | 2 | 19454 | 49 |
NTRK3,GRIA3 |
1.989e-02 | -3.92 | peripheral nervous system development | biological process | GO:0007422 | 84 | 2 | 18204 | 47 |
SCN8A,ASIC2 |
1.998e-02 | -3.91 | GJC2 (gap junction protein gamma 2) | protein interactions | 57165 | 8 | 1 | 19454 | 49 |
CHRM2 |
1.998e-02 | -3.91 | PEX5L (peroxisomal biogenesis factor 5 like) | protein interactions | 51555 | 8 | 1 | 19454 | 49 |
HCN1 |
1.998e-02 | -3.91 | ATP9B (ATPase phospholipid transporting 9B (putative)) | protein interactions | 374868 | 8 | 1 | 19454 | 49 |
PDE2A |
1.998e-02 | -3.91 | KMO (kynurenine 3-monooxygenase) | protein interactions | 8564 | 8 | 1 | 19454 | 49 |
GPHN |
1.998e-02 | -3.91 | DHRS11 (dehydrogenase/reductase 11) | protein interactions | 79154 | 8 | 1 | 19454 | 49 |
DLG3 |
1.998e-02 | -3.91 | GRM4 (glutamate metabotropic receptor 4) | protein interactions | 2914 | 8 | 1 | 19454 | 49 |
GRM7 |
1.998e-02 | -3.91 | SAG (S-antigen visual arrestin) | protein interactions | 6295 | 8 | 1 | 19454 | 49 |
CHRM2 |
1.998e-02 | -3.91 | RASSF4 (Ras association domain family member 4) | protein interactions | 83937 | 8 | 1 | 19454 | 49 |
DLG4 |
1.998e-02 | -3.91 | GRIK4 (glutamate ionotropic receptor kainate type subunit 4) | protein interactions | 2900 | 8 | 1 | 19454 | 49 |
GRIK2 |
2.010e-02 | -3.91 | thyroid-carcinoma-Hurthle_cell_carcinoma | COSMIC cancer mutations | thyroid-carcinoma-Hurthle_cell_carcinoma | 203 | 3 | 16828 | 48 |
SCN8A,GABRD,SYT7 |
2.010e-02 | -3.91 | Hurthle_cell_carcinoma | COSMIC cancer mutations | Hurthle_cell_carcinoma | 203 | 3 | 16828 | 48 |
SCN8A,GABRD,SYT7 |
2.027e-02 | -3.90 | Signaling by PDGF | REACTOME pathways | R-HSA-186797 | 376 | 4 | 10285 | 29 |
DLG4,NRG3,GRIN2B,GRIN1 |
2.034e-02 | -3.90 | clathrin-sculpted gamma-aminobutyric acid transport vesicle | cellular component | GO:0061200 | 8 | 1 | 19108 | 49 |
SYT1 |
2.034e-02 | -3.90 | clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane | cellular component | GO:0061202 | 8 | 1 | 19108 | 49 |
SYT1 |
2.034e-02 | -3.90 | cytoskeleton of presynaptic active zone | cellular component | GO:0048788 | 8 | 1 | 19108 | 49 |
RIMS2 |
2.047e-02 | -3.89 | positive regulation of neuron projection arborization | biological process | GO:0150012 | 8 | 1 | 18204 | 47 |
DLG4 |
2.047e-02 | -3.89 | regulation of glucagon secretion | biological process | GO:0070092 | 8 | 1 | 18204 | 47 |
SYT7 |
2.047e-02 | -3.89 | cellular response to macrophage colony-stimulating factor stimulus | biological process | GO:0036006 | 8 | 1 | 18204 | 47 |
PDE2A |
2.047e-02 | -3.89 | phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway | biological process | GO:0007207 | 8 | 1 | 18204 | 47 |
CHRM2 |
2.047e-02 | -3.89 | positive regulation of vesicle fusion | biological process | GO:0031340 | 8 | 1 | 18204 | 47 |
SYT1 |
2.047e-02 | -3.89 | adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway | biological process | GO:0007197 | 8 | 1 | 18204 | 47 |
CHRM2 |
2.047e-02 | -3.89 | atrioventricular valve formation | biological process | GO:0003190 | 8 | 1 | 18204 | 47 |
OLFM1 |
2.047e-02 | -3.89 | thermoception | biological process | GO:0050955 | 8 | 1 | 18204 | 47 |
GRIK2 |
2.047e-02 | -3.89 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 1 | 18204 | 47 |
NRG3 |
2.047e-02 | -3.89 | negative regulation of synaptic transmission, glutamatergic | biological process | GO:0051967 | 8 | 1 | 18204 | 47 |
GRIK2 |
2.047e-02 | -3.89 | micturition | biological process | GO:0060073 | 8 | 1 | 18204 | 47 |
KCNMA1 |
2.049e-02 | -3.89 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 3 | 10285 | 29 |
ASIC2,GABRB2,GABRA1 |
2.050e-02 | -3.89 | MHD1 | prosite domains | PS51258 | 7 | 1 | 12186 | 36 |
CADPS |
2.062e-02 | -3.88 | SEC23A (SEC23 homolog A, COPII coat complex component) | protein interactions | 10484 | 232 | 3 | 19454 | 49 |
CADPS,ALK,NTRK3 |
2.078e-02 | -3.87 | response to cAMP | biological process | GO:0051591 | 86 | 2 | 18204 | 47 |
HCN1,PDE2A |
2.092e-02 | -3.87 | phosphatidylinositol-4,5-bisphosphate binding | molecular function | GO:0005546 | 84 | 2 | 18094 | 48 |
SYT7,SYT1 |
2.103e-02 | -3.86 | adenylate cyclase regulator activity | molecular function | GO:0010854 | 8 | 1 | 18094 | 48 |
GRM7 |
2.103e-02 | -3.86 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 48 |
SCN8A |
2.109e-02 | -3.86 | PRKCB (protein kinase C beta) | protein interactions | 5579 | 234 | 3 | 19454 | 49 |
GABRB2,GRIN2B,GRIN1 |
2.117e-02 | -3.86 | positive regulation of phosphorylation | biological process | GO:0042327 | 619 | 5 | 18204 | 47 |
TENM1,ALK,DLG3,NTRK3,DLG4 |
2.124e-02 | -3.85 | associative learning | biological process | GO:0008306 | 87 | 2 | 18204 | 47 |
GRIN1,CSMD1 |
2.126e-02 | -3.85 | skin-neck-malignant_melanoma | COSMIC cancer mutations | skin-neck-malignant_melanoma | 1223 | 8 | 16828 | 48 |
CSMD2,GRIN2B,RIMS2,GRM7,ALK,KCTD16,GRID2,DPP10 |
2.127e-02 | -3.85 | ConA-like_dom_sf | interpro domains | IPR013320 | 219 | 3 | 18521 | 50 |
NRXN1,NRXN2,ALK |
2.133e-02 | -3.85 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 46 | 16828 | 48 |
HCN1,NRG3,GPHN,KCNC1,STXBP5,SYT1,GRIN2B,NTRK3,GRID2,KCNT1,GABRB2,CHRM2,CELF5,CNTN5,FGF12,SYT7,DPP10,KCNIP2,CELF2,CACNA1H,DLG4,RALYL,KCTD16,PDE2A,ALK,TENM1,SCN8A,GABRA1,CADPS,MCTP1,GRM7,CSMD2,CACNA1A,GABRD,KCNMA1,CACNA1G,NRXN1,NRXN2,GABBR2,OLFM1,RIMS2,GRIK2,GRIN1,CELF4,FAM131A,GRIA3 |
2.140e-02 | -3.84 | ENaC_CS | interpro domains | IPR020903 | 8 | 1 | 18521 | 50 |
ASIC2 |
2.140e-02 | -3.84 | GAF-like_dom_sf | interpro domains | IPR029016 | 8 | 1 | 18521 | 50 |
PDE2A |
2.140e-02 | -3.84 | GPCR_3_mtglu_rcpt | interpro domains | IPR000162 | 8 | 1 | 18521 | 50 |
GRM7 |
2.143e-02 | -3.84 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 18 | 16828 | 48 |
KCNIP2,DPP10,GABRA1,SCN8A,HCN1,CNTN5,ALK,GABRB2,KCNT1,FAM131A,GRID2,NTRK3,GRIK2,RIMS2,GRIN2B,CACNA1A,CSMD2,CACNA1H |
2.148e-02 | -3.84 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 18 | 16828 | 48 |
GABRB2,ALK,CNTN5,HCN1,SCN8A,GABRA1,DPP10,KCNIP2,CACNA1H,CSMD2,CACNA1A,RIMS2,GRIN2B,GRIK2,NTRK3,GRID2,FAM131A,KCNT1 |
2.169e-02 | -3.83 | positive regulation of peptidyl-serine phosphorylation | biological process | GO:0033138 | 88 | 2 | 18204 | 47 |
NTRK3,TENM1 |
2.170e-02 | -3.83 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | WikiPathways | WP706 | 162 | 3 | 5310 | 20 |
GABRA1,GRIN1,CHRM2 |
2.189e-02 | -3.82 | neuron projection cytoplasm | cellular component | GO:0120111 | 89 | 2 | 19108 | 49 |
GRIK2,DLG4 |
2.202e-02 | -3.82 | neck | COSMIC cancer mutations | neck | 1231 | 8 | 16828 | 48 |
CSMD2,GRIN2B,RIMS2,ALK,GRM7,KCTD16,GRID2,DPP10 |
2.227e-02 | -3.80 | NGF signalling via TRKA from the plasma membrane | REACTOME pathways | R-HSA-187037 | 387 | 4 | 10285 | 29 |
GRIN1,DLG4,NRG3,GRIN2B |
2.244e-02 | -3.80 | stomach | COSMIC cancer mutations | stomach | 15550 | 48 | 16828 | 48 |
KCTD16,RALYL,DLG4,CELF2,CACNA1H,KCNIP2,DPP10,DLG3,SYT7,FGF12,CNTN5,CELF5,CHRM2,GABRB2,KCNT1,NTRK3,GRID2,GRIN2B,SYT1,STXBP5,KCNC1,GPHN,NRG3,HCN1,GRIA3,FAM131A,GRIN1,CELF4,GRIK2,RIMS2,OLFM1,GABBR2,NRXN1,NRXN2,KCNMA1,CACNA1G,GPR85,GABRD,CACNA1A,CSMD2,GRM7,MCTP1,CADPS,GABRA1,SCN8A,TENM1,ALK,PDE2A |
2.245e-02 | -3.80 | KCNG3 (potassium voltage-gated channel modifier subfamily G member 3) | protein interactions | 170850 | 9 | 1 | 19454 | 49 |
KCNC1 |
2.245e-02 | -3.80 | KCNV2 (potassium voltage-gated channel modifier subfamily V member 2) | protein interactions | 169522 | 9 | 1 | 19454 | 49 |
KCNC1 |
2.245e-02 | -3.80 | MPND (MPN domain containing) | protein interactions | 84954 | 9 | 1 | 19454 | 49 |
DLG4 |
2.245e-02 | -3.80 | GABRB2 (gamma-aminobutyric acid type A receptor subunit beta2) | protein interactions | 2561 | 9 | 1 | 19454 | 49 |
GABRA1 |
2.245e-02 | -3.80 | CAMK2N1 (calcium/calmodulin dependent protein kinase II inhibitor 1) | protein interactions | 55450 | 9 | 1 | 19454 | 49 |
GRIN2B |
2.252e-02 | -3.79 | - | gene3d domains | 6.10.250.2180 | 7 | 1 | 14470 | 47 |
CACNA1A |
2.252e-02 | -3.79 | - | gene3d domains | 6.10.250.2500 | 7 | 1 | 14470 | 47 |
CACNA1A |
2.260e-02 | -3.79 | ganglioneuroblastoma | COSMIC cancer mutations | ganglioneuroblastoma | 8 | 1 | 16828 | 48 |
ALK |
2.260e-02 | -3.79 | papillary_adenocarcinoma | COSMIC cancer mutations | papillary_adenocarcinoma | 8 | 1 | 16828 | 48 |
NTRK3 |
2.260e-02 | -3.79 | thymus-thymic_carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | thymus-thymic_carcinoma-squamous_cell_carcinoma | 8 | 1 | 16828 | 48 |
ALK |
2.260e-02 | -3.79 | stomach-carcinoma-papillary_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-papillary_adenocarcinoma | 8 | 1 | 16828 | 48 |
NTRK3 |
2.272e-02 | -3.78 | human chr6q24.3 | chromosome location | human chr6q24.3 | 12 | 1 | 26134 | 50 |
STXBP5 |
2.277e-02 | -3.78 | LETHAL2GIANT | prints domains | PR00962 | 4 | 1 | 5227 | 30 |
STXBP5 |
2.277e-02 | -3.78 | SHAWCHANNEL | prints domains | PR01498 | 4 | 1 | 5227 | 30 |
KCNC1 |
2.277e-02 | -3.78 | ERBIN (erbb2 interacting protein) | protein interactions | 55914 | 241 | 3 | 19454 | 49 |
GRIN2B,NTRK3,DLG4 |
2.278e-02 | -3.78 | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 48 |
NTRK3,GABRB2,ALK |
2.278e-02 | -3.78 | atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 48 |
GABRB2,NTRK3,ALK |
2.285e-02 | -3.78 | chromaffin granule membrane | cellular component | GO:0042584 | 9 | 1 | 19108 | 49 |
SYT1 |
2.300e-02 | -3.77 | adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway | biological process | GO:0007196 | 9 | 1 | 18204 | 47 |
GRM7 |
2.300e-02 | -3.77 | vesicle-mediated cholesterol transport | biological process | GO:0090119 | 9 | 1 | 18204 | 47 |
SYT7 |
2.300e-02 | -3.77 | response to cGMP | biological process | GO:0070305 | 9 | 1 | 18204 | 47 |
PDE2A |
2.300e-02 | -3.77 | cerebellar granular layer morphogenesis | biological process | GO:0021683 | 9 | 1 | 18204 | 47 |
GRID2 |
2.300e-02 | -3.77 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 47 |
NRXN1 |
2.300e-02 | -3.77 | C21-steroid hormone biosynthetic process | biological process | GO:0006700 | 9 | 1 | 18204 | 47 |
CACNA1H |
2.300e-02 | -3.77 | SA node cell to atrial cardiac muscle cell communication | biological process | GO:0086070 | 9 | 1 | 18204 | 47 |
CACNA1G |
2.300e-02 | -3.77 | negative regulation of cAMP-mediated signaling | biological process | GO:0043951 | 9 | 1 | 18204 | 47 |
PDE2A |
2.300e-02 | -3.77 | sensory perception of sour taste | biological process | GO:0050915 | 9 | 1 | 18204 | 47 |
ASIC2 |
2.300e-02 | -3.77 | regulation of potassium ion export across plasma membrane | biological process | GO:1903764 | 9 | 1 | 18204 | 47 |
KCNIP2 |
2.300e-02 | -3.77 | urinary tract smooth muscle contraction | biological process | GO:0014848 | 9 | 1 | 18204 | 47 |
KCNMA1 |
2.340e-02 | -3.76 | ASC | prosite domains | PS01206 | 8 | 1 | 12186 | 36 |
ASIC2 |
2.344e-02 | -3.75 | positive regulation of catalytic activity | biological process | GO:0043085 | 868 | 6 | 18204 | 47 |
DLG3,TENM1,ALK,NTRK3,GRIN2B,DLG4 |
2.345e-02 | -3.75 | TANC1 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1) | protein interactions | 85461 | 94 | 2 | 19454 | 49 |
GRIN2B,DLG4 |
2.355e-02 | -3.75 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 11 | 16828 | 48 |
GRIK2,GRID2,CSMD2,GRIN2B,SYT1,GRM7,NRG3,CADPS,KCNMA1,PDE2A,ALK |
2.355e-02 | -3.75 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 11 | 16828 | 48 |
GRIN2B,SYT1,CSMD2,GRM7,GRIK2,GRID2,KCNMA1,ALK,PDE2A,CADPS,NRG3 |
2.359e-02 | -3.75 | transport vesicle membrane | cellular component | GO:0030658 | 240 | 3 | 19108 | 49 |
MCTP1,SYT7,SYT1 |
2.363e-02 | -3.75 | adenylate cyclase inhibiting G protein-coupled glutamate receptor activity | molecular function | GO:0001640 | 9 | 1 | 18094 | 48 |
GRM7 |
2.363e-02 | -3.75 | intracellularly cAMP-activated cation channel activity | molecular function | GO:0005222 | 9 | 1 | 18094 | 48 |
HCN1 |
2.363e-02 | -3.75 | G protein-coupled glutamate receptor activity | molecular function | GO:0098988 | 9 | 1 | 18094 | 48 |
GRM7 |
2.363e-02 | -3.75 | arrestin family protein binding | molecular function | GO:1990763 | 9 | 1 | 18094 | 48 |
CHRM2 |
2.373e-02 | -3.74 | Signaling by GPCR | REACTOME pathways | R-HSA-372790 | 1299 | 8 | 10285 | 29 |
GRIN1,GRM7,DLG4,CHRM2,NRG3,GABBR2,GRIN2B,PDE2A |
2.376e-02 | -3.74 | clathrin-coated endocytic vesicle | cellular component | GO:0045334 | 93 | 2 | 19108 | 49 |
SYT1,CHRM2 |
2.391e-02 | -3.73 | SCN4A (sodium voltage-gated channel alpha subunit 4) | protein interactions | 6329 | 95 | 2 | 19454 | 49 |
SCN8A,DLG3 |
2.394e-02 | -3.73 | bone-ilium-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-ilium-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 84 | 2 | 16828 | 48 |
CADPS,TENM1 |
2.404e-02 | -3.73 | ENaC | interpro domains | IPR001873 | 9 | 1 | 18521 | 50 |
ASIC2 |
2.404e-02 | -3.73 | Peptidase_S9 | interpro domains | IPR001375 | 9 | 1 | 18521 | 50 |
DPP10 |
2.404e-02 | -3.73 | Quino_amine_DH_bsu | interpro domains | IPR011044 | 9 | 1 | 18521 | 50 |
OLFM1 |
2.405e-02 | -3.73 | Complement Module, domain 1 | gene3d domains | 2.10.70.10 | 74 | 2 | 14470 | 47 |
CSMD1,CSMD2 |
2.417e-02 | -3.72 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 8 | 18204 | 47 |
OLFM1,RIMS2,ASIC2,DLG4,SYT1,NRXN1,GRID2,ALK |
2.452e-02 | -3.71 | ASC | pfam domains | PF00858 | 9 | 1 | 17795 | 49 |
ASIC2 |
2.452e-02 | -3.71 | Peptidase_S9 | pfam domains | PF00326 | 9 | 1 | 17795 | 49 |
DPP10 |
2.457e-02 | -3.71 | cell development | biological process | GO:0048468 | 2236 | 11 | 18204 | 47 |
NRXN1,ALK,KCNIP2,HCN1,DLG4,CNTN5,CELF4,TENM1,PDE2A,GRM7,GABRB2 |
2.476e-02 | -3.70 | regulation of transferase activity | biological process | GO:0051338 | 645 | 5 | 18204 | 47 |
DLG4,DLG3,ALK,NTRK3,TENM1 |
2.486e-02 | -3.69 | LIN7C (lin-7 homolog C, crumbs cell polarity complex component) | protein interactions | 55327 | 97 | 2 | 19454 | 49 |
DLG4,NTRK3 |
2.486e-02 | -3.69 | CCDC115 (coiled-coil domain containing 115) | protein interactions | 84317 | 97 | 2 | 19454 | 49 |
NTRK3,ALK |
2.486e-02 | -3.69 | Synaptic vesicle cycle | KEGG pathways | ko04721 | 63 | 2 | 7161 | 28 |
SYT1,CACNA1A |
2.486e-02 | -3.69 | Synaptic vesicle cycle | KEGG pathways | hsa04721 | 63 | 2 | 7161 | 28 |
CACNA1A,SYT1 |
2.491e-02 | -3.69 | SLC35A3 (solute carrier family 35 member A3) | protein interactions | 23443 | 10 | 1 | 19454 | 49 |
PDE2A |
2.510e-02 | -3.68 | Ca2+ activated K+ channels | REACTOME pathways | R-HSA-1296052 | 9 | 1 | 10285 | 29 |
KCNMA1 |
2.518e-02 | -3.68 | oesophagus | COSMIC cancer mutations | oesophagus | 14970 | 47 | 16828 | 48 |
GRIA3,GRIN1,GRIK2,CELF4,FAM131A,RIMS2,OLFM1,NRXN1,NRXN2,GABBR2,GABRD,GPR85,CACNA1G,KCNMA1,CSMD2,CACNA1A,GRM7,MCTP1,GABRA1,CADPS,TENM1,SCN8A,PDE2A,ALK,KCTD16,RALYL,DLG4,CELF2,CACNA1H,KCNIP2,SYT7,DLG3,DPP10,CELF5,FGF12,CNTN5,GABRB2,CHRM2,KCNT1,NTRK3,GRID2,SYT1,GRIN2B,STXBP5,KCNC1,NRG3,HCN1 |
2.531e-02 | -3.68 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 5 | 16828 | 48 |
NTRK3,ALK,CSMD2,KCNMA1,GRIN2B |
2.534e-02 | -3.68 | MAP4K5 (mitogen-activated protein kinase kinase kinase kinase 5) | protein interactions | 11183 | 98 | 2 | 19454 | 49 |
NTRK3,ALK |
2.534e-02 | -3.68 | MB21D2 (Mab-21 domain containing 2) | protein interactions | 151963 | 98 | 2 | 19454 | 49 |
NTRK3,ALK |
2.534e-02 | -3.68 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 2 | 19454 | 49 |
NTRK3,ALK |
2.534e-02 | -3.68 | PTK2B (protein tyrosine kinase 2 beta) | protein interactions | 2185 | 98 | 2 | 19454 | 49 |
DLG4,DLG3 |
2.534e-02 | -3.68 | Nateglinide Action Pathway | SMPDB pathways | SMP0000453 | 5 | 1 | 1369 | 7 |
CACNA1A |
2.534e-02 | -3.68 | Glibenclamide Action Pathway | SMPDB pathways | SMP0000460 | 5 | 1 | 1369 | 7 |
CACNA1A |
2.534e-02 | -3.68 | Pancreas Function | SMPDB pathways | SMP0000643 | 5 | 1 | 1369 | 7 |
CACNA1A |
2.534e-02 | -3.68 | Repaglinide Action Pathway | SMPDB pathways | SMP0000454 | 5 | 1 | 1369 | 7 |
CACNA1A |
2.534e-02 | -3.68 | Gliclazide Action Pathway | SMPDB pathways | SMP0000461 | 5 | 1 | 1369 | 7 |
CACNA1A |
2.536e-02 | -3.67 | cholinergic synapse | cellular component | GO:0098981 | 10 | 1 | 19108 | 49 |
CHRM2 |
2.543e-02 | -3.67 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 7 | 18204 | 47 |
GABRB2,CACNA1H,GRIN1,HCN1,CACNA1A,NTRK3,PDE2A |
2.543e-02 | -3.67 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | 393 | 4 | 16828 | 48 |
CELF4,SYT7,CELF5,GRIN2B |
2.543e-02 | -3.67 | essential_thrombocythaemia | COSMIC cancer mutations | essential_thrombocythaemia | 393 | 4 | 16828 | 48 |
SYT7,CELF4,CELF5,GRIN2B |
2.553e-02 | -3.67 | inhibitory postsynaptic potential | biological process | GO:0060080 | 10 | 1 | 18204 | 47 |
GRIK2 |
2.553e-02 | -3.67 | aldehyde biosynthetic process | biological process | GO:0046184 | 10 | 1 | 18204 | 47 |
CACNA1H |
2.553e-02 | -3.67 | response to histamine | biological process | GO:0034776 | 10 | 1 | 18204 | 47 |
GABRB2 |
2.553e-02 | -3.67 | regulation of atrial cardiac muscle cell membrane depolarization | biological process | GO:0060371 | 10 | 1 | 18204 | 47 |
CACNA1G |
2.553e-02 | -3.67 | substrate-independent telencephalic tangential interneuron migration | biological process | GO:0021843 | 10 | 1 | 18204 | 47 |
NRG3 |
2.553e-02 | -3.67 | substrate-independent telencephalic tangential migration | biological process | GO:0021826 | 10 | 1 | 18204 | 47 |
NRG3 |
2.553e-02 | -3.67 | regulation of voltage-gated sodium channel activity | biological process | GO:1905150 | 10 | 1 | 18204 | 47 |
FGF12 |
2.555e-02 | -3.67 | regulation of cell morphogenesis | biological process | GO:0022604 | 246 | 3 | 18204 | 47 |
RIMS2,SYT1,DLG4 |
2.566e-02 | -3.66 | GAF | smart domains | SM00065 | 7 | 1 | 9717 | 36 |
PDE2A |
2.566e-02 | -3.66 | Ca_chan_IQ | smart domains | SM01062 | 7 | 1 | 9717 | 36 |
CACNA1A |
2.570e-02 | -3.66 | - | gene3d domains | 3.30.450.40 | 8 | 1 | 14470 | 47 |
PDE2A |
2.579e-02 | -3.66 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 8 | 18204 | 47 |
NTRK3,CACNA1A,KCNC1,PDE2A,CACNA1H,GABRB2,HCN1,GRIN1 |
2.582e-02 | -3.66 | KCTD12 (potassium channel tetramerization domain containing 12) | protein interactions | 115207 | 99 | 2 | 19454 | 49 |
GABBR2,KCTD16 |
2.622e-02 | -3.64 | neurotrophin binding | molecular function | GO:0043121 | 10 | 1 | 18094 | 48 |
NTRK3 |
2.628e-02 | -3.64 | G_PROTEIN_RECEP_F3_1 | prosite domains | PS00979 | 9 | 1 | 12186 | 36 |
GRM7 |
2.630e-02 | -3.64 | APBA1 (amyloid beta precursor protein binding family A member 1) | protein interactions | 320 | 100 | 2 | 19454 | 49 |
DLG4,NRXN1 |
2.646e-02 | -3.63 | human chr3p26.1 | chromosome location | human chr3p26.1 | 14 | 1 | 26134 | 50 |
GRM7 |
2.646e-02 | -3.63 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 50 |
NRXN1 |
2.646e-02 | -3.63 | human chr3p14.2 | chromosome location | human chr3p14.2 | 14 | 1 | 26134 | 50 |
CADPS |
2.665e-02 | -3.62 | ilium | COSMIC cancer mutations | ilium | 89 | 2 | 16828 | 48 |
CADPS,TENM1 |
2.668e-02 | -3.62 | Na_channel_asu | interpro domains | IPR001696 | 10 | 1 | 18521 | 50 |
SCN8A |
2.668e-02 | -3.62 | Na_trans_assoc_dom | interpro domains | IPR010526 | 10 | 1 | 18521 | 50 |
SCN8A |
2.668e-02 | -3.62 | FYVE_2 | interpro domains | IPR041282 | 10 | 1 | 18521 | 50 |
RIMS2 |
2.668e-02 | -3.62 | Na_chnl_inactivation_gate | interpro domains | IPR044564 | 10 | 1 | 18521 | 50 |
SCN8A |
2.691e-02 | -3.62 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | biological process | GO:0000377 | 251 | 3 | 18204 | 47 |
CELF5,CELF2,CELF4 |
2.691e-02 | -3.62 | mRNA splicing, via spliceosome | biological process | GO:0000398 | 251 | 3 | 18204 | 47 |
CELF4,CELF2,CELF5 |
2.693e-02 | -3.61 | Platelet homeostasis | REACTOME pathways | R-HSA-418346 | 91 | 2 | 10285 | 29 |
KCNMA1,PDE2A |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
ALK,NTRK3 |
2.720e-02 | -3.60 | Na_trans_assoc | pfam domains | PF06512 | 10 | 1 | 17795 | 49 |
SCN8A |
2.720e-02 | -3.60 | FYVE_2 | pfam domains | PF02318 | 10 | 1 | 17795 | 49 |
RIMS2 |
2.728e-02 | -3.60 | PATJ (PATJ crumbs cell polarity complex component) | protein interactions | 10207 | 102 | 2 | 19454 | 49 |
NRXN2,GRIN2B |
2.737e-02 | -3.60 | RIMS3 (regulating synaptic membrane exocytosis 3) | protein interactions | 9783 | 11 | 1 | 19454 | 49 |
RIMS2 |
2.737e-02 | -3.60 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 49 |
NRXN1 |
2.737e-02 | -3.60 | SPATS1 (spermatogenesis associated serine rich 1) | protein interactions | 221409 | 11 | 1 | 19454 | 49 |
GPHN |
2.737e-02 | -3.60 | GRIP2 (glutamate receptor interacting protein 2) | protein interactions | 80852 | 11 | 1 | 19454 | 49 |
GRIA3 |
2.737e-02 | -3.60 | CELF3 (CUGBP Elav-like family member 3) | protein interactions | 11189 | 11 | 1 | 19454 | 49 |
CELF5 |
2.737e-02 | -3.60 | SV2C (synaptic vesicle glycoprotein 2C) | protein interactions | 22987 | 11 | 1 | 19454 | 49 |
SYT1 |
2.746e-02 | -3.60 | regulation of transporter activity | biological process | GO:0032409 | 253 | 3 | 18204 | 47 |
FGF12,DLG4,KCNIP2 |
2.778e-02 | -3.58 | ARFGAP3 (ADP ribosylation factor GTPase activating protein 3) | protein interactions | 26286 | 103 | 2 | 19454 | 49 |
NTRK3,ALK |
2.778e-02 | -3.58 | PLEKHA1 (pleckstrin homology domain containing A1) | protein interactions | 59338 | 103 | 2 | 19454 | 49 |
ALK,NTRK3 |
2.785e-02 | -3.58 | Neurotoxicity of clostridium toxins | REACTOME pathways | R-HSA-168799 | 10 | 1 | 10285 | 29 |
SYT1 |
2.785e-02 | -3.58 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 1 | 10285 | 29 |
NRG3 |
2.786e-02 | -3.58 | symmetric synapse | cellular component | GO:0032280 | 11 | 1 | 19108 | 49 |
CHRM2 |
2.786e-02 | -3.58 | presynaptic cytoskeleton | cellular component | GO:0099569 | 11 | 1 | 19108 | 49 |
RIMS2 |
2.786e-02 | -3.58 | G protein-coupled receptor complex | cellular component | GO:0097648 | 11 | 1 | 19108 | 49 |
GABBR2 |
2.788e-02 | -3.58 | Long-term potentiation | KEGG pathways | hsa04720 | 67 | 2 | 7161 | 28 |
GRIN2B,GRIN1 |
2.788e-02 | -3.58 | Long-term potentiation | KEGG pathways | ko04720 | 67 | 2 | 7161 | 28 |
GRIN2B,GRIN1 |
2.794e-02 | -3.58 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 5 | 18204 | 47 |
TENM1,GRIN2B,GRID2,NTRK3,ALK |
2.800e-02 | -3.58 | Effects of Botulinum toxin | Pathway Interaction DB | botulinumtoxinpathway | 9 | 1 | 2226 | 7 |
SYT1 |
2.801e-02 | -3.58 | abdomen | COSMIC cancer mutations | abdomen | 603 | 5 | 16828 | 48 |
PDE2A,ALK,DPP10,KCNMA1,GABBR2 |
2.802e-02 | -3.57 | RNA splicing, via transesterification reactions | biological process | GO:0000375 | 255 | 3 | 18204 | 47 |
CELF5,CELF2,CELF4 |
2.804e-02 | -3.57 | negative regulation of neuron migration | biological process | GO:2001223 | 11 | 1 | 18204 | 47 |
NRG3 |
2.804e-02 | -3.57 | positive regulation of acrosome reaction | biological process | GO:2000344 | 11 | 1 | 18204 | 47 |
CACNA1H |
2.804e-02 | -3.57 | olefinic compound biosynthetic process | biological process | GO:0120255 | 11 | 1 | 18204 | 47 |
CACNA1H |
2.804e-02 | -3.57 | retinal cone cell development | biological process | GO:0046549 | 11 | 1 | 18204 | 47 |
HCN1 |
2.804e-02 | -3.57 | ectodermal placode formation | biological process | GO:0060788 | 11 | 1 | 18204 | 47 |
NRG3 |
2.804e-02 | -3.57 | regulation of cGMP-mediated signaling | biological process | GO:0010752 | 11 | 1 | 18204 | 47 |
PDE2A |
2.804e-02 | -3.57 | regulation of dopamine receptor signaling pathway | biological process | GO:0060159 | 11 | 1 | 18204 | 47 |
ALK |
2.804e-02 | -3.57 | ectodermal placode morphogenesis | biological process | GO:0071697 | 11 | 1 | 18204 | 47 |
NRG3 |
2.804e-02 | -3.57 | positive regulation of voltage-gated potassium channel activity | biological process | GO:1903818 | 11 | 1 | 18204 | 47 |
KCNIP2 |
2.804e-02 | -3.57 | negative regulation of excitatory postsynaptic potential | biological process | GO:0090394 | 11 | 1 | 18204 | 47 |
CELF4 |
2.832e-02 | -3.56 | human chr12q21.2 | chromosome location | human chr12q21.2 | 15 | 1 | 26134 | 50 |
SYT1 |
2.838e-02 | -3.56 | MUSCARINICR | prints domains | PR00243 | 5 | 1 | 5227 | 30 |
CHRM2 |
2.847e-02 | -3.56 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 47 |
ALK,NTRK3,NRG3,GRID2,GRIN2B,GRIA3,GRIN1,GRIK2,GRM7,CELF4 |
2.853e-02 | -3.56 | eye | COSMIC cancer mutations | eye | 606 | 5 | 16828 | 48 |
NTRK3,ALK,CSMD2,KCNMA1,GRIN2B |
2.861e-02 | -3.55 | astrocytoma_Grade_III | COSMIC cancer mutations | astrocytoma_Grade_III | 1544 | 9 | 16828 | 48 |
TENM1,HCN1,FGF12,GRM7,ALK,MCTP1,GABBR2,NRG3,GRID2 |
2.878e-02 | -3.55 | EPS8 (EGFR pathway substrate 8, signaling adaptor) | protein interactions | 2059 | 105 | 2 | 19454 | 49 |
NTRK3,PDE2A |
2.880e-02 | -3.55 | intracellularly cyclic nucleotide-activated monoatomic cation channel activity | molecular function | GO:0005221 | 11 | 1 | 18094 | 48 |
HCN1 |
2.880e-02 | -3.55 | cyclic nucleotide-activated monoatomic ion channel activity | molecular function | GO:0043855 | 11 | 1 | 18094 | 48 |
HCN1 |
2.880e-02 | -3.55 | benzodiazepine receptor activity | molecular function | GO:0008503 | 11 | 1 | 18094 | 48 |
GABRA1 |
2.880e-02 | -3.55 | voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | molecular function | GO:0099508 | 11 | 1 | 18094 | 48 |
KCNC1 |
2.886e-02 | -3.55 | - | gene3d domains | 1.10.357.50 | 9 | 1 | 14470 | 47 |
CADPS |
2.891e-02 | -3.54 | ductal_carcinoma_in_situ | COSMIC cancer mutations | ductal_carcinoma_in_situ | 93 | 2 | 16828 | 48 |
NTRK3,ALK |
2.891e-02 | -3.54 | carcinoma_in_situ | COSMIC cancer mutations | carcinoma_in_situ | 93 | 2 | 16828 | 48 |
NTRK3,ALK |
2.891e-02 | -3.54 | breast-carcinoma_in_situ-ductal_carcinoma_in_situ | COSMIC cancer mutations | breast-carcinoma_in_situ-ductal_carcinoma_in_situ | 93 | 2 | 16828 | 48 |
ALK,NTRK3 |
2.905e-02 | -3.54 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 41 | 16828 | 48 |
DPP10,SYT7,KCNIP2,GABBR2,NRXN1,NRXN2,CHRM2,GABRB2,CNTN5,FGF12,KCNMA1,CACNA1G,CELF5,RALYL,GRIK2,GRIN1,CELF4,KCTD16,GRIA3,OLFM1,CACNA1H,RIMS2,GABRA1,NRG3,CADPS,MCTP1,KCNC1,ALK,PDE2A,HCN1,SCN8A,TENM1,GRID2,NTRK3,KCNT1,GRM7,STXBP5,CACNA1A,SYT1,GRIN2B,CSMD2 |
2.905e-02 | -3.54 | cerebellum development | biological process | GO:0021549 | 103 | 2 | 18204 | 47 |
GRID2,KCNC1 |
2.916e-02 | -3.54 | EPH-Ephrin signaling | REACTOME pathways | R-HSA-2682334 | 95 | 2 | 10285 | 29 |
GRIN1,GRIN2B |
2.940e-02 | -3.53 | response to organonitrogen compound | biological process | GO:0010243 | 915 | 6 | 18204 | 47 |
PDE2A,KCNC1,CACNA1A,GRIN1,HCN1,GABRB2 |
2.958e-02 | -3.52 | breast-carcinoma | COSMIC cancer mutations | breast-carcinoma | 15030 | 47 | 16828 | 48 |
NRG3,KCNC1,HCN1,NTRK3,GRID2,KCNT1,STXBP5,GRIN2B,SYT1,DLG3,SYT7,DPP10,KCNIP2,GABRB2,CHRM2,CELF5,CNTN5,FGF12,RALYL,DLG4,KCTD16,CELF2,CACNA1H,CADPS,GABRA1,MCTP1,PDE2A,ALK,TENM1,SCN8A,GRM7,CSMD2,CACNA1A,NRXN1,NRXN2,GABBR2,GABRD,CACNA1G,GPR85,KCNMA1,CELF4,GRIN1,GRIK2,FAM131A,GRIA3,OLFM1,RIMS2 |
2.979e-02 | -3.51 | myelofibrosis | COSMIC cancer mutations | myelofibrosis | 413 | 4 | 16828 | 48 |
CNTN5,RIMS2,GRIN2B,ALK |
2.979e-02 | -3.51 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | 413 | 4 | 16828 | 48 |
ALK,CNTN5,RIMS2,GRIN2B |
2.980e-02 | -3.51 | APLP2 (amyloid beta precursor like protein 2) | protein interactions | 334 | 107 | 2 | 19454 | 49 |
GRIN2B,GRIN1 |
2.982e-02 | -3.51 | NPY4R (neuropeptide Y receptor Y4) | protein interactions | 5540 | 12 | 1 | 19454 | 49 |
ALK |
2.982e-02 | -3.51 | TIGD3 (tigger transposable element derived 3) | protein interactions | 220359 | 12 | 1 | 19454 | 49 |
RALYL |
2.982e-02 | -3.51 | SHISA4 (shisa family member 4) | protein interactions | 149345 | 12 | 1 | 19454 | 49 |
CHRM2 |
2.982e-02 | -3.51 | SLC52A2 (solute carrier family 52 member 2) | protein interactions | 79581 | 12 | 1 | 19454 | 49 |
CHRM2 |
2.982e-02 | -3.51 | CACNA1S (calcium voltage-gated channel subunit alpha1 S) | protein interactions | 779 | 12 | 1 | 19454 | 49 |
RIMS2 |
2.996e-02 | -3.51 | G alpha (i) signalling events | REACTOME pathways | R-HSA-418594 | 242 | 3 | 10285 | 29 |
GRM7,GABBR2,CHRM2 |
3.000e-02 | -3.51 | modified amino acid binding | molecular function | GO:0072341 | 102 | 2 | 18094 | 48 |
SYT1,SYT7 |
3.010e-02 | -3.50 | gland morphogenesis | biological process | GO:0022612 | 105 | 2 | 18204 | 47 |
NRG3,CSMD1 |
3.010e-02 | -3.50 | regulation of postsynapse organization | biological process | GO:0099175 | 105 | 2 | 18204 | 47 |
GRID2,GRIN2B |
3.019e-02 | -3.50 | EGF | smart domains | SM00181 | 184 | 3 | 9717 | 36 |
NRXN1,TENM1,NRXN2 |
3.031e-02 | -3.50 | DRD2 (dopamine receptor D2) | protein interactions | 1813 | 108 | 2 | 19454 | 49 |
GABBR2,CADPS |
3.035e-02 | -3.49 | clathrin-sculpted vesicle | cellular component | GO:0060198 | 12 | 1 | 19108 | 49 |
SYT1 |
3.035e-02 | -3.49 | juxtaparanode region of axon | cellular component | GO:0044224 | 12 | 1 | 19108 | 49 |
DLG4 |
3.036e-02 | -3.49 | G protein-coupled receptor signaling pathway | biological process | GO:0007186 | 1178 | 7 | 18204 | 47 |
GPR85,TENM1,PDE2A,GRM7,RIMS2,CHRM2,GABBR2 |
3.056e-02 | -3.49 | regulation of synaptic vesicle membrane organization | biological process | GO:1901632 | 12 | 1 | 18204 | 47 |
SYT1 |
3.056e-02 | -3.49 | regulation of synaptic vesicle fusion to presynaptic active zone membrane | biological process | GO:0031630 | 12 | 1 | 18204 | 47 |
SYT1 |
3.056e-02 | -3.49 | positive regulation of catecholamine secretion | biological process | GO:0033605 | 12 | 1 | 18204 | 47 |
SYT1 |
3.056e-02 | -3.49 | negative regulation of response to oxidative stress | biological process | GO:1902883 | 12 | 1 | 18204 | 47 |
MCTP1 |
3.056e-02 | -3.49 | sinoatrial node development | biological process | GO:0003163 | 12 | 1 | 18204 | 47 |
CACNA1G |
3.056e-02 | -3.49 | AV node cell to bundle of His cell communication | biological process | GO:0086067 | 12 | 1 | 18204 | 47 |
CACNA1G |
3.056e-02 | -3.49 | neuronal ion channel clustering | biological process | GO:0045161 | 12 | 1 | 18204 | 47 |
KCNIP2 |
3.056e-02 | -3.49 | response to macrophage colony-stimulating factor | biological process | GO:0036005 | 12 | 1 | 18204 | 47 |
PDE2A |
3.083e-02 | -3.48 | NOS1AP (nitric oxide synthase 1 adaptor protein) | protein interactions | 9722 | 109 | 2 | 19454 | 49 |
FGF12,NTRK3 |
3.094e-02 | -3.48 | tubular_adenocarcinoma | COSMIC cancer mutations | tubular_adenocarcinoma | 11 | 1 | 16828 | 48 |
NTRK3 |
3.094e-02 | -3.48 | stomach-carcinoma-tubular_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-tubular_adenocarcinoma | 11 | 1 | 16828 | 48 |
NTRK3 |
3.124e-02 | -3.47 | myxoid-round_cell | COSMIC cancer mutations | myxoid-round_cell | 97 | 2 | 16828 | 48 |
GRIK2,HCN1 |
3.124e-02 | -3.47 | soft_tissue-fat-liposarcoma-myxoid-round_cell | COSMIC cancer mutations | soft_tissue-fat-liposarcoma-myxoid-round_cell | 97 | 2 | 16828 | 48 |
GRIK2,HCN1 |
3.129e-02 | -3.46 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 36 |
NTRK3,ALK |
3.137e-02 | -3.46 | import into cell | biological process | GO:0098657 | 687 | 5 | 18204 | 47 |
CACNA1G,CACNA1A,SYT7,CACNA1H,SYT1 |
3.138e-02 | -3.46 | dipeptidyl-peptidase activity | molecular function | GO:0008239 | 12 | 1 | 18094 | 48 |
DPP10 |
3.138e-02 | -3.46 | G protein-coupled neurotransmitter receptor activity | molecular function | GO:0099528 | 12 | 1 | 18094 | 48 |
CHRM2 |
3.138e-02 | -3.46 | phosphate ion binding | molecular function | GO:0042301 | 12 | 1 | 18094 | 48 |
PDE2A |
3.146e-02 | -3.46 | Cargo recognition for clathrin-mediated endocytosis | REACTOME pathways | R-HSA-8856825 | 99 | 2 | 10285 | 29 |
SYT1,CHRM2 |
3.186e-02 | -3.45 | cortical cytoskeleton | cellular component | GO:0030863 | 109 | 2 | 19108 | 49 |
RIMS2,DLG4 |
3.193e-02 | -3.44 | Rab_BD | interpro domains | IPR010911 | 12 | 1 | 18521 | 50 |
RIMS2 |
3.193e-02 | -3.44 | V_SNARE_CC | interpro domains | IPR042855 | 12 | 1 | 18521 | 50 |
STXBP5 |
3.193e-02 | -3.44 | K_chnl_volt-dep_EAG/ELK/ERG | interpro domains | IPR003938 | 12 | 1 | 18521 | 50 |
HCN1 |
3.202e-02 | -3.44 | Helix hairpin bin | gene3d domains | 1.10.287.630 | 10 | 1 | 14470 | 47 |
HCN1 |
3.210e-02 | -3.44 | positive regulation of molecular function | biological process | GO:0044093 | 1192 | 7 | 18204 | 47 |
DLG4,GRIN2B,NTRK3,ALK,KCNIP2,TENM1,DLG3 |
3.224e-02 | -3.43 | LGALS3BP (galectin 3 binding protein) | protein interactions | 3959 | 276 | 3 | 19454 | 49 |
GPHN,GABRA1,NTRK3 |
3.226e-02 | -3.43 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 49 |
RIMS2 |
3.226e-02 | -3.43 | ZFP69B (ZFP69 zinc finger protein B) | protein interactions | 65243 | 13 | 1 | 19454 | 49 |
KCTD16 |
3.226e-02 | -3.43 | ZNF79 (zinc finger protein 79) | protein interactions | 7633 | 13 | 1 | 19454 | 49 |
FGF12 |
3.226e-02 | -3.43 | CACNB4 (calcium voltage-gated channel auxiliary subunit beta 4) | protein interactions | 785 | 13 | 1 | 19454 | 49 |
CACNA1A |
3.226e-02 | -3.43 | CABP1 (calcium binding protein 1) | protein interactions | 9478 | 13 | 1 | 19454 | 49 |
CACNA1A |
3.226e-02 | -3.43 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 49 |
NRXN1 |
3.226e-02 | -3.43 | PPM1L (protein phosphatase, Mg2+/Mn2+ dependent 1L) | protein interactions | 151742 | 13 | 1 | 19454 | 49 |
PDE2A |
3.226e-02 | -3.43 | IGLC6 (immunoglobulin lambda constant 6) | protein interactions | 3542 | 13 | 1 | 19454 | 49 |
HCN1 |
3.241e-02 | -3.43 | GGA3 (golgi associated, gamma adaptin ear containing, ARF binding protein 3) | protein interactions | 23163 | 112 | 2 | 19454 | 49 |
NTRK3,ALK |
3.241e-02 | -3.43 | CAV2 (caveolin 2) | protein interactions | 858 | 112 | 2 | 19454 | 49 |
PDE2A,KCNMA1 |
3.247e-02 | -3.43 | regulation of protein kinase activity | biological process | GO:0045859 | 469 | 4 | 18204 | 47 |
DLG4,DLG3,NTRK3,TENM1 |
3.284e-02 | -3.42 | early phagosome | cellular component | GO:0032009 | 13 | 1 | 19108 | 49 |
SYT7 |
3.306e-02 | -3.41 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 47 |
GRID2 |
3.306e-02 | -3.41 | ectodermal placode development | biological process | GO:0071696 | 13 | 1 | 18204 | 47 |
NRG3 |
3.306e-02 | -3.41 | phagosome-lysosome fusion | biological process | GO:0090385 | 13 | 1 | 18204 | 47 |
SYT7 |
3.306e-02 | -3.41 | regulation of postsynaptic density assembly | biological process | GO:0099151 | 13 | 1 | 18204 | 47 |
GRID2 |
3.306e-02 | -3.41 | cerebellar granular layer development | biological process | GO:0021681 | 13 | 1 | 18204 | 47 |
GRID2 |
3.306e-02 | -3.41 | regulation of dendritic spine maintenance | biological process | GO:1902950 | 13 | 1 | 18204 | 47 |
GRIN2B |
3.306e-02 | -3.41 | positive regulation of calcium ion transport into cytosol | biological process | GO:0010524 | 13 | 1 | 18204 | 47 |
GRIN1 |
3.306e-02 | -3.41 | retinal cone cell differentiation | biological process | GO:0042670 | 13 | 1 | 18204 | 47 |
HCN1 |
3.306e-02 | -3.41 | nervous system process involved in regulation of systemic arterial blood pressure | biological process | GO:0001976 | 13 | 1 | 18204 | 47 |
ASIC2 |
3.309e-02 | -3.41 | positive regulation of phosphorus metabolic process | biological process | GO:0010562 | 697 | 5 | 18204 | 47 |
DLG4,TENM1,ALK,DLG3,NTRK3 |
3.309e-02 | -3.41 | positive regulation of phosphate metabolic process | biological process | GO:0045937 | 697 | 5 | 18204 | 47 |
DLG3,ALK,NTRK3,TENM1,DLG4 |
3.332e-02 | -3.40 | phosphatidylinositol bisphosphate binding | molecular function | GO:1902936 | 108 | 2 | 18094 | 48 |
SYT1,SYT7 |
3.333e-02 | -3.40 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 3 | 18204 | 47 |
KCNMA1,ASIC2,PDE2A |
3.347e-02 | -3.40 | HS2ST1 (heparan sulfate 2-O-sulfotransferase 1) | protein interactions | 9653 | 114 | 2 | 19454 | 49 |
ASIC2,PDE2A |
3.364e-02 | -3.39 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 3 | 16828 | 48 |
NRG3,SYT1,GABBR2 |
3.364e-02 | -3.39 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 3 | 16828 | 48 |
GABBR2,SYT1,NRG3 |
3.364e-02 | -3.39 | temporal_lobe | COSMIC cancer mutations | temporal_lobe | 101 | 2 | 16828 | 48 |
ALK,FGF12 |
3.371e-02 | -3.39 | left | COSMIC cancer mutations | left | 12 | 1 | 16828 | 48 |
ALK |
3.395e-02 | -3.38 | oxidoreductase activity, acting on other nitrogenous compounds as donors | molecular function | GO:0016661 | 13 | 1 | 18094 | 48 |
GPHN |
3.395e-02 | -3.38 | calcium-activated potassium channel activity | molecular function | GO:0015269 | 13 | 1 | 18094 | 48 |
KCNMA1 |
3.395e-02 | -3.38 | myosin II binding | molecular function | GO:0045159 | 13 | 1 | 18094 | 48 |
STXBP5 |
3.396e-02 | -3.38 | GABAARALPHA | prints domains | PR01079 | 6 | 1 | 5227 | 30 |
GABRA1 |
3.426e-02 | -3.37 | telencephalon development | biological process | GO:0021537 | 276 | 3 | 18204 | 47 |
ALK,KCNC1,NRG3 |
3.438e-02 | -3.37 | Gastrin-CREB signalling pathway via PKC and MAPK | REACTOME pathways | R-HSA-881907 | 443 | 4 | 10285 | 29 |
GRIN1,NRG3,GRIN2B,DLG4 |
3.444e-02 | -3.37 | metencephalon development | biological process | GO:0022037 | 113 | 2 | 18204 | 47 |
GRID2,KCNC1 |
3.447e-02 | -3.37 | SH3_1 | pfam domains | PF00018 | 106 | 2 | 17795 | 49 |
DLG4,DLG3 |
3.454e-02 | -3.37 | GPCR_3_9-Cys_sf | interpro domains | IPR038550 | 13 | 1 | 18521 | 50 |
GRM7 |
3.454e-02 | -3.37 | Olfac-like_dom | interpro domains | IPR003112 | 13 | 1 | 18521 | 50 |
OLFM1 |
3.454e-02 | -3.37 | GPCR_3_9-Cys_dom | interpro domains | IPR011500 | 13 | 1 | 18521 | 50 |
GRM7 |
3.465e-02 | -3.36 | NEDD4L (NEDD4 like E3 ubiquitin protein ligase) | protein interactions | 23327 | 284 | 3 | 19454 | 49 |
DLG3,FGF12,HCN1 |
3.466e-02 | -3.36 | cGMP signaling | KEGG pathways | hsa_M00694 | 9 | 1 | 7161 | 28 |
PDE2A |
3.466e-02 | -3.36 | cGMP signaling | KEGG pathways | M00694 | 9 | 1 | 7161 | 28 |
PDE2A |
3.470e-02 | -3.36 | KCNC1 (potassium voltage-gated channel subfamily C member 1) | protein interactions | 3746 | 14 | 1 | 19454 | 49 |
KCNC1 |
3.470e-02 | -3.36 | CIMAP1D (CIMAP1 family member D) | protein interactions | 284451 | 14 | 1 | 19454 | 49 |
GPHN |
3.470e-02 | -3.36 | CHGA (chromogranin A) | protein interactions | 1113 | 14 | 1 | 19454 | 49 |
SYT1 |
3.470e-02 | -3.36 | GRID2 (glutamate ionotropic receptor delta type subunit 2) | protein interactions | 2895 | 14 | 1 | 19454 | 49 |
GRIK2 |
3.470e-02 | -3.36 | ABTB1 (ankyrin repeat and BTB domain containing 1) | protein interactions | 80325 | 14 | 1 | 19454 | 49 |
NTRK3 |
3.470e-02 | -3.36 | RNF121 (ring finger protein 121) | protein interactions | 55298 | 14 | 1 | 19454 | 49 |
PDE2A |
3.470e-02 | -3.36 | KCNIP2 (potassium voltage-gated channel interacting protein 2) | protein interactions | 30819 | 14 | 1 | 19454 | 49 |
KCNIP2 |
3.490e-02 | -3.36 | V_SNARE | prosite domains | PS50892 | 12 | 1 | 12186 | 36 |
STXBP5 |
3.490e-02 | -3.36 | RABBD | prosite domains | PS50916 | 12 | 1 | 12186 | 36 |
RIMS2 |
3.520e-02 | -3.35 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 36 |
ALK,NTRK3 |
3.522e-02 | -3.35 | NCD3G | pfam domains | PF07562 | 13 | 1 | 17795 | 49 |
GRM7 |
3.522e-02 | -3.35 | OLF | pfam domains | PF02191 | 13 | 1 | 17795 | 49 |
OLFM1 |
3.527e-02 | -3.34 | SERPINH1 (serpin family H member 1) | protein interactions | 871 | 286 | 3 | 19454 | 49 |
ALK,GABRA1,NTRK3 |
3.532e-02 | -3.34 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 49 |
SYT1 |
3.532e-02 | -3.34 | voltage-gated sodium channel complex | cellular component | GO:0001518 | 14 | 1 | 19108 | 49 |
SCN8A |
3.556e-02 | -3.34 | peptidyl-tyrosine autophosphorylation | biological process | GO:0038083 | 14 | 1 | 18204 | 47 |
ALK |
3.556e-02 | -3.34 | G protein-coupled glutamate receptor signaling pathway | biological process | GO:0007216 | 14 | 1 | 18204 | 47 |
GRM7 |
3.556e-02 | -3.34 | negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | biological process | GO:0106072 | 14 | 1 | 18204 | 47 |
PDE2A |
3.556e-02 | -3.34 | neurotransmitter receptor localization to postsynaptic specialization membrane | biological process | GO:0099645 | 14 | 1 | 18204 | 47 |
DLG4 |
3.556e-02 | -3.34 | cyclic nucleotide catabolic process | biological process | GO:0009214 | 14 | 1 | 18204 | 47 |
PDE2A |
3.556e-02 | -3.34 | negative regulation of adenylate cyclase activity | biological process | GO:0007194 | 14 | 1 | 18204 | 47 |
GABBR2 |
3.556e-02 | -3.34 | response to light intensity | biological process | GO:0009642 | 14 | 1 | 18204 | 47 |
KCNC1 |
3.556e-02 | -3.34 | protein localization to postsynaptic specialization membrane | biological process | GO:0099633 | 14 | 1 | 18204 | 47 |
DLG4 |
3.556e-02 | -3.34 | regulation of long-term synaptic depression | biological process | GO:1900452 | 14 | 1 | 18204 | 47 |
GRID2 |
3.556e-02 | -3.34 | regulation of NMDA receptor activity | biological process | GO:2000310 | 14 | 1 | 18204 | 47 |
DLG4 |
3.556e-02 | -3.34 | Huntington's disease | KEGG pathways | ko05016 | 187 | 3 | 7161 | 28 |
GRIN1,GRIN2B,DLG4 |
3.556e-02 | -3.34 | Huntington's disease | KEGG pathways | hsa05016 | 187 | 3 | 7161 | 28 |
GRIN1,GRIN2B,DLG4 |
3.561e-02 | -3.34 | protein-containing complex organization | biological process | GO:0043933 | 2067 | 10 | 18204 | 47 |
SYT1,HCN1,DLG4,CELF5,GRIN2B,KCNC1,GRIN1,CELF4,CELF2,KCTD16 |
3.574e-02 | -3.33 | human chr15q25.3 | chromosome location | human chr15q25.3 | 19 | 1 | 26134 | 50 |
NTRK3 |
3.606e-02 | -3.32 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 1 | 10285 | 29 |
NRG3 |
3.606e-02 | -3.32 | Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels | REACTOME pathways | R-HSA-112308 | 13 | 1 | 10285 | 29 |
CACNA1A |
3.612e-02 | -3.32 | regulation of cation channel activity | biological process | GO:2001257 | 116 | 2 | 18204 | 47 |
FGF12,KCNIP2 |
3.620e-02 | -3.32 | THAP1 (THAP domain containing 1) | protein interactions | 55145 | 119 | 2 | 19454 | 49 |
FGF12,RALYL |
3.647e-02 | -3.31 | mucinous_adenocarcinoma | COSMIC cancer mutations | mucinous_adenocarcinoma | 13 | 1 | 16828 | 48 |
NTRK3 |
3.647e-02 | -3.31 | stomach-carcinoma-mucinous_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-mucinous_adenocarcinoma | 13 | 1 | 16828 | 48 |
NTRK3 |
3.647e-02 | -3.31 | autonomic_ganglia-adrenal_gland-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-adrenal_gland-paraganglioma-benign | 13 | 1 | 16828 | 48 |
PDE2A |
3.652e-02 | -3.31 | mRNA regulatory element binding translation repressor activity | molecular function | GO:0000900 | 14 | 1 | 18094 | 48 |
CELF4 |
3.652e-02 | -3.31 | dopamine receptor binding | molecular function | GO:0050780 | 14 | 1 | 18094 | 48 |
DLG4 |
3.656e-02 | -3.31 | pulmonary_blastoma | COSMIC cancer mutations | pulmonary_blastoma | 648 | 5 | 16828 | 48 |
SYT7,PDE2A,ALK,RIMS2,CACNA1A |
3.656e-02 | -3.31 | pleura-pulmonary_blastoma | COSMIC cancer mutations | pleura-pulmonary_blastoma | 648 | 5 | 16828 | 48 |
ALK,SYT7,PDE2A,CACNA1A,RIMS2 |
3.676e-02 | -3.30 | TMEM201 (transmembrane protein 201) | protein interactions | 199953 | 120 | 2 | 19454 | 49 |
GABRD,ALK |
3.683e-02 | -3.30 | GOPC (golgi associated PDZ and coiled-coil motif containing) | protein interactions | 57120 | 291 | 3 | 19454 | 49 |
GRID2,NTRK3,ALK |
3.714e-02 | -3.29 | ADGRB2 (adhesion G protein-coupled receptor B2) | protein interactions | 576 | 15 | 1 | 19454 | 49 |
DLG4 |
3.714e-02 | -3.29 | MEGF6 (multiple EGF like domains 6) | protein interactions | 1953 | 15 | 1 | 19454 | 49 |
CACNA1A |
3.714e-02 | -3.29 | TC2N (tandem C2 domains, nuclear) | protein interactions | 123036 | 15 | 1 | 19454 | 49 |
CADPS |
3.714e-02 | -3.29 | FZD1 (frizzled class receptor 1) | protein interactions | 8321 | 15 | 1 | 19454 | 49 |
DLG4 |
3.714e-02 | -3.29 | CCDC127 (coiled-coil domain containing 127) | protein interactions | 133957 | 15 | 1 | 19454 | 49 |
PDE2A |
3.714e-02 | -3.29 | GPR88 (G protein-coupled receptor 88) | protein interactions | 54112 | 15 | 1 | 19454 | 49 |
GRIN1 |
3.714e-02 | -3.29 | MEP1B (meprin A subunit beta) | protein interactions | 4225 | 15 | 1 | 19454 | 49 |
ALK |
3.714e-02 | -3.29 | PRR16 (proline rich 16) | protein interactions | 51334 | 15 | 1 | 19454 | 49 |
DLG4 |
3.714e-02 | -3.29 | RGS9 (regulator of G protein signaling 9) | protein interactions | 8787 | 15 | 1 | 19454 | 49 |
GRIN1 |
3.714e-02 | -3.29 | CACNA1H (calcium voltage-gated channel subunit alpha1 H) | protein interactions | 8912 | 15 | 1 | 19454 | 49 |
KCNMA1 |
3.715e-02 | -3.29 | Recoverin | interpro domains | IPR028846 | 14 | 1 | 18521 | 50 |
KCNIP2 |
3.754e-02 | -3.28 | positive regulation of cell communication | biological process | GO:0010647 | 1792 | 9 | 18204 | 47 |
NTRK3,NRXN1,GRIN2B,SYT1,DLG4,RIMS2,TENM1,GRIN1,GRIK2 |
3.759e-02 | -3.28 | human chr18q12.2 | chromosome location | human chr18q12.2 | 20 | 1 | 26134 | 50 |
CELF4 |
3.759e-02 | -3.28 | human chr12p13.1 | chromosome location | human chr12p13.1 | 20 | 1 | 26134 | 50 |
GRIN2B |
3.775e-02 | -3.28 | OLF | prosite domains | PS51132 | 13 | 1 | 12186 | 36 |
OLFM1 |
3.775e-02 | -3.28 | G_PROTEIN_RECEP_F3_2 | prosite domains | PS00980 | 13 | 1 | 12186 | 36 |
GRM7 |
3.777e-02 | -3.28 | positive regulation of signaling | biological process | GO:0023056 | 1794 | 9 | 18204 | 47 |
SYT1,DLG4,NTRK3,NRXN1,GRIN2B,GRIK2,GRIN1,RIMS2,TENM1 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
KCNC1 |
3.805e-02 | -3.27 | cellular response to acidic pH | biological process | GO:0071468 | 15 | 1 | 18204 | 47 |
ASIC2 |
3.805e-02 | -3.27 | tertiary alcohol metabolic process | biological process | GO:1902644 | 15 | 1 | 18204 | 47 |
CACNA1H |
3.805e-02 | -3.27 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 47 |
KCNMA1 |
3.805e-02 | -3.27 | potassium ion export across plasma membrane | biological process | GO:0097623 | 15 | 1 | 18204 | 47 |
KCNIP2 |
3.805e-02 | -3.27 | negative regulation of amino acid transport | biological process | GO:0051956 | 15 | 1 | 18204 | 47 |
GRM7 |
3.805e-02 | -3.27 | negative regulation of cyclase activity | biological process | GO:0031280 | 15 | 1 | 18204 | 47 |
GABBR2 |
3.805e-02 | -3.27 | dense core granule localization | biological process | GO:0032253 | 15 | 1 | 18204 | 47 |
CADPS |
3.805e-02 | -3.27 | heart valve formation | biological process | GO:0003188 | 15 | 1 | 18204 | 47 |
OLFM1 |
3.805e-02 | -3.27 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 47 |
DLG4 |
3.805e-02 | -3.27 | glucocorticoid metabolic process | biological process | GO:0008211 | 15 | 1 | 18204 | 47 |
CACNA1H |
3.805e-02 | -3.27 | apical protein localization | biological process | GO:0045176 | 15 | 1 | 18204 | 47 |
HCN1 |
3.842e-02 | -3.26 | regulation of peptidyl-serine phosphorylation | biological process | GO:0033135 | 120 | 2 | 18204 | 47 |
TENM1,NTRK3 |
3.844e-02 | -3.26 | EXOC7 (exocyst complex component 7) | protein interactions | 23265 | 123 | 2 | 19454 | 49 |
DLG3,GRIN2B |
3.878e-02 | -3.25 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 7 | 16828 | 48 |
NTRK3,CADPS,DLG3,GABRA1,GRIN2B,CSMD2,ALK |
3.878e-02 | -3.25 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 1 | 10285 | 29 |
NRG3 |
3.901e-02 | -3.24 | TNK2 (tyrosine kinase non receptor 2) | protein interactions | 10188 | 124 | 2 | 19454 | 49 |
NTRK3,ALK |
3.908e-02 | -3.24 | voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization | molecular function | GO:0086008 | 15 | 1 | 18094 | 48 |
KCNIP2 |
3.915e-02 | -3.24 | regulation of anatomical structure size | biological process | GO:0090066 | 498 | 4 | 18204 | 47 |
TENM1,OLFM1,ASIC2,KCNMA1 |
3.925e-02 | -3.24 | prostate-adenoma | COSMIC cancer mutations | prostate-adenoma | 1634 | 9 | 16828 | 48 |
SYT1,CSMD2,GRM7,PDE2A,GABRB2,GABBR2,GRIN1,CADPS,GRID2 |
3.930e-02 | -3.24 | mixed_adenosquamous_carcinoma | COSMIC cancer mutations | mixed_adenosquamous_carcinoma | 110 | 2 | 16828 | 48 |
NTRK3,ALK |
3.943e-02 | -3.23 | human chr10q23.1 | chromosome location | human chr10q23.1 | 21 | 1 | 26134 | 50 |
NRG3 |
3.951e-02 | -3.23 | HUDSXLRNA | prints domains | PR00961 | 7 | 1 | 5227 | 30 |
CELF2 |
3.956e-02 | -3.23 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | ZAR1L (zygote arrest 1 like) | protein interactions | 646799 | 16 | 1 | 19454 | 49 |
GPHN |
3.956e-02 | -3.23 | RBM18 (RNA binding motif protein 18) | protein interactions | 92400 | 16 | 1 | 19454 | 49 |
SYT1 |
3.956e-02 | -3.23 | CACNB1 (calcium voltage-gated channel auxiliary subunit beta 1) | protein interactions | 782 | 16 | 1 | 19454 | 49 |
CACNA1A |
3.956e-02 | -3.23 | GABBR2 (gamma-aminobutyric acid type B receptor subunit 2) | protein interactions | 9568 | 16 | 1 | 19454 | 49 |
KCTD16 |
3.956e-02 | -3.23 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 1 | 19454 | 49 |
DLG4 |
3.956e-02 | -3.23 | KCNH1 (potassium voltage-gated channel subfamily H member 1) | protein interactions | 3756 | 16 | 1 | 19454 | 49 |
KCNC1 |
3.956e-02 | -3.23 | WASH6P (WASP family homolog 6, pseudogene) | protein interactions | 653440 | 16 | 1 | 19454 | 49 |
NTRK3 |
3.956e-02 | -3.23 | GABRB3 (gamma-aminobutyric acid type A receptor subunit beta3) | protein interactions | 2562 | 16 | 1 | 19454 | 49 |
GABRB2 |
3.956e-02 | -3.23 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 49 |
DLG4 |
3.956e-02 | -3.23 | KLKB1 (kallikrein B1) | protein interactions | 3818 | 16 | 1 | 19454 | 49 |
GPHN |
3.956e-02 | -3.23 | KCNJ4 (potassium inwardly rectifying channel subfamily J member 4) | protein interactions | 3761 | 16 | 1 | 19454 | 49 |
DLG4 |
3.956e-02 | -3.23 | TTLL10 (tubulin tyrosine ligase like 10) | protein interactions | 254173 | 16 | 1 | 19454 | 49 |
CADPS |
3.973e-02 | -3.23 | benign | COSMIC cancer mutations | benign | 265 | 3 | 16828 | 48 |
PDE2A,CACNA1H,CNTN5 |
3.995e-02 | -3.22 | liposarcoma | COSMIC cancer mutations | liposarcoma | 111 | 2 | 16828 | 48 |
HCN1,GRIK2 |
4.000e-02 | -3.22 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 6 | 16828 | 48 |
GABBR2,CACNA1A,ALK,STXBP5,CELF4,GRIN1 |
4.006e-02 | -3.22 | cellular response to chemical stimulus | biological process | GO:0070887 | 2411 | 11 | 18204 | 47 |
CHRM2,KCNC1,DLG4,HCN1,SYT1,PDE2A,ASIC2,CACNA1A,GRIN1,CACNA1H,GABRB2 |
4.016e-02 | -3.21 | NTPCR (nucleoside-triphosphatase, cancer-related) | protein interactions | 84284 | 126 | 2 | 19454 | 49 |
NTRK3,ALK |
4.022e-02 | -3.21 | ErbB receptor signaling network | Pathway Interaction DB | erbb_network_pathway | 13 | 1 | 2226 | 7 |
NRG3 |
4.027e-02 | -3.21 | node of Ranvier | cellular component | GO:0033268 | 16 | 1 | 19108 | 49 |
SCN8A |
4.036e-02 | -3.21 | skin-malignant_melanoma | COSMIC cancer mutations | skin-malignant_melanoma | 15741 | 48 | 16828 | 48 |
GRID2,NTRK3,KCNT1,STXBP5,SYT1,GRIN2B,GPHN,NRG3,KCNC1,HCN1,DLG4,RALYL,KCTD16,CELF2,CACNA1H,DPP10,DLG3,SYT7,KCNIP2,CHRM2,GABRB2,CNTN5,FGF12,CELF5,GRM7,CACNA1A,CSMD2,CADPS,GABRA1,MCTP1,ALK,PDE2A,SCN8A,TENM1,FAM131A,GRIN1,GRIK2,CELF4,GRIA3,OLFM1,RIMS2,GABBR2,NRXN1,NRXN2,CACNA1G,GPR85,KCNMA1,GABRD |
4.048e-02 | -3.21 | regulation of endocytosis | biological process | GO:0030100 | 295 | 3 | 18204 | 47 |
SYT7,DLG4,MCTP1 |
4.054e-02 | -3.21 | regulation of postsynaptic specialization assembly | biological process | GO:0099150 | 16 | 1 | 18204 | 47 |
GRID2 |
4.054e-02 | -3.21 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 47 |
DLG4 |
4.054e-02 | -3.21 | regulation of short-term neuronal synaptic plasticity | biological process | GO:0048172 | 16 | 1 | 18204 | 47 |
GRIK2 |
4.054e-02 | -3.21 | glutamatergic neuron differentiation | biological process | GO:1905962 | 16 | 1 | 18204 | 47 |
GRID2 |
4.054e-02 | -3.21 | positive regulation of dendrite development | biological process | GO:1900006 | 16 | 1 | 18204 | 47 |
ALK |
4.054e-02 | -3.21 | regulation of transmission of nerve impulse | biological process | GO:0051969 | 16 | 1 | 18204 | 47 |
FGF12 |
4.074e-02 | -3.20 | TUBA3C (tubulin alpha 3c) | protein interactions | 7278 | 127 | 2 | 19454 | 49 |
GRM7,OLFM1 |
4.082e-02 | -3.20 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 3 | 18204 | 47 |
GRID2,NRXN1,ASIC2 |
4.127e-02 | -3.19 | human chr5p12 | chromosome location | human chr5p12 | 22 | 1 | 26134 | 50 |
HCN1 |
4.132e-02 | -3.19 | STIM2 (stromal interaction molecule 2) | protein interactions | 57620 | 128 | 2 | 19454 | 49 |
NTRK3,ALK |
4.132e-02 | -3.19 | SYT2 (synaptotagmin 2) | protein interactions | 127833 | 128 | 2 | 19454 | 49 |
NRXN1,SYT1 |
4.137e-02 | -3.19 | mammary gland development | biological process | GO:0030879 | 125 | 2 | 18204 | 47 |
NRG3,CSMD1 |
4.138e-02 | -3.18 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 7 | 16828 | 48 |
GRIN2B,CSMD2,ALK,CADPS,DLG3,GABRA1,NTRK3 |
4.143e-02 | -3.18 | GPCR, family 3, nine cysteines domain | gene3d domains | 2.10.50.30 | 13 | 1 | 14470 | 47 |
GRM7 |
4.143e-02 | -3.18 | iswi atpase | gene3d domains | 1.20.5.1190 | 13 | 1 | 14470 | 47 |
SCN8A |
4.150e-02 | -3.18 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 1 | 10285 | 29 |
NRG3 |
4.150e-02 | -3.18 | LGI-ADAM interactions | REACTOME pathways | R-HSA-5682910 | 15 | 1 | 10285 | 29 |
DLG4 |
4.163e-02 | -3.18 | cyclase regulator activity | molecular function | GO:0010851 | 16 | 1 | 18094 | 48 |
GRM7 |
4.163e-02 | -3.18 | cGMP binding | molecular function | GO:0030553 | 16 | 1 | 18094 | 48 |
PDE2A |
4.194e-02 | -3.17 | pancreas-pancreatic_intraepithelial_neoplasia_(PanIN) | COSMIC cancer mutations | pancreas-pancreatic_intraepithelial_neoplasia_(PanIN) | 673 | 5 | 16828 | 48 |
CACNA1G,KCNMA1,GRIN2B,CSMD2,GRIK2 |
4.194e-02 | -3.17 | pancreatic_intraepithelial_neoplasia_(PanIN) | COSMIC cancer mutations | pancreatic_intraepithelial_neoplasia_(PanIN) | 673 | 5 | 16828 | 48 |
KCNMA1,GRIN2B,CACNA1G,CSMD2,GRIK2 |
4.196e-02 | -3.17 | right | COSMIC cancer mutations | right | 15 | 1 | 16828 | 48 |
ALK |
4.197e-02 | -3.17 | response to ethanol | biological process | GO:0045471 | 126 | 2 | 18204 | 47 |
GRIN1,GRIN2B |
4.198e-02 | -3.17 | IL13RA1 (interleukin 13 receptor subunit alpha 1) | protein interactions | 3597 | 17 | 1 | 19454 | 49 |
DLG4 |
4.198e-02 | -3.17 | NEU3 (neuraminidase 3) | protein interactions | 10825 | 17 | 1 | 19454 | 49 |
NTRK3 |
4.198e-02 | -3.17 | CYP20A1 (cytochrome P450 family 20 subfamily A member 1) | protein interactions | 57404 | 17 | 1 | 19454 | 49 |
PDE2A |
4.198e-02 | -3.17 | MFSD10 (major facilitator superfamily domain containing 10) | protein interactions | 10227 | 17 | 1 | 19454 | 49 |
PDE2A |
4.226e-02 | -3.16 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 6 | 16828 | 48 |
STXBP5,ALK,CACNA1A,CELF4,GRIN1,GABBR2 |
4.235e-02 | -3.16 | cNMP-bd_CS | interpro domains | IPR018488 | 16 | 1 | 18521 | 50 |
HCN1 |
4.257e-02 | -3.16 | positive regulation of protein serine/threonine kinase activity | biological process | GO:0071902 | 127 | 2 | 18204 | 47 |
TENM1,NTRK3 |
4.273e-02 | -3.15 | acetylcholine-gated channel complex | cellular component | GO:0005892 | 17 | 1 | 19108 | 49 |
STXBP5 |
4.273e-02 | -3.15 | presynaptic active zone cytoplasmic component | cellular component | GO:0098831 | 17 | 1 | 19108 | 49 |
RIMS2 |
4.301e-02 | -3.15 | positive regulation of neurotransmitter secretion | biological process | GO:0001956 | 17 | 1 | 18204 | 47 |
SYT1 |
4.301e-02 | -3.15 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 47 |
PDE2A |
4.301e-02 | -3.15 | negative regulation of receptor internalization | biological process | GO:0002091 | 17 | 1 | 18204 | 47 |
DLG4 |
4.301e-02 | -3.15 | regulation of excitatory synapse assembly | biological process | GO:1904889 | 17 | 1 | 18204 | 47 |
GRID2 |
4.301e-02 | -3.15 | regulation of postsynaptic density organization | biological process | GO:1905874 | 17 | 1 | 18204 | 47 |
GRID2 |
4.301e-02 | -3.15 | positive regulation of vascular permeability | biological process | GO:0043117 | 17 | 1 | 18204 | 47 |
PDE2A |
4.301e-02 | -3.15 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 47 |
CACNA1G |
4.312e-02 | -3.14 | Insulin secretion | KEGG pathways | hsa04911 | 85 | 2 | 7161 | 28 |
RIMS2,KCNMA1 |
4.331e-02 | -3.14 | Signalling by NGF | REACTOME pathways | R-HSA-166520 | 477 | 4 | 10285 | 29 |
NRG3,GRIN2B,DLG4,GRIN1 |
4.340e-02 | -3.14 | positive regulation of cellular component biogenesis | biological process | GO:0044089 | 515 | 4 | 18204 | 47 |
ASIC2,NRXN1,TENM1,GRID2 |
4.367e-02 | -3.13 | HAL (histidine ammonia-lyase) | protein interactions | 3034 | 132 | 2 | 19454 | 49 |
HCN1,KCTD16 |
4.378e-02 | -3.13 | response to organophosphorus | biological process | GO:0046683 | 129 | 2 | 18204 | 47 |
PDE2A,HCN1 |
4.393e-02 | -3.13 | fat | COSMIC cancer mutations | fat | 117 | 2 | 16828 | 48 |
HCN1,GRIK2 |
4.400e-02 | -3.12 | cytoplasmic region | cellular component | GO:0099568 | 307 | 3 | 19108 | 49 |
RIMS2,DLG4,GRIK2 |
4.420e-02 | -3.12 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 1 | 10285 | 29 |
NRG3 |
4.420e-02 | -3.12 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 1 | 10285 | 29 |
NRG3 |
4.427e-02 | -3.12 | GABRA1 (gamma-aminobutyric acid type A receptor subunit alpha1) | protein interactions | 2554 | 133 | 2 | 19454 | 49 |
GABRB2,GABRA1 |
4.440e-02 | -3.11 | detection of external stimulus | biological process | GO:0009581 | 130 | 2 | 18204 | 47 |
ASIC2,GRIK2 |
4.440e-02 | -3.11 | GNA14 (G protein subunit alpha 14) | protein interactions | 9630 | 18 | 1 | 19454 | 49 |
CHRM2 |
4.440e-02 | -3.11 | APOBEC1 (apolipoprotein B mRNA editing enzyme catalytic subunit 1) | protein interactions | 339 | 18 | 1 | 19454 | 49 |
CELF2 |
4.440e-02 | -3.11 | RHBDL1 (rhomboid like 1) | protein interactions | 9028 | 18 | 1 | 19454 | 49 |
DLG3 |
4.440e-02 | -3.11 | MVB12B (multivesicular body subunit 12B) | protein interactions | 89853 | 18 | 1 | 19454 | 49 |
PDE2A |
4.455e-02 | -3.11 | YojJ-like | gene3d domains | 1.10.287.770 | 14 | 1 | 14470 | 47 |
ASIC2 |
4.487e-02 | -3.10 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 2 | 19454 | 49 |
PDE2A,SYT1 |
4.487e-02 | -3.10 | MDH1 (malate dehydrogenase 1) | protein interactions | 4190 | 134 | 2 | 19454 | 49 |
CHRM2,CSMD2 |
4.503e-02 | -3.10 | MTABOTROPICR | prints domains | PR00593 | 8 | 1 | 5227 | 30 |
GRM7 |
4.519e-02 | -3.10 | calyx of Held | cellular component | GO:0044305 | 18 | 1 | 19108 | 49 |
KCNC1 |
4.547e-02 | -3.09 | SEL1L (SEL1L adaptor subunit of SYVN1 ubiquitin ligase) | protein interactions | 6400 | 135 | 2 | 19454 | 49 |
GABRA1,NTRK3 |
4.547e-02 | -3.09 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 2 | 19454 | 49 |
NTRK3,GRIN1 |
4.549e-02 | -3.09 | negative regulation of lyase activity | biological process | GO:0051350 | 18 | 1 | 18204 | 47 |
GABBR2 |
4.549e-02 | -3.09 | phagolysosome assembly | biological process | GO:0001845 | 18 | 1 | 18204 | 47 |
SYT7 |
4.549e-02 | -3.09 | negative regulation of vascular permeability | biological process | GO:0043116 | 18 | 1 | 18204 | 47 |
PDE2A |
4.549e-02 | -3.09 | regulation of calcium ion transport into cytosol | biological process | GO:0010522 | 18 | 1 | 18204 | 47 |
GRIN1 |
4.549e-02 | -3.09 | regulation of acrosome reaction | biological process | GO:0060046 | 18 | 1 | 18204 | 47 |
CACNA1H |
4.549e-02 | -3.09 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 47 |
DLG4 |
4.549e-02 | -3.09 | secretory granule localization | biological process | GO:0032252 | 18 | 1 | 18204 | 47 |
CADPS |
4.608e-02 | -3.08 | AHCYL2 (adenosylhomocysteinase like 2) | protein interactions | 23382 | 136 | 2 | 19454 | 49 |
FGF12,NTRK3 |
4.608e-02 | -3.08 | NUDT19 (nudix hydrolase 19) | protein interactions | 390916 | 136 | 2 | 19454 | 49 |
ALK,NTRK3 |
4.615e-02 | -3.08 | cell cortex | cellular component | GO:0005938 | 313 | 3 | 19108 | 49 |
DLG4,GRM7,RIMS2 |
4.625e-02 | -3.07 | detection of abiotic stimulus | biological process | GO:0009582 | 133 | 2 | 18204 | 47 |
ASIC2,GRIK2 |
4.626e-02 | -3.07 | CNMP_BINDING_1 | prosite domains | PS00888 | 16 | 1 | 12186 | 36 |
HCN1 |
4.650e-02 | -3.07 | response to light stimulus | biological process | GO:0009416 | 312 | 3 | 18204 | 47 |
KCNC1,ASIC2,GRIN1 |
4.671e-02 | -3.06 | transmembrane receptor protein tyrosine kinase activator activity | molecular function | GO:0030297 | 18 | 1 | 18094 | 48 |
NRG3 |
4.671e-02 | -3.06 | adrenergic receptor binding | molecular function | GO:0031690 | 18 | 1 | 18094 | 48 |
DLG4 |
4.677e-02 | -3.06 | human chr7q31.1 | chromosome location | human chr7q31.1 | 25 | 1 | 26134 | 50 |
GPR85 |
4.681e-02 | -3.06 | PLCB2 (phospholipase C beta 2) | protein interactions | 5330 | 19 | 1 | 19454 | 49 |
ALK |
4.681e-02 | -3.06 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 49 |
NRXN1 |
4.681e-02 | -3.06 | ADRB1 (adrenoceptor beta 1) | protein interactions | 153 | 19 | 1 | 19454 | 49 |
DLG4 |
4.681e-02 | -3.06 | PEX2 (peroxisomal biogenesis factor 2) | protein interactions | 5828 | 19 | 1 | 19454 | 49 |
PDE2A |
4.681e-02 | -3.06 | NANOS1 (nanos C2HC-type zinc finger 1) | protein interactions | 340719 | 19 | 1 | 19454 | 49 |
GRIN1 |
4.681e-02 | -3.06 | CRIM1 (cysteine rich transmembrane BMP regulator 1) | protein interactions | 51232 | 19 | 1 | 19454 | 49 |
CACNA1A |
4.690e-02 | -3.06 | Trafficking of GluR2-containing AMPA receptors | REACTOME pathways | R-HSA-416993 | 17 | 1 | 10285 | 29 |
GRIA3 |
4.690e-02 | -3.06 | RHO GTPases activate CIT | REACTOME pathways | R-HSA-5625900 | 17 | 1 | 10285 | 29 |
DLG4 |
4.690e-02 | -3.06 | Acetylcholine Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-264642 | 17 | 1 | 10285 | 29 |
SYT1 |
4.714e-02 | -3.05 | OLF | smart domains | SM00284 | 13 | 1 | 9717 | 36 |
OLFM1 |
4.723e-02 | -3.05 | regulation of developmental growth | biological process | GO:0048638 | 314 | 3 | 18204 | 47 |
SYT1,OLFM1,RIMS2 |
4.730e-02 | -3.05 | FUT8 (fucosyltransferase 8) | protein interactions | 2530 | 138 | 2 | 19454 | 49 |
GABRD,PDE2A |
4.730e-02 | -3.05 | SYAP1 (synapse associated protein 1) | protein interactions | 94056 | 138 | 2 | 19454 | 49 |
ALK,NTRK3 |
4.742e-02 | -3.05 | thymic_carcinoma | COSMIC cancer mutations | thymic_carcinoma | 17 | 1 | 16828 | 48 |
ALK |
4.742e-02 | -3.05 | bone-sacrum-chordoma | COSMIC cancer mutations | bone-sacrum-chordoma | 17 | 1 | 16828 | 48 |
ALK |
4.752e-02 | -3.05 | MAM_dom | interpro domains | IPR000998 | 18 | 1 | 18521 | 50 |
ALK |
4.754e-02 | -3.05 | Rap1 signaling pathway | KEGG pathways | ko04015 | 210 | 3 | 7161 | 28 |
GRIN2B,GRIN1,FGF12 |
4.754e-02 | -3.05 | Rap1 signaling pathway | KEGG pathways | hsa04015 | 210 | 3 | 7161 | 28 |
GRIN1,FGF12,GRIN2B |
4.761e-02 | -3.04 | secretory granule membrane | cellular component | GO:0030667 | 317 | 3 | 19108 | 49 |
CADPS,SYT1,STXBP5 |
4.785e-02 | -3.04 | anion binding | molecular function | GO:0043168 | 2412 | 11 | 18094 | 48 |
GPHN,GRIN1,GRIN2B,HCN1,SYT1,NTRK3,SCN8A,GRM7,PDE2A,SYT7,ALK |
4.791e-02 | -3.04 | protein kinase activator activity | molecular function | GO:0030295 | 132 | 2 | 18094 | 48 |
NRG3,ALK |
4.792e-02 | -3.04 | EXOC3 (exocyst complex component 3) | protein interactions | 11336 | 139 | 2 | 19454 | 49 |
DLG3,GRIN2B |
4.792e-02 | -3.04 | MON2 (MON2 homolog, regulator of endosome-to-Golgi trafficking) | protein interactions | 23041 | 139 | 2 | 19454 | 49 |
NTRK3,PDE2A |
4.795e-02 | -3.04 | positive regulation of reactive oxygen species biosynthetic process | biological process | GO:1903428 | 19 | 1 | 18204 | 47 |
GRIN1 |
4.795e-02 | -3.04 | regulation of synaptic vesicle endocytosis | biological process | GO:1900242 | 19 | 1 | 18204 | 47 |
SYT7 |
4.795e-02 | -3.04 | regulation of glutamate secretion | biological process | GO:0014048 | 19 | 1 | 18204 | 47 |
GRM7 |
4.795e-02 | -3.04 | excretion | biological process | GO:0007588 | 19 | 1 | 18204 | 47 |
KCNMA1 |
4.795e-02 | -3.04 | presynapse assembly | biological process | GO:0099054 | 19 | 1 | 18204 | 47 |
CNTN5 |
4.814e-02 | -3.03 | regulation of MAP kinase activity | biological process | GO:0043405 | 136 | 2 | 18204 | 47 |
TENM1,NTRK3 |
4.844e-02 | -3.03 | MAM | pfam domains | PF00629 | 18 | 1 | 17795 | 49 |
ALK |
4.853e-02 | -3.03 | STX3 (syntaxin 3) | protein interactions | 6809 | 140 | 2 | 19454 | 49 |
SYT1,STXBP5 |
4.884e-02 | -3.02 | clathrin-coated vesicle membrane | cellular component | GO:0030665 | 138 | 2 | 19108 | 49 |
CHRM2,SYT1 |
4.916e-02 | -3.01 | LLGL1 (LLGL scribble cell polarity complex component 1) | protein interactions | 3996 | 141 | 2 | 19454 | 49 |
CACNA1A,NTRK3 |
4.921e-02 | -3.01 | EPCAM (epithelial cell adhesion molecule) | protein interactions | 4072 | 20 | 1 | 19454 | 49 |
NTRK3 |
4.921e-02 | -3.01 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 1 | 19454 | 49 |
NRXN1 |
4.921e-02 | -3.01 | DOK5 (docking protein 5) | protein interactions | 55816 | 20 | 1 | 19454 | 49 |
NTRK3 |
4.921e-02 | -3.01 | GGT1 (gamma-glutamyltransferase 1) | protein interactions | 2678 | 20 | 1 | 19454 | 49 |
KCNMA1 |
4.921e-02 | -3.01 | RGS7 (regulator of G protein signaling 7) | protein interactions | 6000 | 20 | 1 | 19454 | 49 |
CHRM2 |
4.921e-02 | -3.01 | VMAC (vimentin type intermediate filament associated coiled-coil protein) | protein interactions | 400673 | 20 | 1 | 19454 | 49 |
DLG4 |
4.921e-02 | -3.01 | CRHR1 (corticotropin releasing hormone receptor 1) | protein interactions | 1394 | 20 | 1 | 19454 | 49 |
DLG4 |
4.921e-02 | -3.01 | PMM1 (phosphomannomutase 1) | protein interactions | 5372 | 20 | 1 | 19454 | 49 |
CACNA1A |
4.924e-02 | -3.01 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 48 |
SCN8A |
4.945e-02 | -3.01 | Ig_I-set | interpro domains | IPR013098 | 132 | 2 | 18521 | 50 |
NTRK3,CNTN5 |
4.946e-02 | -3.01 | ovary-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-small_cell_carcinoma | 125 | 2 | 16828 | 48 |
ALK,NTRK3 |
4.960e-02 | -3.00 | Serotonin Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-181429 | 18 | 1 | 10285 | 29 |
SYT1 |
4.960e-02 | -3.00 | Norepinephrine Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-181430 | 18 | 1 | 10285 | 29 |
SYT1 |
4.963e-02 | -3.00 | thyroid-carcinoma-medullary_carcinoma | COSMIC cancer mutations | thyroid-carcinoma-medullary_carcinoma | 290 | 3 | 16828 | 48 |
ALK,NTRK3,NRG3 |
4.963e-02 | -3.00 | medullary_carcinoma | COSMIC cancer mutations | medullary_carcinoma | 290 | 3 | 16828 | 48 |
ALK,NRG3,NTRK3 |
4.979e-02 | -3.00 | vesicle | cellular component | GO:0031982 | 4141 | 16 | 19108 | 49 |
NRXN1,CADPS,CHRM2,SCN8A,GRIN1,GABRB2,GRIA3,GRIN2B,RIMS2,ALK,MCTP1,SYT7,GABRA1,SYT1,DLG4,STXBP5 |
4.983e-02 | -3.00 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 2 | 17795 | 49 |
NTRK3,ALK |